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Insulin regulated aminopeptidase (IRAP, EC 3.4.11.3) is a promising drug target for 
treatment of cognitive impairment. This membrane-bound ectopeptidase is densely concentrated 
in areas of the brain associated with cognition and is known to hydrolyze neuropeptides involved 
in memory and learning in vitro. A hypothesis is that inhibition of IRAP may extend the lifetime 
of beneficial neuropeptides in the extracellular space, mitigating the effects of diseases such as 
Alzheimer’s. A challenge in testing this hypothesis is the lack of available methods for 
quantitatively measuring ectopeptidase activity in vivo.  
This work describes the development of analytical techniques to aid in the understanding 
of ectopeptidases and the fate of neuropeptides in the extracellular space. We have done this by 
enhancing the sensitivity and quantitative capabilities of detection methods including capillary 
liquid chromatography-tandem mass spectrometry for online collection of neuropeptides and by 
the development of a novel sampling technique called electroosmotic perfusion-microdialysis 
(EOP-MD). With EOP-MD, substrate peptides are perfused using electroosmotic flow and 
hydrolysis products along with unhydrolyzed substrate are collected at the microdialysis probe. 
The advantage of using this approach compared to conventional microdialysis is that the volume 
of substrate and the residence time in the tissue can be controlled using current. Additionally, 
spatial resolution is dependent on the distance between the EOP and MD probes, which is 
approximately 100 µm. We have demonstrated this approach by observing leucine enkephalin 
hydrolysis in the anesthetized rat brain in the presence and absence of the IRAP inhibitor HFI-419.  
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 1 
1.0 Introduction 
Ectopeptidases are important drug targets in the search for therapies to address central 
nervous system afflictions, including cognitive impairment and pain.1 These membrane-bound 
enzymes have active sites open to the extracellular space (ECS) and act as the primary regulation 
mechanism for neuropeptides, a diverse class of signaling molecules.2 Neuropeptides are released 
in small concentrations by volume transmission into the ECS, where they elicit effects through 
interactions with receptors.3-4 Unlike classical neurotransmitters, such as dopamine and serotonin, 
their effects are modulated by degradation by ectopeptidases rather than cellular reuptake.5 
Resulting hydrolysis products can also act in signaling with activities different from the parent 
peptide. Thus, release of a particular peptide can initiate a cascade of effects throughout the central 
nervous system.  
Central infusions of neuropeptides such as the enkephalins, galanin, oxytocin, and 
vasopressin have beneficial effects on cognition and learning, seizure activity, emotional disorders, 
and brain plasticity.6-10 Thus, it is possible that specific inhibitors to target certain ectopeptidases 
may extend the extracellular lifetime of these beneficial neuropeptides. The potential benefits of 
using the endogenous neuropeptide system to treat cognitive diseases include high drug specificity 
and fewer side effects.11  
Despite the benefits of exploiting this system to treat central nervous system diseases, 
difficulty in studying ectopeptidases and their substrates in vivo limits our understanding of the 
effects of inhibition, both desired and undesired. This is especially a problem for ectopeptidases 
such as insulin regulated aminopeptidase (IRAP, EC 3.4.11.3), an important drug target for 
cognitive enhancers but whose role in the brain and natural endogenous substrates are largely 
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unknown.12 There is an unmet need for quantitative in vivo methods for probing ectopeptidase 
activity and understanding the fate neuropeptide hydrolysis products in the ECS.13 Insight into 
these processes will help determine the biological roles of these important signaling molecules as 
well as potential effects of pharmacological manipulation. 
1.1 Insulin Regulated Aminopeptidase (IRAP) 
A number of ectopeptidases play a role in modulating the activity of neuropeptides in the 
ECS including dipeptidyl peptidase IV (EC 3.4.14.5), aminopeptidase N (EC 3.4.11.2), and neutral 
endopeptidase (EC 3.4.24.11). These ectopeptidases are relatively well-characterized in terms of 
binding site specificity and artificial substrates and inhibitors are readily available for probing 
enzymatic activity.2 The focus of this dissertation will be on developing methods for the study of 
IRAP, a recently discovered ectopeptidase that has shown promise as a drug target for the 
development of cognitive enhancers.12  
IRAP was first discovered in the mid-1990s when it was found to be co-localized with the 
GLUT4 transporter in adipocytes.14-15  It was hypothesized that the protein had a role in glucose 
shuttling and was also found to have aminopeptidase activity, suggesting a function in regulating 
peptide hormones.14-15 Shortly after, a third group identified IRAP in the placenta as placental 
leucine aminopeptidase/ oxytocinase, where it was thought to have a role in regulating oxytocin 
levels throughout pregnancy.16 The authors noted that IRAP was likely synthesized as a 
transmembrane protein but was detectable in a soluble form in placental plasma.16 IRAP was found 
to be widely distributed in tissues throughout the body including skeletal muscle, cardiac tissue, 
digestive organs, and the brain, further contributing to the mystery of the function of this 
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peptidase.16 In vitro studies showed that IRAP hydrolyzed several neuropeptides involved in 
cognitive and emotional processing, including the enkephalins17-18, dynorphin A 1-8,19 arginine-
vasopressin17, 20, oxytocin17, 21, somatostatin20. A role for IRAP in regulating these particular 
neuropeptides seems to be mirrored in histological studies showing that IRAP is highly 
concentrated in areas involved in cognition, including the hippocampus, prefrontal cortex, and the 
amygdala, though it is also widely distributed in other areas of the brain.22 
In 2001, IRAP was identified as the angiotensin IV (AT4, VYIHPF) receptor.23 AT4 was 
thought to be an inactive byproduct of the renin-angiotensin system but in the 1970-80s it was 
found that intracerebroventricular (icv) infusions of the AT4 precursor angiotensin II (AT2) 
stimulated the release of vasopressin24, and dopamine25-26. This led to the discovery that AT2 also 
enhances rodent performance in memory and learning27-38 tests, reverses some forms of cognitive 
impairment39-43, and protects against the effects of ischemia44-45. It was later concluded that the 
beneficial effects of AT2 are dependent upon its metabolism to AT4.33, 46-55 Discovery of a distinct 
AT4 receptor further suggested a bioactive role for AT4.56-57  When this receptor was later 
identified as IRAP, it was hypothesized that the cognitive effects of AT4 were due to binding and 
inhibition of IRAP, extending the lifetime of cognitive-enhancing peptides in the extracellular 
space. 23, 58-60 While there is still debate over the identity of IRAP as the AT4 receptor61, perfusion 
of specific inhibitors shows similar cognitive effects as those seen with AT4 and its ligands.62-67 
Thus, IRAP has become a target for the development of drugs to treat cognitive impairment, 
though the role of IRAP in the brain and relevant in vivo substrates are still unknown.66, 68-69  
 4 
1.2 In vivo Sampling Methods 
Understanding the roles of ectopeptidases has been limited, in part, by challenges in 
studying endogenous neuropeptides. Low concentrations (pM) in the extracellular space require 
the use of careful sample handling and highly sensitive and specific detection methods.70 This 
makes it difficult to accurately measure not only basal levels but also changes in concentration due 
to binding or degradation processes.13  
One in vivo sampling technique that has been used to study neuropeptides in the ECS is 
push-pull perfusion (PPP).71-74 This method involves a probe consisting of two capillaries, one for 
perfusion and the other for collection. Artificial cerebrospinal fluid (aCSF) is infused through the 
perfusion probe while vacuum is applied at the collection end. This process must be carefully 
balanced so that fluid is replaced at the same rate that it is withdrawn.75 Extracellular contents are 
contained within the collection capillary, where they can be analyzed offline. The main advantage 
of PPP is that analytes can be collected at nearly 100% efficiency, meaning nearly all the fluid 
perfused into the ECS, along with analytes that have diffused into the fluid, is recovered in the 
collection capillary.76 This is especially important for low-abundance analytes, such as 
neuropeptides. An accompanying disadvantage is that there is no barrier preventing large analytes 
such as soluble enzymes and proteins from entering the collection probe, leading to possible 
degradation of collected analytes as well as technical issues, such as capillary clogging. Another 
downside is that low flow rates (nL/ min) must be used to minimize tissue damage.76-77 This results 
in impractical sample volumes.  
The most common sampling method for studying neuropeptides is microdialysis, in which 
a microbore probe consisting of inlet and outlet tubing connected by a molecular weight cutoff 
membrane is inserted into the ECS of a particular brain region.78-79 The probe is continuously 
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perfused with a physiological solution, such as aCSF, creating a concentration gradient that drives 
analytes across the membrane. Dialysate is collected at the probe outlet. This method allows 
continuous, online collection at practical (µL/ min.) flow rates. Online collection of neuropeptides 
is ideal, both to prevent degradation upon collection80 and to minimize adsorptive losses81 from 
these mass-limited samples due to sample handling and storage. Additionally, microdialysis can 
be coupled with a variety of separation and detection methods to suit the needs of the analyte of 
interest.  
1.3 Neuropeptide Separation and Detection 
Although a main advantage of using microdialysis is the ability to collect microliter sample 
volumes, an accompanying problem is analyte dilution. Capillary liquid chromatography (cLC) is 
particularly suited to this challenge due to small column diameters (≤150 μm), which decrease 
radial dilution and improve concentration sensitivity.82-83 A drawback is that small columns are 
also susceptible to volume overload, in which large injection volumes result in altered peak shapes 
and decreased sensitivity.83-87 Fortunately, capillary columns have limited thermal mass, which 
allows the use of fast and efficient temperature changes to focus large volume injections and 
mitigate the effects of volume overload.88-91  
Coupling cLC with tandem mass spectrometry (MS2) has emerged as the gold standard for 
in vivo neuropeptide detection.92 By using mass detection, substrates and hydrolysis products can 
be detected simultaneously and with high sensitivity.93 In addition, it is amenable to online 
neuropeptide analysis, though this approach has only been used sparingly.94-97 Though cLC-MS is 
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becoming an increasingly popular method for studying neuropeptides in microdialysate, 
quantitative detection at basal levels is still a challenge. 
1.4 Measuring Enzyme Activity In vivo 
Portions of this section are based on a review that was published in Annual Review of Analytical 
Chemistry98 
Direct in vivo measurements of endogenous neuropeptides using the aforementioned 
approaches could be invaluable in determining where a particular neuropeptide acts and the 
relative quantities at which it is present, but more information is required to understand the relative 
affinity of a peptide substrate for an ectopeptidase of interest as well as the kinetics of substrate 
hydrolysis. This information is critical in elucidating the relevant in vivo substrates of a particular 
ectopeptidase, such as IRAP. 
Methods for measuring enzyme activity ex vivo or in vivo tend to fall into the categories of 
either imaging-based techniques or sampling-based techniques. Imaging-based techniques such as 
fluorescence99-101, and magnetic resonance imaging102-103 often rely on detectable probes or labels 
to generate or dampen a signal when enzymatic activity occurs. This work has been particularly 
useful for qualitative clinical applications, such as identifying the location of a tumor. These 
techniques also have the advantage of being minimally invasive. Conversely, sampling-based 
techniques involve implantation of a physical probe into the tissue. Such approaches are frequently 
applied to biochemical or pharmacokinetic studies and offer the ability to locally affect the 
sampling environment by perfusion of drugs or other analytes.  
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1.4.1  Imaging-based Techniques 
Among the imaging-based techniques, fluorescence is common. Several fluorescent probes 
have been developed for imaging tumors in rodents based on the upregulated activity of certain 
enzymes, including cysteine and serine proteases104 and more specifically, cathepsin D105, 
asparaginyl endopeptidase106, and β-galactosidase.107 Design of these probes involves creative 
chemistry and strategies for enhancing signal-to-noise ratio, but in vivo applications are largely 
focused on the spatiotemporal aspects of cancer detection and monitoring rather than quantitative 
elucidation of the role of a particular peptidase. 
A historically important ex vivo approach for measuring enzymatic activity in the brain is 
in situ zymography (ISZ), which uses a “dye quenched,” or DQ-collagen to measure matrix 
metalloproteinase (MMP) activity in brain tissue slices. A fluorescent signal is generated upon 
hydrolysis of the derivatized collagen substrate, providing information about both the activity of 
the enzyme as well as location. This approach has been used in both frozen108 and fixed109-111 
tissues to study MMP roles in ischemia108, seizures110, and long-term potentiation112 in the brain. 
This concept has also been applied in vivo using Förster (or fluorescence) resonance energy 
transfer (FRET)113-based substrates, which consist of a fluorophore and a quencher separated by 
an amino acid linker sequence. The linker confers enzymatic specificity and fluorescence is 
detected upon hydrolysis. A method known as differential in vivo zymography utilizes this 
concept, with different fluorophores corresponding to different enzymes.114  This has allowed 
monitoring of MMP activity changes throughout zebrafish development. The limitation of 
zymography is that it is almost exclusively used to study MMPs.  
Magnetic resonance spectroscopy (MRS) has been used to study enzymatic activity of 
natural substrates by observing the magnetization transfer among functional groups on different 
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molecules containing the same active nucleus, such as 31P. This has allowed the in vivo 
measurement of creatinine kinase and ATP synthase activity in the liver and muscle as well as 
other phosphorylation events.115 1H MRS has been used to monitor the levels of 2-
hydroxyglutarate in brain tumors, a metabolite and possible biomarker for isocitrate 
dehydrogenase-mutated gliomas.116 Another MRS approach that has been used in the brain is the 
perfusion of 15N-labeled glutamate along with 15NH4Cl for a period of time allowing for [5-15N]-
glutamine synthesis followed by perfusion of 14NH4Cl.117 By monitoring the decline in [5-15N]-
glutamine its hydrolysis rate can be determined. This approach has been combined with 
microdialysis collection of extracellular glutamine to study glutamine export to the extracellular 
space.118 MRS-based techniques offer the ability to make quantitative rate measurements along 
with imaging capabilities. A weakness is that their detection limits (mM) are relatively high for 
neuropeptide studies. 
Mass spectrometry imaging (MSI) is a versatile and sensitive approach that allows 
identification of chemical species while maintaining spatial resolution. This is particularly 
important in elucidating the function of a peptide substrate or ectopeptidase in the brain. The major 
advantage of matrix-assisted laser desorption/ionization (MALDI)-based approaches is that 
natural substrates and hydrolysis products, both known and unknown, can be analyzed directly 
without further chemical modification.119 MALDI coupled with time of flight (TOF) analyzers has 
been combined with in situ histochemistry to map angiotensin degradation in mouse kidney 
slices120 and to study the effect of different aminopeptidase inhibitors on dynorphin B metabolism 
in the rat brain using frozen tissue slices.119 The Li group used MALDI-LTQ-Orbitrap XL to 
perform multiple data dependent acquisition steps in a spiral sequence at each raster step.121 This 
allowed the identification of one novel and 38 known endogenous neuropeptides in blue crab 
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(Callinectes sapidus) brain slices.121 The power of MSI lies in the ability to detect natural 
substrates and products with high sensitivity and specificity. The downside is that it is limited to 
ex vivo analyses.  
1.4.2  Sampling-based Techniques 
As previously stated, microdialysis is the most commonly used in vivo sampling technique 
and has been applied to the study of enzymatic activity in the ECS. Enzymatic studies using 
microdialysis usually involve introducing a substrate by retrodialysis. The substrate diffuses out 
of the probe, where it is hydrolyzed by ectopeptidases, and resulting products as well as 
unhydrolyzed substrate diffuse back to the probe. Alternatively, substrates can be centrally infused 
into the brain and products collected in a particular brain region using microdialysis. These 
approaches have been used to investigate Peptide E122, beta-endorphin123, dynorphin A124, 
angiotension II50, and substance P94 degradation in the rat striatum. Klintenberg and Andren 
extended this approach to find differences in dynorphin A metabolism in unilaterally 6-
hydroxydopamine lesioned rat striata.125  By lesioning one side of the brain and implanting probes 
bilaterally, the authors found lower levels of dynorphin A hydrolysis products in the lesioned side 
of the brain compared to the intact side, suggesting that dynorphin A metabolism is altered in 
Parkinson’s disease.125  
Though the majority of neuropeptide degradation studies are qualitative in nature, the 
Stenken group has attempted to develop models for quantifying enzyme activity using 
microdialysis.126-127 These studies have been performed in situ128-129 and in vivo130, though not in 
the brain. Substrates, in some cases isotope-labeled, are introduced to the tissue by retrodialysis.  
The concentration collected at the outlet of the probe is compared to that which was introduced at 
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the inlet. This relates to the extraction fraction (EF) of the probe and is a function of membrane 
properties, analyte mass transport through the probe and the medium, perfusion flow rate, and 
substrate uptake and degradative processes in the tissue.131 Changes in EF throughout an 
experiment were attributed to enzymatic activity.132 Though this metric was sensitive to changes 
in enzymatic activity in vitro and in situ, changes in microdialysis EF were not sensitive enough 
to detect changes in enzymatic activity in in vivo studies looking at glucose metabolism133 and 
MMP-1/9 activity134. The latter work suggested that this is because EF is more affected by analyte 
mass transport than enzymatic processes in vivo.131, 135-136  
The complex processes dictating analyte delivery to the tissue limit quantitation of 
enzymatic activity by microdialysis. Clearance mechanisms in the ECS change the concentration 
gradient external to the probe which changes the amount of substrate that is delivered to the 
tissue.131, 136-137 This requires long equilibration times to achieve steady-state.130 Treatments that 
block uptake or metabolic processes alter the concentration gradient, which could change the 
recovery of the probe.137 Thus, measurements made in the absence of inhibitor may not be directly 
related to those made with inhibitor treatment. Since enzymatic rates are concentration-dependent, 
many experiments are necessary to assess the effects of experimental factors such as probe 
geometry and flow rate and conclude that a change in EF is due to a biological process rather than 
some other form of mass transport.138 Even so, there is a narrow range of clearance rates that can 
be detected in this way. 131, 136 
Our group has developed a method for probing the extracellular space using electroosmotic 
perfusion, in which current is used to perfuse substrate peptides into the tissue, where they are 
hydrolyzed in the ECS by ectopeptidases.139-140 Hydrolysis products and unhydrolyzed substrate 
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are collected and analyzed to determine enzyme activity. Because the analyte residence time can 
be controlled by current, quantitative parameters of enzyme activity can be determined.  
1.4.2.1 Electroosmotic Perfusion-based Sampling 
Substrate peptide-containing solutions are perfused into the tissue via a fused silica 
capillary. Electroosmotic flow results from a current passing through the solution (Figure 1).141 
An uneven distribution of positive ions in the double layer move in the direction of the negative 
electrode, resulting in bulk fluid flow.141-142  
 
Figure 1 Schematic of the double layer that forms due to interactions between surface charges at the capillary 
wall and mobile ions in the electrolyte solution, resulting in bulk fluid flow when an electric field is applied.  
The electroosmotic flow rate (m3/s), Ueo, is dependent upon the applied current (A), i, as 
seen in Equation 1: 
Equation 1 
𝑈𝑈𝑒𝑒𝑒𝑒 =  −𝜀𝜀𝑤𝑤𝜁𝜁𝜂𝜂 𝑖𝑖𝜎𝜎𝑒𝑒𝑒𝑒   
 
where εw is the permittivity of water (F/m), η is the dynamic viscosity (Pa s), ζ is the potential at 
an imaginary plane between the fixed charges on the surface of the capillary and the solution (V), 
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and σel is the conductivity of the electrolyte solution (S/m).143 An analogous expression based on 
a modified Darcy’s law can be used to describe the superficial electroosmotic velocity (ueo) in a 
porous medium in the absence of a pressure gradient (Equation 2): 
Equation 2 
𝑢𝑢𝑒𝑒𝑒𝑒 =  𝜀𝜀𝑤𝑤𝜁𝜁𝜂𝜂 Δ𝑉𝑉𝐿𝐿   
 
where ∆V is the voltage-drop over a distance, L.144-146 Equation 2 demonstrates mathematically 
that the electroosmotic velocity can in fact be controlled using current.  
To compare EOP to pressure-driven methods such as push-pull perfusion, we can compare 
Equation 2 to Equation 3, the superficial velocity of a pressure-driven fluid, up, through a porous 
medium: 
Equation 3 
 𝑢𝑢𝑝𝑝 =  −Δ𝑃𝑃𝐿𝐿 𝜅𝜅𝜂𝜂  
 
where ∆P is the pressure-drop over and κ is the hydraulic permeability of the medium, which is 
approximately 10-15 m2 in the gray matter147 of the brain. At constant current, electroosmotic flow 
is not dependent upon the permeability of the tissue148, which varies throughout the brain147. This 
means that electroosmotic flow is more uniform in a heterogenous medium whereas pressure-
driven flow will favor flow through tissue that has lower permeabilities, such as white matter.149 
This quality gives electroosmotic flow an advantage over pressure-driven flow for measuring 
ectopeptidase activity.  
Xu, et al. first reported the use of electroosmotic sampling in a study of leucine-enkephalin 
(LE, YGGFL) degradation in OHSCs.139 A tissue culture was placed on an insert membrane in 
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contact with a bath consisting of a solution of LE and an internal standard yaGfl, where lowercase 
letters denote a D-amino acid. The internal standard is resistant to hydrolysis and serves as a 
measure of the substrate concentration in the absence of hydrolysis. A 150 µm ID x 30 cm long 
capillary was placed on the surface of the tissue in the CA3 region of the hippocampus, with its 
distal end in contact with an electrolyte solution in which a platinum electrode was immersed. A 
second platinum electrode was placed in the tissue bath to complete the circuit. When an electric 
field was applied, electroosmotic flow drove peptides from the bath, through the tissue, and into 
the collection capillary. The contents of the collection capillary were then ejected into a vial and 
analyzed using HPLC-EC. By measuring hydrolysis in the presence of multiple inhibitors, it was 
determined that a bestatin-sensitive aminopeptidase is primarily responsible for LE degradation to 
GGFL in the ECS of the hippocampal CA3 region. It was also reported that the Michaelis Menten 
constant, Km, for LE conversion to GGFL was 1.2 ± 0.5 mM, which was consistent with other 
literature reports. This work was the first to determine Michaelis Menten parameters based on live 
tissue measurements. Wu, et al. later used a similar approach to quantify coenzyme A degradation 
in the ECS of OHSCs using with online capillary electrophoresis – laser induced fluorescence.150   
In single-probe electroosmotic perfusion studies the spatial resolution is largely dictated 
by the inner diameter of the collection capillary. The perfusion volume of the peptide is also not 
easily controlled. For these reasons, Rupert, et al. developed a two-probe electroosmotic push-pull 
perfusion (EOPPP) technique.140 With EOPPP, peptide substrates were perfused using a pulled-
tip source capillary (“push”) and hydrolysis products and unhydrolyzed substrate were collected 
using the collection capillary (“pull”). The advantage of this technique is that the spatial resolution 
is dependent upon the distance between the two probes (40-100 µm). This allowed comparison of 
galanin hydrolysis between two regions within the hippocampus, the CA1 and the CA3.140 This 
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method also provided quantitative evidence that LE degradation is higher in the CA1 region 
compared to the CA3, which may contribute to higher instances of cell death in the CA1 during 
oxygen-glucose deprivation (OGD), an ex vivo model for ischemia.148, 151 It was also shown that 
administration of bestatin following OGD statistically reduced cell death in the CA1. This work 
demonstrates the importance of performing quantitative measurements of ectopeptidase activity in 
a spatially-resolved manner in order to understand the mechanisms of peptide modulation.   
The ex vivo work described here represents a major technological stride in studying 
ectopeptidases in brain tissue. The next logical step for improving the versatility of this technique 
is to adapt it for in vivo use. This dissertation describes the steps we have taken to develop a method 
for in vivo ectopeptidase activity measurements in the anesthetized rat. Our approach was to first 
develop novel focusing techniques for enhancing sensitivity of peptide detection with cLC152, then 
to apply proteomics-based strategies for peptide quantitation to the online detection of endogenous 
neuropeptides97, and finally to design and fabricate a device capable of performing electroosmotic 
perfusion in vivo. Though this method can be used to study virtually any ectopeptidase in the ECS, 
our emphasis is on its application to the study of IRAP activity and potential substrates.  
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2.0 Improving the Sensitivity, Resolution, and Peak Capacity of Gradient Elution in 
Capillary Liquid Chromatography with Large-Volume Injections by Using Temperature-
Assisted On-column Solute Focusing 
Reprinted with permission from Analytical Chemistry 2016, 88, 5112-5121. Copyright (2016) 
American Chemical Society. 
 
 Capillary HPLC (cLC) with gradient elution is the separation method of choice for the 
fields of proteomics and metabolomics. This is due to the complementary nature of cLC flow rates 
and electrospray or nanospray ionization mass spectrometry (ESI-MS). The small column 
diameters result in good mass sensitivity. Good concentration sensitivity is also possible by 
injection of relatively large volumes of solution and relying on solvent-based solute focusing. 
However, if the injection volume is too large or solutes are poorly retained during injection, 
volume overload occurs which leads to altered peak shapes, decreased sensitivity and lower peak 
capacity. Solutes that elute early even with the use of a solvent gradient are especially vulnerable 
to this problem. In this paper we describe a simple, automated instrumental method, Temperature-
Assisted On-column Solute Focusing (TASF), that is capable of focusing large volume injections 
of small molecules and peptides under gradient conditions. By injecting a large sample volume 
while cooling a short segment of the column inlet at sub-ambient temperatures, solutes are 
concentrated into narrow bands at the head of the column. Rapidly raising the temperature of this 
segment of the column leads to separations with less peak broadening in comparison to solvent 
focusing alone.  For large volume injections of both mixtures of small molecules and a bovine 
serum albumin tryptic digest, TASF improved the peak shape and resolution in chromatograms. 
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TASF showed the most dramatic improvements with shallow gradients, which is particularly 
useful for biological applications. Results demonstrate the ability of TASF with gradient elution 
to improve the sensitivity, resolution, and peak capacity of volume overloaded samples beyond 
gradient compression alone. Additionally, we have developed and validated a double extrapolation 
method for predicting retention factors at extremes of temperature and mobile phase composition. 
Using this method, the effects of TASF can be predicted, allowing determination of the usefulness 
of this technique for a particular application.  
2.1 Introduction 
 With the advent of electrospray ionization mass spectrometry (ESI-MS), capillary HPLC 
(cLC) has become a widely used separation method. Due to reduced volumetric flow rates and 
increased ionization efficiency, cLC couples particularly well with ESI-MS.82, 153-155 This has led 
to cLC’s dominance in the fields of proteomics156-161, metabolomics,155, 158, 162-167 and in vivo 
determination of neuropeptides.168-172 Combined with gradient elution, peak capacities exceeding 
800173-174 have been achieved. In their work with ultra-high-pressure cLC, Shen et al. were able to 
identify over 2000 peptides and 5000 metabolites using tandem MS for detection.174 High 
sensitivity with small volume samples is particularly important as interest in developing cLC for 
clinical use is growing,163, 175-179 with some recent methods achieving full or partial FDA 
validation.82 Of course, the increased concentration sensitivity of cLC systems82, 154, 165, 180-186 can 
be advantageously applied to any analysis based on small volume samples.  
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 A disadvantage accompanying the use of small diameter columns is the potential for 
volume overload, the situation in which the injection volume is large enough to alter a solute’s 
peak shape.154, 187-190 While a solvent gradient/reversed phase cLC system may not be highly 
susceptible to volume overload for the more hydrophobic solutes, the more polar solutes still can 
suffer from broadening due to volume overload.187, 189 Of course, which solutes in a sample fall 
into the “more polar” class and suffer volume overload and which fall into the “more hydrophobic” 
class and do not depends on the injection volume and the particular chromatographic conditions.89, 
187, 189, 191 Volume overload decreases the overall peak capacity and sensitivity of the method.187, 
189-190, 192 Manipulating the gradient to avoid having solutes in the early eluting, “more polar” class 
flies in the face of gradient optimization188, 193-195 which attempts to use all of the peak capacity 
available in the specified separation time. What is needed is a general approach for focusing large-
volume injections (>100% of the column volume) that allows an analytical method to take 
advantage of the full peak capacity of the gradient system and sensitivity of a capillary scale 
column.   
 Due to low thermal mass and thin silica walls, rapid heating and cooling of cLC columns 
is possible without increasing bandspreading from radial thermal gradients.196-197 Additionally, 
elevated temperature is effective in improving the efficiency of capillary columns.198 However, 
elevated temperatures also add to the challenge of managing large volume injections because 
increasing temperature typically decreases retention making volume overload more of a problem.  
Since retention in LC is temperature dependent, transient temperature changes can be used to alter 
retention factors in chromatographically useful ways.199-203 Solute trapping using sub-ambient 
temperatures has been explored. Holm, et al., developed a capillary column oven in which the 
column was placed on a “cold zone” held at 0 °C during injection then manually moved in space 
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to a “hot zone” for the separation phase. Using this approach, the authors were able to minimize 
peak widths of large-volume injections of the antioxidant Irganox 1076 (clog P 13.9)204 in a neat 
acetonitrile mobile phase.205 Eghbali, et al., used dry ice and boiling water to cool/heat circulating 
nitrogen gas, allowing focusing of the protein lysozyme at -20 °C near the end of the column.206 
While each work demonstrated the effectiveness of temperature focusing, the former involved very 
hydrophobic solutes and the authors of the latter work doubted the usefulness of their approach for 
small molecules.206 Additionally, neither approach was automated which limits throughput and 
threatens irreproducibility.  
 We have previously shown that temperature-assisted solute focusing (TASF) is effective 
in improving volume-overloaded isocratic separations of hydroxybenzoate esters beyond that 
achieved with solvent focusing alone.207-208 With TASF the head of the column is cooled to sub-
ambient temperatures during injection. This results in focusing of solutes into narrow bands at the 
head of the column. Subsequently raising the temperature increases solute velocity to achieve a 
separation in a reasonable time. However, previous TASF studies were done using small molecules 
and under isocratic conditions and with a simple approach to controlling temperature. In this paper 
we demonstrate that our fully automated TASF apparatus used with reversed-phase LC (RPLC) is 
a practical method for focusing large volume injections of both small molecules (values of log P 
(or clog P) range from 1.16 to 4.75)209-210 and peptides and can also focus solute bands beyond 
gradient compression alone. In order to be able to simulate or predict the outcome of a TASF-
enhanced separation, values of both very high and very low retention factors, k’, are needed. We 
developed and validated a double extrapolation procedure based on an equation by Neue and 
Kuss211 and the van ‘t Hoff relationship for obtaining such k’ values. 
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2.2 Experimental 
2.2.1  Reagents and Solutions 
 Uracil, acetanilide, methyl and ethyl esters of p-hydroxybenzoic acid (parabens), 
acetophenone, propiophenone, butyrophenone, benzophenone, valerophenone, hexanophenone, 
heptanophenone, and octanophenone were from Sigma-Aldrich (St. Louis, MO). Stock solutions, 
25 mM, were made in acetonitrile (Chromsolv, LC-MS grad, Fisher Scientific, Fair Lawn NJ. 
Samples were diluted to concentrations from 5 to 20 μM with deionized water. Sample 
concentrations were selected to maximize concentration while factoring in column loadability and 
solubility. Water was from a Millipore Milli-Q Synthesis A10 purification system (Billerica, MA). 
Peptide samples were from an LC-MS grade BSA tryptic digest from Fisher. The lyophilized 
sample was diluted, as per reagent instructions, to 1 pmol/μL in 95:5 0.1% formic acid: acetonitrile. 
Formic acid was from Sigma. The BSA sample was stored at -5 °C when not in use and used within 
48 hours of thawing/dilution. 
2.2.2  Instrumentation 
 A Thermo/Dionex UltiMate 3000 Nano LC (NCS-3500RS, Germering, Germany) system 
consisting of a nanoflow pump, a low-pressure loading pump, integrated column oven, and WPS-
3000RS autosampler was used for this work. Autosampler temperature was set to 35 °C for small 
molecule work (to increase sample solubility) and 5 °C for BSA samples. Detection was achieved 
by a Waters Acquity TUV detector (Millford, MA) fitted with a 10 nL flow cell. Signal from the 
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detector was interfaced with an external Thermo analog-to-digital converter. Acquisition rate was 
100 Hz. The system was controlled by Chromeleon software (version 6.8).  
2.2.3  TASF Hardware 
 Hardware for this system is similar to that used previously.208 Briefly, timed injections 
were made using an external 6-port Cheminert injection valve (C72x-669D, VICI Valco, Houston, 
TX) fitted with a 75 µm x 75 cm nanoViper capillary (Thermo) loop. Samples were loaded into 
the sample loop using the loading pump and autosampler of the NSC-3500 system. Focusing 
segment temperature was controlled by a 1.0 x 1.0 cm Peltier thermoelectric device (TEC, Custom 
Thermoelectric, 04801-rG30-34RB, Bishopville, MD). To improve heat transfer between the TEC 
and heat sink compared to our previous system, the TEC was silver soldered to a custom liquid 
cooled copper heat sink. Heat sink temperature was regulated using a HAAKE A80 temperature 
controlled cooler (Thermo, Paramus, NJ) pumping an ethylene glycol/water mixture at about 1 
L/min. The TEC was powered by a MAXIM Integrated 1968 electronic TEC driver (Sunnyvale, 
CA). Temperature was monitored by a 36-gage type-T thermocouple from Omega Engineering 
(Stamford, CT) interfaced with a National Instruments 9211 4-channel thermocouple module 
(Austin, TX). TEC temperature was logged at 7 Hz and controlled using a simple feedback loop 
written in LabVIEW 2015 (NI). TEC control, remote start, and valve injection signals were made 
by a USB-6008 multifunction DAQ (NI). The downstream, isothermal segment of the column was 
heated resistively using a Kapton resistive heater (KH-106-10-P, Omega) and a Love Model 1500 
proportional-integral-derivative (PID) controller (Dwyer Instruments, Michigan City, IN) as 
described previously.212  
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2.2.4  TASF Control 
 Temperature transients must be fast to ensure efficient release of focused bands as well as 
precisely controlled to ensure reproducibility and minimize temperature over- and undershoot. To 
achieve this, a commercially available electronic TEC driver was used to run a high power, low 
thermal mass TEC with control software written in-house. A simple feedback loop-based routine 
was developed in LabVIEW to control the driver. At the beginning of a day, the software “learns” 
the relationship between temperature and control voltage. This is achieved by setting an arbitrary 
temperature in the software for which the driver establishes a voltage to maintain that temperature 
at the TEC (±0.05 °C). Temperature measurements and voltage adjustments are made at 7 Hz. The 
program stores the maximum and minimum voltages required to reach the separation and focusing 
temperatures, respectively. In operation, a LabVIEW program initiates a temperature change at a 
programmed time. When the target temperature is raised, it applies a control voltage corresponding 
to a temperature that is a few degrees below the target. Then a feedback loop takes over. Based 
upon ∆T, the difference between the measured and target temperatures, the program increases the 
control voltage, in steps that can be defined by the user, to approach the target temperature. The 
steps become smaller as ∆T becomes smaller. When ∆T changes sign, so does the control voltage 
steps. For cooling, the process is analogous. By adjusting the voltage step size for a particular 
range of values of ∆T, the approach to the final voltage can be made more aggressive with a slight 
overshoot or gentler with no overshoot. While not a proportional-integral-derivative (PID) control 
algorithm, this program mimics a PID result and works equally well in the heating and cooling 
modes without the need for separate PID parameters in each operational mode.   
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2.2.5  Chromatographic Conditions 
 5 μL of each sample were delivered from the autosampler to the valve by the loading pump, 
which served to fill the 1 μL sample loop. A one-minute delay between autosampler injection and 
valve injection was employed to ensure the injection plug was centered in the sample loop. 
2.2.6  Column Preparation  
 Columns were packed in-house following a previously developed method.207-208 Briefly, 
100 μm fused silica capillaries from Polymicro Technologies (Phoenix, AZ) were packed with 
Acquity CSH C18 1.7 μm particles (Waters). Column length, 14.2 cm, was controlled by defining 
the volume of slurry in the column packing bomb. Following packing with stationary phase the 
remainder of the capillary blank was packed with 8 μm solid silica spheres (Thermo). Column 
length was trimmed to a final length of 16.7 cm. We refer to these dual-phase columns as ‘packed-
void’ columns. The column fluid volume, not including the packed-void segment, was estimated 
at 683 nL. A 5.0 cm x 100 μm, single-phase column was used for solute retention studies.  
2.2.7  van`t Hoff Retention Studies 
 Temperature was controlled by the column oven of the Ultimate 3000 system. Extra-
column time was determined to be 0.35 minutes by making 50 nL timed injections into the 25 μm 
ID detection capillary. Isocratic runs were performed for each solute under at least 4 different 
mobile phase compositions and 5 temperatures between 30 and 65 °C. See Table 1 (SI) for exact 
conditions used for each solute. The minimum temperature of 30 °C was dictated by the column 
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oven’s lack of cooling capabilities. The order of temperatures was randomized and at least one 
hour of equilibration time was given between temperature changes to ensure temperature stability. 
Detection conditions were identical to those described above. 
2.2.8  TASF Conditions 
 For TASF experiments the focusing temperature was -7.5 °C and the separation 
temperature was 65 °C. The temperature range was dictated by the maximum achievable by the 
TEC under experimental conditions. The lower temperature was the minimum practical based on 
our pump’s maximum pressure and issues related to condensation at the TEC surface. The focusing 
temperature was held during the time of injection plus an additional 5 seconds. The column was 
equilibrated at the initial conditions for 5 minutes prior to the start of each run. The TEC was held 
at the focusing temperature for 1 minute prior to injection. Thus, the gradient time was coordinated 
to begin at the start of injection. After focusing, the temperature was raised quickly to the 
separation temperature and remained there for the remainder of the run. All runs were performed 
a minimum of three times. 
2.2.9  Chromatography 
 Timed injections of solutions of small organic molecules (20 μM acetanilide, 15 μM 
acetophenone, 5 μM hexano- to octanophenone, and 7 μM benzophenone) from the 1 μL loop 
served to introduce samples. The volume of injection is deduced from the injection time and the 
flow rate, 1.00 μL/min. The initial gradient used consisted of 5-75% ACN over 12 minutes (5.8% 
ACN/min). UV absorbance was measured at 254 nm. Additional runs performed to create a variety 
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of gradient steepness were: 14.2% ACN/min and 2.7% ACN/min. To determine the usefulness of 
TASF with different injection volumes, the small molecule mixture described previously was 
injected at volumes of 50, 150, 250, 500, and 1000 nL. To maintain detectable signals, solute 
concentrations were increased accordingly. For this study, the gradient conditions were 5 to 75% 
ACN over 12 minutes. 
 For peptide experiments, 2 μL of the BSA sample were injected using an overfilled-loop. 
Gradient conditions were 5-40% ACN over 15 minutes with a flow rate of 1.00 μL/min. The 
separation temperature was 65 °C and the focusing temperature was -7.5 °C. The focusing 
temperature was held for 125 seconds. UV absorbance was measured at 214 nm. 
 All chromatograms were analyzed using a simple peak finding, integration and 
characterization program written in-house in MATLAB R2015a (MathWorks, Matick, MA).  
2.3 Results and Discussion 
2.3.1  Theory 
 A brief review of the dominant contributions to peak broadening when considering volume 
overload will explain conceptually how TASF works. Observed peak variance in time units, σt,obs, 
is dominated by independent broadening processes occurring before, during, and after separation 
on the column.213  
Equation 4  
σt, obs
2 = σt, pre2  + σt,  col2  + σt, post2   
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Since post-column dispersion, σt,post, can be considered small with appropriate detection under both 
TASF and isothermal conditions it is not considered further.  
Equation 5 
σt, obs
2  ≈  σt, pre 2 + σt,  col2    
 
In volume overload, the variance due to the injection volume dominates the precolumn 
contribution. Thus, the injection variance is dependent on both injection volume, Vinj, and column 
characteristics, including radius, rc, as seen in Equation 6.  
Equation 6 
σt, pre
2 ≈ σ
𝑡𝑡,   𝑖𝑖𝑖𝑖𝑖𝑖2  = � Vinj√12π rc2 εTot (1 + k1)�2 �1 + keffuav �2  
 
εTot represents the total porosity of the column. The retention factor during injection, k1, and keff, 
the effective retention factor at elution as defined by Snyder and Dolan,214 are temperature-
dependent terms; 𝑢𝑢𝑎𝑎𝑎𝑎 is the average linear velocity, which converts length units to time units.  
According to Equation 6, injection variance is largely dependent on the k1 term and because this 
term is in the denominator, small values of k1 result in larger values of σinj. TASF acts by lowering 
the temperature at the head of the column thus increasing k1 and decreasing broadening due to 
injection.192 This effect is most obvious for compounds that have relatively small retention factors 
at the column temperature. 
 Peak width in gradient elution is determined by way of Equation 7, which is based on linear 
solvent strength theory (LSST).214 
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Equation 7 
σt, col
2  = 𝑡𝑡0
√𝑁𝑁
 G(p) (1 + keff)  
 
where t0 is the dead time of the column and G(p) is the gradient compression factor. This factor, 
which is dependent on gradient steepness, represents the compression of the solute band on the 
column. It arises because the velocity of the solute front is lower than that of the rear.214 TASF 
takes advantage of the temperature dependence of retention factors to minimize injection variance 
whereas gradients partially reverse the effects of column band spreading, reducing the column 
variance. Thus, the actions of TASF and gradients are independent of one another and can be used 
in conjunction to minimize observed peak broadening.200  
2.3.2  Determination of Retention Factors at Extremes of Temperature and Mobile Phase 
Composition  
 In order to predict the effect of TASF, k1, must be known accurately. As described above, 
TASF will employ temperatures of -7.5 oC and 65 oC. Determining k1 for the more hydrophobic 
solutes at the former temperature and the more hydrophilic solutes at the latter temperature is 
challenging. While others have predicted retention factors at sub-ambient temperatures by 
extrapolation of linear van’t Hoff plots206, to our knowledge no prior studies have examined 
models for extrapolation of retention as a function of temperature and mobile phase composition. 
Thus, we sought a reliable method to extrapolate k1 data obtained under more reasonable 
conditions to our extreme conditions.  
 Extrapolation requires a mathematical model for retention. Three models were considered, 
namely, LSST214 (Eq. 8) and two equations from Neue and Kuss (Eq. 9, 10).211 
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Equation 8 
ln k = ln k0(𝑇𝑇) – S(𝑇𝑇)ϕ  
  
Equation 9 
ln k = ln k0(𝑇𝑇) + 2 ln(1 + a(T) ϕ) - S(𝑇𝑇) ϕ1 + a(T) ϕ  
 
Equation 10 
ln k = ln k0 +
𝐷𝐷
𝑇𝑇
 + 2 ln(1 + a ϕ) - (1 + 𝐷𝐷
𝑇𝑇
) S
1 + a ϕ
  
 
Eqs. 8 and 9 are used at a given temperature, T (K), while Eq. 10 includes a temperature 
dependence. For each equation, k0 or k0(T) is the retention factor in pure water and S and S(T) 
describe the relationship between solute retention and 𝜙𝜙. S(T) and k0(T) are constants in Eqs. 8 and 
9 for a given temperature, T, but vary with temperature. S and k0 in Eq. 7 are constants.211 In 
Equations 9 and 10, a and a(T) account for curvature in the relationship between ln k and 𝜙𝜙, D 
reflects temperature effects.   
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Figure 2 Illustration of k1 determination process for hexanophenone. Figure 2A consists of experimental data 
obtained using the conditions described in the Experimental section. A single extrapolation based on Eq. 9 is 
shown. Figure 2B plots data found as shown in Figure 2A vs. 1/T and extrapolated to – 7.5 oC. 
 
As Eqs. 8 and 9 have temperature-dependent constants, a two-step extrapolation was carried out. 
Figure 1 shows the basic idea. We first determined k’ values for each solute at a minimum of five 
temperatures and four solvent compositions that led to a wide range of measureable values (~1 < 
k’ < 35). These data form the basis for extrapolation [Table 1 (SI)]. As shown in Figure 2A, values 
of k’ for a single temperature and a range of values of 𝜙𝜙 were used in a curve fitting procedure to 
determine the temperature-dependent constants in Eqs. 8 and 9. These values were used to 
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extrapolate to the lowest solvent strength, 𝜙𝜙 = 0.05. Figure 2A shows the fits of Eq. 9 for 
hexanophenone and the extrapolation for one temperature, the dashed line. This procedure was 
repeated for each temperature. The result is a set of (extrapolated) values for k’ as a function of 
temperature at 𝜙𝜙 = 0.05. The second step is to plot these extrapolated values vs 1/T to determine 
the retention enthalpy at the lowest solvent strength, 𝜙𝜙 = 0.05, and further to extrapolate this van 
‘t Hoff plot to the focusing temperature, -7.5 oC (Figure 2B). For Equation 8, ln k0 and S were 
determined at each temperature using linear regression. For Equation 9, the Solver function of 
Excel was used to determine the constants at each temperature by minimizing the sum of squared 
residuals between experimental and calculated values at each 𝜙𝜙. Equation 10 was used differently. 
Solver was used to determine the constants for a single solute (e.g., all of the the points in Figure 
1A) and k’ was calculated by extrapolation to T = -7.5 °C. and 𝜙𝜙 = 0.05. The analogous procedures 
were used for some solutes to get k’ for T = 65 °C. and 𝜙𝜙 = 0.05. 
 The accuracy of each model was determined using two methods. First, for those solutes for 
which experimental data could be obtained at 𝜙𝜙 = 0.05, the processes described above were carried 
out without using the data at 𝜙𝜙 = 0.05. van ‘t Hoff plots based on experimental k’ values and the 
three sets of extrapolated values were compared [Figure 14 (SI)]. The model with the closest slope 
to the experimental data was considered to be most accurate. This turns out to be Eq. 9.  
 The second method was to compare the methylene group selectivity, 𝛼𝛼𝐶𝐶𝐶𝐶2, from 
extrapolated k’ values to a known value. While literature on methylene selectivity at these 
particular conditions is not readily available, ln (𝛼𝛼𝐶𝐶𝐶𝐶2) in pure water has been reported on four 
C18 phases at slightly different temperatures near room temperature.215 Based on these data, at an 
average temperature of 26.8 ± 2.0 °C ln (𝛼𝛼𝐶𝐶𝐶𝐶2) is 1.39 ± 0.01.215 Fortuitously, under our 
experimental conditions (𝜙𝜙 = 0.05 and -7.5 °C), the solvent strength is similar to water at room 
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temperature. This is because a decrease of 5 °C increases retention to about the same extent as a 
1% increase in acetonitrile composition decreases retention.216 Thus, the solvent strength in a water 
mobile phase near room temperature would remain about the same if we decreased the temperature 
from 26.8 °C to -7.5 °C and made the mobile phase composition 6.9% ACN (ΔT/ 5). This is similar 
to our sample composition at the lower temperature (5.0% ACN). Thus, we determined slopes of 
a plot of calculated ln k versus the number of methylene groups at 𝜙𝜙 = 0.05 and -7.5 °C for the 
straight-chain phenones [Figure 15 (SI)]. These slopes are 𝛼𝛼𝐶𝐶𝐶𝐶2 . Its value was 1.33 when using Eq. 
9 to calculate k’ values. Values from the other two equations were very different [Figure 15 A, C 
(SI)]. Both of our validation methods point to the accuracy of Eq. 9 so retention data extrapolated 
using Eq. 9 were used for subsequent calculations. 
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2.3.3  Small Molecule Studies 
 
Figure 3 Chromatograms of 1000 nL injections of a small molecule mixture under isothermal (black line) and 
TASF (blue line) conditions with a gradient of 5-75% ACN over 12 minutes. Panel A illustrates all the solutes 
of the mixture whereas Panel B shows the early eluting peaks in more detail. The solutes in order of elution 
are: acetanilide, methylparaben, acetophenone, ethylparaben, propiophenone, butyrophenone, benzophenone, 
valerophenone, hexanophenone, heptanophenone, and octanophenone. Figures are representative of n = 3 
replicates.   
 
 The utility of TASF for small molecules is illustrated in Figure 3, in which a chromatogram 
from a large-volume injection of a mixture of small molecules is dramatically improved compared 
to the isothermal separation (Figure 3A). This improvement is especially evident in Figure 3B, 
which shows the first seven peaks in greater detail. Volume overload is visually evident from the 
greater peak width of the first six peaks without TASF. This is consistent with what is expected 
based on Equation 6. The remainder of the separation is virtually identical to the isothermal results 
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as evident in Figure 3A. Figure 4 quantitatively illustrates the effectiveness of TASF for each peak 
in the chromatogram shown in Figure 2. For example, TASF decreases the full width at half-
maximum, FWHM, of the acetanilide peak by a factor of 4.5 despite a low k’ (k1,isothermal = 5.46, 
k1,TASF = 21.3) at the start of the gradient. Thus, TASF reduces volume overload but there is no 
degradation of peak shape for well-retained solutes. Decreased peak width for early eluting solutes 
provides more useable chromatographic space and thus higher peak capacities. By integrating the 
area under 1/w between the first and the last solute retention times194 [Figure 16C (SI)], the peak 
capacity under TASF conditions was found to be 85 as compared to 70 for isothermal conditions. 
By improving peak width and resolution in the first 7.5 minutes of the separation, considerably 
more room is made for the detection of other polar compounds that may not be otherwise resolved.  
 
 
Figure 4 Relative FWHM (FWHM/ FWHMTASF) for isothermal (black dots) and TASF (blue dots) separations 
based on the chromatograms depicted in Figure 3. 
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2.3.4  Injection Volume Studies 
 It is clear that TASF improves chromatography with large-volume injections but to 
determine the point at which TASF is no longer essential in gradient elution for a given injection 
volume, k1, and keff, a range of injection volumes and resulting half-widths were compared. 
Experimental results for first and third peaks of the mixture can be found in Figures 5A and 5B, 
respectively. Both acetanilide and acetophenone showed considerable improvement in peak width 
for a range of large volume injections. For acetophenone overloading effects were no longer 
apparent at injection volumes below 250 nL. At this point, the observed variance is dominated by 
column variance alone and minimal broadening due to injection is seen. However, with TASF, 
injection variance is almost completely eliminated, allowing observed widths of even 1000 nL 
injections to be at or less than peak widths of 50 nL injections (within 10%). A 10% loss of 
efficiency, as indicated by the red dashed line, is tolerable given the benefits of injecting large 
volumes. Using Equations 5 and 6, these results are modeled reasonably well (Figures 5C, D), 
illustrating the ability to predict the usefulness of TASF under particular conditions. 
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Figure 5 Experimental and predicted peak widths under isothermal (black dots) and TASF (blue dots) 
conditions for injection volumes ranging from 50-1000 nL. Panels A and B are the experimental values for 
acetanilide and acetophenone, respectively and Panels C and D are the calculated values for acetanilide and 
acetophenone, respectively found using Equations 6 and 7 and based on experimental conditions. The red 
dashed line indicates 10% greater peak width than that measured at the 50 nL injection volume. Calculations 
are based on n = 3 replicates at each condition. 
2.3.5  Gradient Slope Studies 
 Gradient compression, G(p), narrows solute zones due to increasing solvent strength, 
resulting in decreased peak widths.187, 214 The gradient compression effect is dependent on the 
slope of the gradient, b, which can be calculated using the LSST parameter, S, the difference 
between the initial and final mobile phase composition, Δ𝜙𝜙, and the duration of the gradient, tg.214  
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Equation 11 
G(p) = � 1+ p + p23 �   0.5
1 + p
 
 
Equation 12 
p = k1 b
(1 + k1)
  
 
Equation 13 
b =  S Δϕ t0
tg
  
 
It is of interest to determine the effects of TASF with changing gradient slope. This was examined 
by varying the tg and final 𝜙𝜙, resulting in gradient slopes of 0.2 (tg = 24 min., ϕf = 0.7), 0.5 (tg = 
12 min., ϕf = 0.75), and 1.1 (tg = 6 min., ϕf = 0.9). It is clear in Figure 6 that TASF focuses more 
polar solutes beyond gradient compression in each scenario. Furthermore, this effect is greatest for 
the shallowest gradient slope, as seen in Figure 7. Based on Equation 9, steep gradient slopes and 
small k1 values result in highest solvent-based gradient compression.214 Therefore, TASF has the 
greatest impact when used with a shallow gradient, which is pertinent to the separation of complex 
mixtures since these mixtures are commonly analyzed using long, shallow gradients.217 This is 
consistent with peptide studies using end-of-the-column focusing, wherein solute trapping time 
was highest for long gradients.206 While the greatest advantage of TASF is realized with the 
shallowest gradient, there is still considerable decrease in peak width for polar solutes with the 
steepest gradient. This demonstrates the ability of TASF to focus beyond what can be achieved 
with gradient compression alone due to the complimentary nature of these focusing techniques.   
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Figure 6 Chromatograms of a 1000 nL injection of the small molecule mixture under isothermal (black line) 
and TASF (blue line) conditions with varying gradient steepness. A: 5-90% ACN over 6 minutes (14.2% ACN/ 
min.). B: 5-75% ACN over 12 minutes (5.8% ACN/ min.). C: 5-70% over 24 minutes (2.7% ACN/ min.). 
Chromatograms are representative of n = 3 replicates. 
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Figure 7 Comparison of relative peak widths (FWHMiso / FWHMTASF) at varying gradient steepness depicted 
in Figure 5. The green dots indicate the 14.2% ACN/ min. gradient, blue dots indicate the 5.8% ACN/ min. 
gradient, and red dots indicate the 2.7% ACN/ min. gradient. The black dashed line indicates FWHMTASF/ 
FWHMTASF. 
2.3.6  Predictability 
 Rearrangement of Equations 2 and 3 models the influence of TASF with gradient elution, 
which can be used to predict experimental results and determine the critical values that characterize 
the usefulness of this technique.  
Equation 14 
k1 = 
1
�γ2 - 1
 � Vinj
√12 π r c2εTot
� �
(1 + ke)
uav σcol,t
�  - 1  
 
Equation 15 
k1 = 
1
�γ2 - 1
 � Vinj
Vcol σcol,l
�  - 1  
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Replacing the denominator of the first bracketed term with its physical definition of the column 
volume, Vcol, and substitution of the second bracketed term with the inverse of the column 
broadening term in length units, 𝜎𝜎col,l, leads to Eq. 15. The square of the ratio of the column length, 
L, and the latter quantity is the number of theoretical plates, N. This leads to Equation 16 where 
we indicate that N is an “observed” quantity, in this case including gradient compression.  
Equation 16 
k1 = 
1
�γ2 - 1
Vinj Nobs1 2⁄
Vcol √12  - 1  
 
γ represents a tolerance term, indicating the acceptable increase in peak width one is willing to 
tolerate in making large-volume injections. Although the definition of N in terms of a peak width 
in units of time in gradient elution differs from that in isocratic elution,214 in units of length on 
column, they are the same. Equation 16 can be used easily to estimate the potential effectiveness 
of TASF for a particular separation. Using Equation 16 it was determined that the minimum k1 
required to achieve an observed variance equal to 1.1 times the column variance (𝛾𝛾 = 1.1) with a 
1000 nL injection is 170. This is consistent with the experimental results seen in Figure 3. For 
reference, the predicted k1 under TASF conditions for acetanilide is 21.3, acetophenone is 59.8, 
and propiophenone is 410. Those solutes with k1 < 170 show dramatic improvement in peak width 
with TASF while the peaks with k1 > 170 had widths that are relatively close under TASF and 
isothermal conditions.  
 Eq. 16 can be rearranged to show the largest injection volume that can be used under given 
conditions, Eq. 17. 
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Equation 17 
Vinj
Vcol 
 = 
(k1+1)�12�γ2 - 1�
�Nobs
          
 
Here it can be clearly seen that the effect of gradient compression as expressed in Nobs is to increase 
the allowable volume injected. Using Equations 7 and 17, the combined effects of gradient elution 
and TASF can be reasonably estimated, allowing prediction of TASF utility for a particular solute 
prior to experimentation. 
2.3.7  Peptide Mixture Studies 
 In general the effect of changing 𝜙𝜙 on retention is more dramatic for larger molecular 
weight solutes such as peptides, resulting in greater gradient compression.187  We have shown that 
TASF is able to focus large injections of small molecules beyond gradient compression alone so 
it seems reasonable that biological samples could also benefit from this effect. Indeed, Eghbali et 
al. focused targeted proteins at the end of the column by lowering the temperature of the end of 
the column during select portions of a gradient elution run.206 Figure 8A shows chromatograms of 
a BSA tryptic digest from injections of over 290% of the column volume, 2 μL. Focusing time was 
increased to 125 s to accommodate the additional injection time. With TASF, peak shapes for early 
eluting solutes are significantly improved as is resolution, particularly up to the 6-minute mark. 
Most noticeable are the four additional peaks detected between 3.5 and 4.5 minutes. We can infer 
the effect of TASF by considering the total peak area over time, shown in Figure 7. From 6 min to 
the end of the chromatogram, the areas of the two chromatograms are virtually identical. This is 
consistent with TASF having little influence over solute behavior for those solutes that would have 
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focused effectively without TASF. In the earliest part of the chromatogram following the injection 
transient, the areas of the two chromatograms have different trajectories. The isothermal trace 
increases rapidly near 3.5 min as poorly retained solutes elute. This shows that while early eluting 
solutes are detected, they are not resolved. Conversely, with TASF, there is a slow, stepwise 
increase in area corresponding to the well-resolved peaks in the 4-6 minute region. This highlights 
the ability to resolve early eluting solute peaks using TASF that were otherwise.   
 The appearance of the additional unknown early eluting peaks and improvement in peak 
shape for multiple solutes highlights the benefit of placing the focusing segment at the column 
inlet. In this configuration the approach is general, applicable to all solutes in the mixture with 
negative retention enthalpies not just beneficial for a few specific solutes in select regions of the 
chromatogram. This feature has obvious implications for the determination of multiple solutes in 
complex mixtures where elution times for target analytes may not accommodate multiple focusing, 
release and thermal re-equilibrations of the focusing segment. 
 In the example just described, the sample was prepared in 5% acetonitrile to facilitate 
dissolution of the peptides but this limits solvent focusing. Biological samples are often prepared 
in pure aqueous solvents, which improves solvent focusing but may exclude less soluble peptides 
from detection. TASF could therefore be useful when the sample must contain some organic 
solvent by providing additional focusing without sacrificing solubility.  
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Figure 8 Separation of a 2 μL injection of BSA tryptic digest under isothermal (black line) and TASF (blue 
line) conditions. Panel A has four traces. The bottom two are the chromatograms and the top two are 
integrations of the chromatograms. The inset shows an enlargement of the peak area trace from the start of 
integration (2.5 min.) to 6 min. Panel B is an enlargement of the first 6 minutes of the chromatogram, 
illustrating the increased sensitivity and resolution of poorly retained solutes. A gradient of 5-40% ACN over 
15 minutes was used for these experiments. Chromatograms are representative of n = 2 replicates. 
2.4 Conclusions 
 These results clearly illustrate the effectiveness of TASF for increasing sensitivity for 
volume-overloaded solutes beyond what can be achieved with solvent gradient elution alone. This 
is not only applicable for complex mixtures of small molecules, but also for biological samples. 
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Additionally, this completely instrumental technique offers an automated method to improved 
sensitivity, peak capacity, and resolution over a range of injection volumes and gradient 
conditions. Furthermore, using our double extrapolation method for predicting retention factors at 
extremes of temperature and mobile phase composition, can be modeled successfully using simple 
equations, allowing prediction of the utility of TASF for a particular application.  
 It should be noted that in theory, TASF is capable of focusing even more polar compounds 
than those used here. Stationary and mobile phase conditions can be tailored to a particular sample 
mixture. As long as the solutes of interest have negative enthalpies under those conditions, 
increased separation performance with TASF is a possibility. As this is often the case for stationary 
phases such as HILIC,218-221 mixed mode,222 and carbon phases,223-229 it is clear that the benefits 
of TASF can be widely applied to a range of applications beyond conventional reversed phase. 
2.5 Supporting Information for Gradient Elution Temperature-Assisted On-column Solute 
Focusing  
2.5.1  Flow Rate Calibration 
To verify the flow of solvent delivered by the system, varying injection volumes of 1 mM 
uracil were delivered into a 55 cm x 25 μm ID open capillary spanning the injection valve and the 
UV detector flow cell. The mobile phase was 50:50 0.1% TFA ACN/ 0.1% TFA H2O and the flow 
rate was set to 1.00 μL/min. Uracil absorbance was measured at 254 nm. Timed injections were 
used to deliver injection volumes of 0.05, 0.1, 0.2, 0.4, 0.6, and 0.8 μL in random order. Each 
sample was repeated at least three times. Under these conditions, all peaks had flat tops so the half-
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width, w1/2, of the peak should be equivalent to the width in time units of the injection, tinj, as seen 
in Equation 18.  
Equation 18 
tinj = w1/2 = 
1
F
Vinj 
 
Thus, a plot of width vs. injection time should yield a line with a slope of one, as seen in 
Figure 9. The equation of this plot was y=0.9989 (±0.0012)x + 0.00252 (±0.00054) with 95% 
confidence. This resulted in a calculated flow rate of 1.001 ±0.002 μL/min, which is tolerable in 
the scope of this work.  
 
 
Figure 9 Peak half-widths for varying injection volumes into an open tube for the flow rate validation. Each 
point represents n = 3 replicates. 
2.5.2  Dwell Time Determination 
The dwell time of the system was measured using a method described elsewhere.230 The 
mobile phase consisted of pure water in channel A and 0.1% acetone in water in channel B. The 
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injection valve was connected to the flow cell by the same 55 cm x 25 μm ID open capillary used 
throughout the work reported here. A gradient of 10-90% B was delivered over ten minutes using 
flow rates of 1.00 μL/min and 1.20 μL/min. Runs were repeated at each flow rate in triplicate. One 
such chromatogram can be found in Figure 10.  
 
 
Figure 10 Chromatogram of 10-90% 0.1% acetone/ H2O gradient over 10 minutes for the determination of the 
dwell volume. Chromatogram is representative of n = 3 replicates. 
 
To determine the dwell time, a baseline was drawn at the beginning and end of the gradient 
and the time at which the detector response is at the half point of the gradient, t1/2, was determined. 
The dwell time, td, was then calculated using Equation 19 where tg is the gradient time. This was 
calculated to be 0.907 ±0.025 minutes.  
Equation 19 
td = t1/2 - 
1
2
t
g
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2.5.3  TASF Hardware 
 The TEC temperature was controlled via a feedback loop in which the voltage at the desired 
temperature was ‘stored’ allowing set temperatures to be achieved quickly and reproducibly 
following several training runs prior to the start of the experiments. The feedback loop operated 
by slowly increasing or decreasing the current depending on the overall difference between the 
actual temperature and desired temperature. For example, following a cooling cycle, the voltage 
was raised rapidly to 95% of the maximum voltage then the increment by which the voltage was 
raised further slowed until the desired temperature was reached. This is demonstrated in the 
temperature trace shown in Figure 11A. This trace was reproducible for all experiments and once 
the desired temperature was reached, temperatures did not fluctuate more than ±0.1 °C from the 
set point (Figure 12).  
 
 
Figure 11 Panel A is the TEC temperature profile of the small molecule mixture separation (Fig. 3). Panel B is 
the corresponding pressure trace under isothermal (black line) and TASF (red line) conditions. 
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Figure 12 Demonstration of the programmed control of the TEC. Panel A shows the TEC transition from 
focusing to separation. Panel B shows the temperature trace during the separation phase. Panel C shows cooling 
of the TEC from the separation to the focusing temperature. 
 
As expected, changing temperatures are also reflected in changing pressures due to the 
change in viscosity of the mobile phase. Figure 11B demonstrates the pressure cost of TASF (red 
line) over isothermal separation of the small molecule mixture (black line). It is seen for both traces 
that valve actuation causes a pressure drop during injection and then pressure decreases 
accordingly with the increase of organic modifier in the mobile phase. Pressure then increases 
again during mobile phase re-equilibration. This is consistent with what has been described 
previously.231 The focusing temperature used resulted in approximately 100 bar greater pressures 
during injection and is well within the capabilities of most HPLC pumps and a reasonable 
compromise for improved peak shapes and separation efficiencies. The pressure increase at the 
end of the run corresponds to cooling the TEC prior to the start of the next run. These pressure 
traces were consistent over all runs and sample types (Figure 13).  
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Figure 13 The pressure trace of the separation of the BSA tryptic digest (Figure 8) under isothermal (black 
line) and TASF (red line) conditions.  
2.5.4  Determination of Retention Factors 
Table 1 Mobile Phase Compositionsa 
a Retention times were measured on a 100 μm ID x 5.5 cm. column packed as described in the experimental
section with a flow rate of 1 μL/ min. Parabens and phenones were analyzed separately to avoid cross-over. 
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Table 2 Calculated Retention Factors at φ=0.05b 
bRetention factors were calculated based on the experimental data from Table 1 and Equation 9.
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Figure 14 Comparison of van’t Hoff plots using extrapolated retention factors (red dots) and experimental data 
(blue dots) for acetophenone at 30 °C and Φ = 0.05. The extrapolated retention factors were calculated using 
Equation 8 for Panel A, Equation 9 for Panel B, and Equation 10 for Panel C. 
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Figure 15 Determination of ln (αCH2) using extrapolated retention factors at -7.5°C and Φ = 0.05. The values in 
Panel A were calculated using Equation 8, Equation 9 was used for Panel B, and Equation 10 was used for 
Panel C.  
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Figure 16 Comparison of peak height (Panel A), resolution (Panel B), and peak capacity (Panel C) of isothermal 
(black dots) and TASF (blue dots) separations of the small molecule mixture depicted in Figure 3. 
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3.0 On-column Dimethylation with Capillary Liquid Chromatography-Tandem Mass 
Spectrometry for Online Determination of Neuropeptides in Rat Brain Microdialysate 
Reprinted with permission from Analytical Chemistry 2018, 90, 4561-4568. Copyright (2018) 
American Chemical Society. 
We have developed a method for online collection and quantitation of neuropeptides in rat 
brain microdialysates using on-column dimethylation with capillary liquid chromatography - 
tandem mass spectrometry (cLC – MS2). This method addresses a number of the challenges of 
quantifying neuropeptides with cLC - MS. It is also a completely automated and robust method 
for the preparation of stable isotope labeled - peptide internal standards to correct for matrix effects 
and thus ensure accurate quantitation. Originally developed for tissue-derived proteomics samples 
(Raijmakers, et al., 2008), the efficacy of on-column dimethylation for native peptides in 
microdialysate has not been demonstrated until now. We have modified the process to make it 
more amenable to the time scale of microdialysis sampling and to reduce the accumulation of non-
volatile contaminants on the column and thus, loss of sensitivity. By decreasing labeling time, we 
have a temporal resolution of one hour from sample loading to elution and our peptide detection 
limits are in the low pM range for 5 μL injections of microdialysate. We have demonstrated the 
effectiveness of this method by quantifying basal and potassium stimulated concentrations of the 
neuropeptides leu-enkephalin and met-enkephalin in the rat hippocampus. To our knowledge, this 
is the first report of quantitation of these peptides in the hippocampus using MS.  
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3.1 Introduction 
Neuropeptides are heavily involved in cell signaling in the brain, with roles in 
neurotransmitter modulation232-234, reward behaviors6, and cognition8, 235. Unsurprisingly, they are 
implicated in a number of central nervous system disorders including addiction7, 236 and 
depression10. Despite their importance, the details of the distance- and time- scales over which 
they function are largely unknown.5 In vivo investigations of extracellular peptides, typically by 
microdialysis,13, 70 are challenging due to the neuropeptides’ low extracellular concentrations 
(pM96, 237-241) and the potential for loss of peptides due to sample handling96, enzymatic 
hydrolysis,80, 242 and adsorption81, 243.  
Ideally, online measurements of peptides in microdialysate by capillary liquid 
chromatography-mass spectrometry (cLC-MS) should be well-suited for the analysis of 
extracellular processes involving peptides. Online measurements reduce sample handling and 
cLC-MS is suited to the small volumes and low concentrations expected96, 239 of peptides in 
dialysate244. As far as we are aware, only Haskins, et al. have used in vivo microdialysis with online 
LC-MS for the analysis of neuropeptides.95-96 While one of these works focused on the discovery 
of novel peptides95, the other involved the quantification of basal and potassium stimulated levels 
of the neuropeptides met-enkephalin (ME, YGGFM) and leu-enkephalin (LE, YGGFL) in the 
anesthetized rat globus pallidus.96 The authors reported higher peptide levels compared to offline 
studies, which they hypothesized could be due in part to the effectiveness of the online process to 
minimize sample loss.96 Thus, online collection and analysis is preferable to offline methods. 
However, the authors injected dialysate directly on the analytical column, which resulted in rapid 
column degradation and necessitated daily replacement. In addition, isotopically labeled standards 
were not included for quantitation. This is essential80 because ionization efficiencies depend on 
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the analyte as well as the ionic and solvent composition of the medium. Thus, quantitation cannot 
be based on detector response alone.70 While some stable isotope-labeled peptide internal 
standards are available, it would be expensive and impractical to use them in multi-peptide 
analyses. An online labeling scheme is preferred.  
Offline amine labeling has been used in measurements of polar, low-molecular weight 
neurotransmitters in microdialysate.244 The benzoyl chloride work of the Kennedy group245 used 
12C6-benzoyl, to label analytes in dialysate offline while internal standards were labeled with a 
“heavy” 13C6-benzoyl group. This method improved quantitative analysis of microdialysate for 70 
small molecule neurotransmitters and metabolites, including dipeptides.246 An offline but on-
column approach used for quantitative proteomics is the dimethylation of primary amines using 
formaldehyde and cyanoborohydride.247 Raijmakers, et al. have shown this to be an effective 
method for protein quantification in tissue-based samples, with higher efficiency and comparable 
sensitivity as in-solution methods.247-248 We theorized that the on-column method could be adapted 
to the online collection of microdialysate. The potential advantages of this approach are that stable 
isotope labeled – internal standards (SIL-ISs) for multiple analytes can be generated 
simultaneously and the labeling reaction rates are compatible with online analysis. Until now, the 
efficacy of this method has not been demonstrated with native peptides, or with microdialysate244, 
or with online in vivo sampling. 
We made a number of modifications to convert the Raijmakers method from tissue-based 
samples to the online analysis of microdialysate. Here, we demonstrate the effectiveness of this 
method by measuring basal and potassium-stimulated levels of LE and ME in the rat hippocampus. 
These endogenous opioids are involved in learning and memory formation in the hippocampus.8 
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 Our method is able to achieve peptide detection limits in the low pM range for 5 μL 
injections and has a temporal resolution of one hour. While certainly this needs to be decreased, it 
is faster than the previous on-column dimethylation work with tissue-based samples248 and 
comparable to the online microdialysis work of Haskins, et al.96 This method also improves the 
robustness of online collection, significantly increasing the number of samples that can be 
analyzed without human intervention. To our knowledge, this is the first report of online collection, 
labeling, and analysis of neuropeptides in in vivo microdialysis samples and the first report of 
enkephalin quantitation in the hippocampal extracellular space using cLC - MS.  
3.2 Experimental 
3.2.1  Peptide Standards 
Stock solutions of LE (American Peptide, Sunnyvale, CA), ME (Sigma-Aldrich, St. Louis, 
MO), and yaGfl (GL Biochem, Shanghai, China) standards were prepared by dissolving the solid 
as received from the manufacturer in water, which was obtained from a Millipore Milli-Q 
Synthesis A10 purification system (Billerca, MA), to a concentration of 1 mM. Serial dilutions 
were then used to prepare 5 nM standards of each peptide. LE, ME, yaGfl standard mixtures were 
then further diluted to the desired concentrated (usually 100 pM) in either water or a modified 
Ringer’s solution consisting of 148 mM NaCl (EMD-Millipore, Darmstadt, Germany), 1.2 mM 
CaCl2 (EMD-Millipore), 2.7 mM KCl (Sigma-Aldrich), and 0.85 mM MgCl2 (Fisher Scientific, 
Fair Lawn, NJ) at pH 7.4. All standards were made fresh daily.  
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3.2.2  Labeling Reagents 
The labeling reagents were prepared in the following way. Triethylammonium acetate 
(TEAA) buffer was prepared by adding 100 mM acetic acid (Fisher Chemical) to 100 mM 
triethylamine (Sigma) to achieve a pH of 7.40. A volume of 350 µL of the TEAA buffer was placed 
into an autosampler vial (Thermo Scientific, Rockwood, TN) followed by 3.50 µL of 0.6 M sodium 
cyanoborohydride (Sigma) and 3.50 µL of 4% formaldehyde (J.T. Baker, Phillipsburg, NJ). Due 
to the toxicity of formaldehyde vapors, the labeling reagent components should be prepared in a 
fume hood. The mixture was then vortexed and placed in the refrigerated autosampler at 5 °C. The 
heavy labeling reagent was prepared using the same procedure but with formaldehyde-d2 (Sigma). 
TEAA, cyanoborohydride, and formaldehyde solutions were made fresh daily.  
3.2.3  HPLC Setup and Conditions 
A Dionex Ultimate 3000 HPLC system (NCS-3500RS, Thermo Scientific, Germering, 
Germany) was used for cLC. The system consisted of an online degasser, a low-flow loading 
pump, a nanoflow analytical pump, an integrated column oven housing two 10-port Cheminert 
high-pressure 1/16” valves (VICI, Valco, Houston, TX), and a WPS-3000 RS autosampler. For 
the analytical pump, channel A contained 0.5% acetic acid in DI water and channel B contained 
0.5% acetic acid in Optima-grade methanol (MeOH, Fisher Scientific). The loading pump mobile 
phase consisted of 0.5% acetic acid in a 98:2 water: methanol mixture. Peptide standards and 
labeling reagents were housed in the temperature-controlled autosampler at 5 °C.  
Capillary columns of 50 µm ID were prepared in-house using polyimide coated fused silica 
(Polymicro, Phoenix, AZ) that was packed at 6000 psi using the downward slurry method as 
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described previously152. The packing material consisted of Acquity BEH 5 µm C18 stationary 
phase (Waters, Milford, MA) suspended in HPLC-grade isopropanol (Fisher Chemical). Methanol 
was the packing solvent. The outlet was fritted prior to packing by mixing a 25% formamide 
(Acros, NJ) solution with KASIL® 1 potassium silicate (Kasil, PQ Corporation, Valley Forge, 
PA), which was then used to moisten a glass microfiber filter (Whatman, UK).249 The capillary 
was dipped onto the filter paper and placed in an oven at 300 °C for 12 hours. After packing, 
columns were trimmed to 4.5 cm and connected to a pulled silica tip using a PTFE sleeve. Pulled 
tips were also prepared in-house using a laser puller (P-2000, Sutter Instruments, Novatao, CA) 
and 25 µm ID capillaries, which were trimmed to a final tip ID of approximately 10 µm and length 
of 2 cm. The pre-column consisted of an Acclaim PepMap 100 C18 column (Thermo Scientific) 
packed with 3 µm particles and dimensions of 75 µm ID x 2 cm length. 
Peptides were eluted at 0.3 µL/min using the following gradient: a step of 2-20% B 
(nominally in 0.1 minutes) then 20-40% B in 5 minutes with a hold at 40% B for 2 minutes. A 
ramp of 40-95% B over 1 minute was then used to remove any highly-retained analytes present in 
the dialysate. The mobile phase was returned to 2% B (nominally in 0.1 minutes) and re-
equilibrated for 7 minutes. A 3-minute column wash with 95% B was then performed to prevent 
carryover. The total analysis time was one hour. 
3.2.4  Mass Spectrometry 
The cLC was coupled to a Thermo Scientific LTQ XL linear ion trap MS using nanospray 
in positive ion mode. A locally constructed stage housed a 6-port 1/16” VICI high-pressure 
Cheminert valve (Valco) connected to a liquid junction tee (Idex, Oak Harbor, WA) by a 25 µm 
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ID x 10 cm long fused silica capillary. Voltage was applied to the tee at the head of the column. 
The selected precursor ions used for MS2 fragmentation and daughter ions used for generating 
extracted ion chromatograms (EIC) and determining peak area can be found in Table 7 (SI) 
The precursor and daughter ions were chosen for each peptide based on information from 
direct infusions of 5 µM standards into the MS at 0.1 µL/min. Peaks were identified based on MS2 
fragmentation patterns and retention times of the standard peptides as well as comparisons to 
expected fragmentations based on sequence (prospector.ucsf.edu/prospector/cgi-bin/mssearch). 
The LC was operated using Chromeleon Xpress with DCMS link to Xcalibur for MS operation 
and chromatograms were analyzed using Xcalibur Qual Browser.  
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3.2.5  On-Column Labeling Procedure 
 
Figure 17 Schematic for two-column labeling setup. Valve 1 is housed on the autosampler, Valve 2 is housed in 
the LC column oven, and Valve 3 is an external valve housed on the MS stage. Valve 2 is a 10-port valve but is 
depicted with 6-ports for clarity. White indicates a valve that is switching. Labeling is performed in the 
following way: (A) A 5-μL sample loop on Valve 2 is filled with microdialysate (MD) and upon switching, the 
sample is directed onto the pre-column (PC) by the loading pump (LP); (B) A series of five autosampler (AS) 
injections delivers reagents from vials (In sequential order: light labeling reagent, formic acid, 100 pM peptide 
aqueous standards, heavy labeling reagent, and formic acid) onto the PC, which react with peptides that have 
adsorbed onto the PC; and (C) Valve 3 switches, directing flow from the analytical pump (AP) through the PC, 
eluting peptides off the PC and onto the analytical column-mass spectrometer (LC-MS) by gradient elution. 
 
There are three stages in the online method (Fig. 17): pre-concentration of peptides in the 
sample (Fig. 17A), reaction of peptides adsorbed to the pre-column with light reagent followed by 
introduction of unlabeled peptide as internal standards and then reaction of peptides adsorbed to 
the pre-column with heavy reagent (Fig. 17B), and finally injection of the isotopically labeled 
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analytes and standards onto the analytical column. The total cycle time is one hour. In more detail, 
Fig. 17A shows perfusate from the probe continuously filling a 5 µL sample loop on Valve 2. Once 
per hour Valve 2 is switched allowing peptides to adsorb at the head of the pre-column. We have 
given this step four minutes at 5 µL/min to ensure complete emptying of the sample loop and 
sufficient de-salting. Valve 2 is reset to the “fill” position. The second stage has three steps (Fig. 
1B) that use the autosampler. The autosampler has five vials as follows: vials 1 and 2 contain light 
labeling reagent and 5% formic acid, respectively. Vial 3 contains the sought-for peptides (100 
pM) that will, when labeled, act as isotopically labeled internal standards. Vials 4 and 5 contain 
the heavy labeling reagent and 5% formic acid, respectively. The sequence represented in Fig. 17B 
is thus, first, labeling of the adsorbed analyte peptides with light reagent followed by quenching, 
injection of the sought-for peptides, then labeling them with heavy reagent following by 
quenching. Each of the five solutions was loaded into a 5 µL loop and then introduced to the pre-
column at 5 µL/min for three minutes. The result is on-column reaction of adsorbed peptides with 
the injected reagents. The third stage is simpler (Fig. 17C). Valve 3 was switched so that the pre-
column is in line with the analytical pump and the analytical column for separation.  
3.2.6  One-column Approach versus Two-column Approach 
Labeling was performed using a one-column setup and a two-column setup. In the one-
column setup, pre-concentration and separation occurred on a single column. For the two-column 
setup, pre-concentration occurred on a pre-column while the separation occurred on a separate 
analytical column. Figure 17 illustrates the two-column setup. The valve configuration for the one-
column setup was identical except the column was positioned between the loading pump and the 
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analytical pump on Valve 3, taking the place of the pre-column. The sequence of events was also 
the same for the one- and two-column approach, except that for the one-column approach, all 
samples and reagents were injected directly onto the analytical column, with the eluate going into 
the inlet of the MS rather than to waste.  
3.2.7  Labeling Tests 
For in vitro labeling tests, the Ringer’s standard consisted of either 50, 100, or 200 pM 
mixtures of LE, ME, and yaGfl in Ringer’s solution, which was injected via syringe pump in the 
exact manner used for an animal experiment. The aqueous standard consisted of either 50, 100, or 
200 pM mixtures of LE, ME, and yaGfl in water, which were injected using the autosampler in the 
same way described for the animal experiments. The concentrations and labeling conditions were 
randomized and repeated for n = 3 replicates. Samples were randomized to prevent bias due to 
carryover effects at higher concentrations and to demonstrate that the method is reproducible when 
going from high to low concentrations and vice versa. Table 8 (SI) shows the ion transitions used. 
3.2.8  Microdialysis and Surgery 
All procedures involving animals were carried out with the approval of the Institutional 
Animal Care and Use Committee of the University of Pittsburgh. Male Sprague-Dawley rats (250–
375g, Charles River, Wilminton, MA) were intubated and anesthetized with isoflurane (S-3 Baxter 
Healthcare, Deerfield, IL) at 0.5 % by volume and wrapped in a homoeothermic blanket (EKEG 
Electronics; Vancouver, BC, Canada), (n=4). Body temperature was maintained at 37.5 oC using 
a heating pad. The rats were placed in a stereotaxic frame (David Kopf Instruments; Tujunga, CA). 
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Microdialysis probes (216 μm o.d., 2 mm in length) were constructed with hollow fiber dialysis 
membrane (Spectra-Por RC Hollow Fiber; MWCO: 13,000 Da, 200 μm i.d., Spectrum 
Laboratories, Inc.; Rancho Dominguez, CA) and fused silica outlet lines (150 μm o.d., 75 μm i.d., 
Polymicro Technologies; Phoenix, AZ) as described elsewhere.250 The scalp was shaved and the 
skull was exposed. A craniotomy was performed and the dura was carefully removed away to 
expose the brain. The incisor bar was adjusted so that the dorsal-ventral measurements at lambda 
and bregma were no more than 0.01 mm apart (flat skull). Microdialysis probes were lowered into 
the hippocampus to a final position of 5.6 mm anterior to bregma, 4.6 mm lateral from midline 
and 5.0 mm below dura251 over a 30-minute period. The probes were perfused throughout all 
implants with Ringer’s at 0.500 μL/min using a syringe pump (Harvard Apparatus, Holliston, 
MA). Potassium stimulation was conducted using a Ringer’s solution containing 100 mM KCl. 
The concentration of NaCl was adjusted to maintain ionic strength. The high potassium Ringer’s 
was administered via a VICI Valco 10-port valve housed in the LC column oven. After 10 minutes 
of high potassium stimulation the valve was switched to resume perfusion with the standard 
Ringer’s solution. On completion of testing, the rats underwent intracardial perfusion and the 
brains were removed for verification of the probe location [Fig. 22 (SI)]. 
3.2.9  Microdialysis Probe Recovery 
The microdialysis probe recovery was tested in vitro by placing a probe in a solution of 
100 pM LE and ME in Ringer’s after removal of the probe from the rat brain. 100 pM yaGfl in 
Ringer’s was perfused through the probe at 0.5 µL/ min and the outlet of the probe was connected 
directly to the cLC sample loop as shown in Figure 17. At least three replicates were obtained for 
each measurement.  
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3.2.10  Data Analysis 
Peak integration was automated using the Xcalibur Qual Browser. Each peak was manually 
inspected prior to area calculation. Relative areas were obtained by dividing the peak area of the 
light peptide by that of its heavy analog. An analysis of variance (ANOVA) was used to compare 
basal relative areas for LE for each of the four rats with the null hypothesis being that the mean 
relative area is the same for each rat (with 95% confidence). A p-value of 0.0004 indicated that 
the null hypothesis should be rejected and a post hoc Tukey test revealed that the measured relative 
areas for Rat 1 were significantly different from those of Rats 2, 3, and 4. For this reason, the 
measured values for each rat are presented individually. The ANOVA was repeated in the same 
way for ME. Although it indicated that there was no significant difference in measurements for 
each rat (p = 0.18), in most cases we were only able to measure ME once in each rat. Thus, we 
have chosen to report ME values for each rat individually.  All statistics were performed using 
StatPlus in Excel. Values are stated as the mean ± the standard error of the mean (SEM).  
3.3 Results and Discussion 
3.3.1  On-column Dimethylation 
While the efficacy of the on-column dimethylation procedure has been shown elsewhere,247 
this technique was originally developed for proteomics applications, which have a few significant 
differences compared to online microdialysis applications. First, proteomics samples typically 
consist of tryptic digests derived from tissue homogenates. Samples go through several purification 
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and pre-concentration steps, which also enable higher ion counts. The microdialysis probe 
typically excludes large proteins, resulting in relatively clean samples, but dialysate still contains 
a high concentration of salts which must be separated from analytes to achieve efficient ionization 
and detection. Thus, a de-salting step was added following sample loading. Low endogenous 
concentrations (pM-nM) in the extracellular space combined with limited microdialysis recoveries 
result in significantly less analyte mass on-column than tryptic digests, so while the previous work 
utilized larger volumes of labeling reagents (40 µL), we have reduced these volumes to 5 µL, 
which also reduces labeling time. We note that each labeling step only required three minutes. This 
reduction in time was necessary to achieve a practical temporal resolution for online microdialysis 
sample collection and near real-time measurements. Previous work utilized a sodium phosphate 
buffer for the labeling reagents. We have chosen to use triethylammonium acetate instead to reduce 
the accumulation of non-volatile salts on the column, which result in decreased sensitivity and 
column lifetime, particularly for the one-column setup.  
3.3.2  Labeling Tests 
It is imperative to establish the completeness of the labeling procedure and to confirm the 
absence of cross-labeling and mixed-labeling which would occur if the first of the two labeling 
reactions was not effectively complete. Recall that the autosampler contains five vials: light 
reagent and quench solution (vials 1 and 2), aqueous peptide standards (vial 3), and heavy reagent 
and quench solution (vials 4 and 5). We determined completeness using two tests: 1) The Ringer’s 
standard (a surrogate for the sample) was injected followed by the sequence of labeling steps (Fig. 
17B) except the introduction of the aqueous standards, i.e., vials 1, 2, 4, 5 were injected in series; 
and 2) The Ringer’s standard was not injected. All steps in Fig. 17B, including the introduction of 
 65 
the aqueous standard, were injected in sequence.  In the first case, the peptide is exposed to both 
light and heavy reagents but should only be light labeled. The presence of the heavy labeled 
peptides would indicate incomplete reaction. In the second case, only heavy labeled peptides 
should be present. The presence of light labeled peptide would indicate carryover of the light 
labeling reagent. In addition, if we observed differences in the amount of light and heavy label 
between the two tests, we would infer an effect of incomplete removal of salt on the reactions.  
We did not detect unlabeled peptide, cross-labeling, or mixed products over a set of 
concentrations of peptides (Figs. S23-25). Ions were present in the expected ratios based on 
relative concentration (1:1). Thus, any amount of unlabeled peptide is below our detection limit 
and thus the labeling is apparently complete at these concentrations.  Given that the ratios between 
light and heavy peptides were as expected, we conclude that the presence of salts in the Ringer’s 
solution did not affect the labeling efficiency or ionization efficiency compared to the aqueous 
standard. Thus, we conclude that this is an effective method for labeling. Previous reports247, 252-
253 have investigated the labeling efficiency of the dimethylation reaction at varying concentrations 
and for various applications and have had similar findings.  
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3.3.3  One-column Setup 
 
Figure 18 Calibration curve for LE using the one-column setup. The relative area is defined as the area of the 
light peptide (in Ringer’s) divided by the area of the heavy peptide (100 pM LE in water). Error bars represent 
the SEM for n = 2 replicates. 
Initially, we investigated the use of online labeling using a single column. With this 
approach, the loading pump directs all sample and reagents onto the analytical column and waste 
is directed into the MS source. This method can be easily adapted to existing LC-MS setups and 
does not necessarily require additional equipment, such as valves. Fig. 18 depicts a calibration 
curve of LE generated using the one-column setup, where the relative area was determined by 
dividing the peak area of the light peptide (prepared in Ringer’s) by the peak area of the heavy 
peptide (100 pM LE in water). The plot should be linear with an intercept equal to approximately 
zero, yet by eye the points do not describe a good straight line (slope (± SEM) is 0.01130 ± 
0.00092) and the intercept (± SEM) is 0.671 ± 0.047. Reproducibility was also a challenge, as 
indicated by large SEMs for replicate measurements. A significant contribution to this poor 
calibration is the decrease in MS sensitivity after several hours of repeat injections. This was likely 
due to the accumulation of non-volatile salts from the Ringer’s solution at the MS inlet. This 
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problem could be prevented if one has a method for preventing eluate from entering the MS source, 
such as diverting the liquid stream from the glass emitter tip using N2.96 Another issue was rapid 
column degradation, which has been reported by others in similar applications96, 254-255. 
Interestingly, this was not an issue with aqueous standards, only those prepared in Ringer’s. 
Larger-bore columns may minimize this effect241 but trade-offs in sensitivity must be considered. 
We found the one-column method useful for method development, especially since it requires 
minimal changes to existing setups and procedures. It could also be utilized for short-term studies 
occurring over a few hours but longer studies require a more robust setup. Thus, we pursued a two-
column approach.  
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3.3.4  Two-column Setup 
 
Figure 19 Quantitation of LE (blue), ME (black), and yaGfl (100 pM, red) (A) based on the peak area of the 
light labeled peptide and (B) based on the relative area, in which the peak area of the light peptide (in Ringer’s) 
is divided by the peak area of the heavy peptide (100 pM in water). Black squares with blue centers indicate 
overlapping data points. Error bars represent the SEM of n = 2 replicates. 
 
It is well-known that internal standards are necessary for MS2 quantitation to correct for 
matrix effects.80 This is particularly true for dialysate samples (Fig. 19). Fig. 19A depicts the peak 
areas of Ringer’s standards that were labeled using the light reagent. In comparison, Fig. 19B 
shows the same data, but expressed as the ratio of the peak area of the light labeled peptide to that 
of the heavy labeled peptide (100 pM in water). The addition of the isotopic standard resulted in 
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improved reproducibility and linearity (Table 3). These results further demonstrate the efficacy of 
this method, as ratios of light to heavy are as expected based on relative concentrations. In Fig. 3, 
yaGfl was present at a concentration of 100 pM in both the Ringer’s and the aqueous standards. 
Though both are normally distributed, the relative standard deviation of the distribution of yaGfl 
relative areas is considerably smaller than that for the peak area of yaGfl alone (Table 4). Thus, 
inclusion of the heavy peptide improves reproducibility of dialysate measurements.     
Table 3 Slope and Intercept of the Calibration Curve Obtained using the Peak Area of the Light Peptide (Fig. 
19A) and the Relative Peak Areaa (Fig. 19B) 
 
 aDefined as the peak area of light peptide divided by the peak area of its heavy analog 
bUnits of Peak Area 
cSEM = standard error of the mean 
dUnits of (Peak Area)(Conc.)-1   
eUnits of Relative Area 
fUnits of (Relative Area)(Conc.)-1   
 Peak Area of Light Peptide Relative Peak Area 
Peptide Intercept
b 
(± SEMc) 
Sloped 
(± SEM) 
Intercepte  
(± SEM) x 104 
Slopef 
(± SEM) x 104 
LE 399 ± 337 76 ± 3  373 ± 115 91.7 ± 1.1 
ME  -23 ± 194 48 ± 2 -26 ± 96 96.47 ± 0.98 
 
Table 4 Mean and Standard Deviationa of Light yaGfl Peak Areas (Fig. 3A) and Relative yaGfl Peak Areasb 
(Fig. 3B)  
 
aStatistics are based on n = 12 measurements. 
bDefined as the peak area of light yaGfl divided by the peak area of heavy yaGfl 
cUnits of Peak Area 
dUnitless 
Parameter 
Peak Area of 
Light yaGflc  
Relative 
Peak Aread 
Mean 16700 1.18 
Standard Deviation 2200 0.078 
Relative SD 0.13 0.066 
Median 16400 1.21 
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3.3.5  In Vivo Microdialysis 
 
Figure 20 Profile of LE (blue) and ME (black) levels during sampling of a single rat. The first point (t=0 hours) 
was collected 15 minutes after probe implantation. Shaded areas represent points collected during 10-minute 
potassium stimulation. The relative area is defined as the peak area of the light peptide divided by the peak 
area of the heavy peptide. 
To demonstrate the utility of this method for studying dynamic changes in endogenous 
neuropeptides in vivo, we monitored LE and ME concentrations in the rat hippocampus. Fig. 20 
depicts recorded LE and ME levels throughout the sampling time for a single rat. This was a typical 
profile obtained for each of the rats (Fig. 26). Interestingly, with each rat we saw an initial high 
peptide level immediately after probe implantation. This phenomenon has been observed in other 
neuropeptide microdialysis studies.93, 238 The calibration curves in Fig. 3B were used to convert 
the relative areas, such as those shown in Fig. 20, to concentrations for each rat. Estimated dialysate 
concentrations of LE and ME can be found in Table 5. ANOVA revealed that basal concentrations 
of Rat 1 were statistically different from the others (see Experimental). This could be because the 
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probe for Rat 1 was slightly outside the targeted area where the other probes were located (Fig. 
S1).  
Table 5 Estimated Concentrationsa,b,c of LE and ME in Dialysate  
aValues are not corrected for probe recovery. 
bLevels were quantified using the regression statistics in Table 3 
cConcentrations are expressed as the mean ± SEM, where the value in parenthesis indicates the number of 
measurements in which the peptide was detected 
dBased on the first potassium stimulation 
ePotassium stimulation was not performed on Rat 2 
fMeasurements that do not have SEM values were only measured once (n = 1) 
 
 LE ME 
Rat Basal Conc. (pM)c 
K+ Stimulatedd 
Conc. (pM) 
Basal 
Conc. (pM)c 
K+ Stimulatedd 
Conc. (pM) 
1 67 ± 12 (n = 3) 126
f 49 ± 8 
(n = 3) 84
f 
2 5.6 ± 1.2 (n = 2) 
Not  
Performede 3.7
f Not  
Performede 
3 4.4 ± 1.2 (n = 4) 8.9
f 2.8f 11f 
4 2.0f 7.5f 9.0f 14 ± 2 (n = 2) 
 
Potassium stimulation is a commonly employed method used to verify the presence of a 
neuropeptide.256-258 Fig. 21 shows the typical EIC and MS spectra for peptides following 
stimulation with potassium. Each peptide was easily identifiable under these conditions. Thus, we 
are observing endogenous neuropeptide release. Peptide response decreased with repeated 
potassium stimulation. This has been observed elsewhere.240 We observed a statistically significant 
2.8-fold increase in LE during potassium stimulation compared to basal levels (Fig. 26). We did 
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not detect a significant increase (defined as p < 0.05) in ME during potassium stimulation (9). This 
was because basal levels were often below the detection limit.  
Figure 21 Peptide detection during potassium stimulation.  A) Chromatograms and corresponding mass 
spectra at the point of elution of B) light LE, C) heavy LE, D) light ME, and E) heavy ME during 10-minute 
stimulation with 100 mM KCl Ringer’s. Light and heavy yaGfl spectra can be found in Figure 27 (SI). 
 
At the end of the sampling time, the microdialysis probe was removed to test for in vitro 
recovery. The recoveries ± SEM were 14.9 ± 1.1% for LE and 13.3 ± 2.4% for ME (n = 3). Probe 
recovery was determined after in vivo use to prevent carryover of standards prior to rat experiments 
and to show that the probe was properly functioning throughout the course of the experiment. 
Thus, we conclude that this method is useful for observing dynamic changes in neuropeptide 
concentrations in the extracellular space.  
Since this is the first report of online labeling and MS quantitation of neuropeptides in rat 
brain microdialysates and the first study quantifying enkephalin levels in the hippocampal 
extracellular space using MS, there is a lack of literature with which to compare our results. The 
closest work consists of two reports, both conducted by Rocha, et al., in which microdialysis 
followed by radioimmunoassay (RIA) was used to compare total opioid peptide (defined as 
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peptides with YGGFM… or YGGFL… N-terminal sequences) levels in the hippocampus of 
control rats to those with induced seizures. They reported total opioid concentrations in control 
animals of 11.2 ± 2.5 pM259 and 24.5 ± 2 pM,260 without correction for probe recovery. These 
values are similar to ours. They also observed approximately 1.5-259 and 4-fold260 increases in total 
opioid levels when stimulating with 100 mM potassium for 10 minutes.  These values are similar 
to the relative changes in LE levels that we observed under the same stimulation conditions.  
Extracellular neuropeptide concentrations are region-dependent.13 Our measured LE and 
ME concentrations were near and at times below our detection limits. Three of our probe locations 
were primarily in the CA1 region of the hippocampus, which has lower enkephalin levels than the 
nearby dentate gyrus and the CA3.49,50 More broadly, RIA and immunohistochemistry 
measurements have shown that LE and ME levels vary considerably among regions of the brain 
and are higher in other brain regions, such as the striatum, compared to the hippocampus.261-266 
Although immunoreactivity is not directly related to extracellular concentrations of the 
pentapeptides, we speculate that the detection limits of this technique will allow for measurements 
in many other brain regions.  
3.3.6  Use of yaGfl as a Quality Control Indicator 
Given the complexity of the experimental setup, we found it useful to include the D-amino 
acid-containing peptide yaGfl in the perfusate to aid in troubleshooting and as a semi-quantitative 
measure of the data quality. This synthetic amino acid was chosen because it is similar in length 
and composition to our analytes of interest and is not hydrolyzed to any detectable extent in the 
extracellular space.267 If a peptide that is hydrolyzed in the extracellular space were used, it would 
not be a suitable control because it would not be known if decreases in signal observed at the 
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detector were due to instrumental issues or enzymatic hydrolysis. The yaGfl present in the 
perfusate was light labeled along with the other peptides in the microdialysate. In order to generate 
a SIL-IS, yaGfl was also contained in the aqueous standard. By pooling data from all four rats, we 
found that the relative area of yaGfl (ratio of light to heavy peak area) was normally distributed, 
with a mean of 0.989 and a standard deviation of  0.067 (n = 23, Table 6). Using this value, we 
can quickly assess the quality of an injection. If we obtain a relative area outside the range of 0.85 
to 1.13, we suspect (with 95% confidence based on 22 degrees of freedom) that there is some 
problematic issue, such as a leak. It is especially important to have a control such as this when 
doing online analysis, which requires rapid troubleshooting to avoid sample loss. Additionally, by 
comparing the SEM of yaGfl measurements to that for a peptide, we can determine if variations in 
peptide levels are due to physiological variations or procedural errors. Thus, yaGfl is a useful 
internal standard to assess point-to-point and rat-to-rat reproducibility.  
Retrodialysis of yaGfl is also useful for determining microdialysis probe extraction 
fraction, which is important for accurate quantitation. This is typically determined in vitro but it is 
helpful to have an in vivo method since the environment of the brain is much different than that of 
a beaker. By comparing the mean relative area ± SEM of yaGfl in the absence of the microdialysis 
membrane (Table 2, 1.180 ± 0.022) to the mean in Table 6, the extraction fraction is 16.19 ± 0.03% 
(1-(0.989/1.180) expressed as a percent). Assuming there is no degradation of yaGfl in the 
extracellular space, the extraction fraction is equal to the probe recovery. This value is within 
reasonable agreement with the LE and ME recoveries and indicates that yaGfl is useful for 
determining probe recovery in vivo.  
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Table 6 Descriptive Statisticsa for the Relative Areab of yaGfl  
aStatistics are based on n = 23 measurements. 
bThe relative area was calculated by dividing the peak area of light yaGfl (from the perfusate) by the peak 
area of heavy yaGfl (100 pM aqueous standard). 
Parameter Value 
Mean 0.989 
Standard Deviation 0.067 
Standard Error 0.014 
Median 0.982 
 
3.4 Conclusion 
We have developed an online, automated method for labeling endogenous neuropeptides 
in microdialysate and corresponding isotopic standards. This allows quantitation of dynamic 
processes occurring in the extracellular space. We have demonstrated this by quantifying LE and 
ME in the anesthetized rat hippocampus under basal and potassium-stimulated conditions. To our 
knowledge this is the first report of online collection and labeling for microdialysis applications 
and the first quantitative study of endogenous LE and ME in the hippocampus using MS2. One 
drawback of this technique is the time required for labeling. In this study we did not optimize the 
labeling procedure for maximum time efficiency. We anticipate improving this for future work, 
both by optimizing labeling steps to achieve complete labeling in the least amount of time and by 
increasing loading flow rates.  
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3.5 Supporting Information for On-column Dimethylation of Neuropeptides in 
Microdialysate 
3.5.1  Mass Spectrometry 
Table 7 Selected Ions for Fragmentation and Quantitation of Neuropeptides  
aIsolation widths were 3 m/z 
bTolerance was ± 0.5 m/z.  
Peptide Abbreviation Precursor m/za Daughter m/zb 
Dimethyl leu-enkephalin Light LE 584.30 425 + 453 
2H4 Dimethyl leu-enkephalin Heavy LE 588.30 429 + 457 
Dimethyl yaGfl Light yaGfl 598.30 439 + 467 
2H4 Dimethyl yaGfl Heavy yaGfl 602.30 443 + 471 
Dimethyl met-enkephalin Light ME 602.30 425 + 453 
2H4 Dimethyl met-enkephalin Heavy ME 606.30 429 + 457 
 
Table 8 Selected Ions for Fragmentation and Quantitation in Labeling Tests  
aIsolation widths were chosen so that multiple analytes, including potential cross-labeled products, could be 
detected in a single fragmentation step. 
Peptide Center m/z 
Isolationa 
Width (m/z) 
Daughter 
m/z 
Leu-enkephalin (LE) 556.60 3 397 + 425 
yaGfl 570.25 3 411 + 439 
Met-enkephalin (ME) 574.20 3 397 + 425 
Light LE 588.30 8 425 + 453 
Heavy LE 588.30 8 429 + 457 
Light yaGfl 602.30 10 439 + 467 
Heavy yaGfl 602.30 10 443 + 471 
Light ME 602.30 10 425 + 453 
Heavy ME 602.30 10 429 + 457 
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3.5.2  Microdialysis Probe Location 
 
Figure 22 Localization of microdialysis probes in the rat brain. (A) Representative microdialysis probe track. (B) 
Schematic reconstructions of positions of the four microdialysis probes (adapted from Paxinos and Watson251). Coordinates 
were chosen to sample from the CA1 region. Note that probe 1 is in the dentate gyrus. Numbers in red correspond to the 
rat numbers in Table 5 of the text. 
3.5.3  Labeling Tests 
 To confirm the absence of unlabeled or cross-labeled peptides, we performed a series of 
tests in which labeling was conducted as described in the text but: 1) The Ringer’s standard was 
injected prior to treatment with labeling reagents and no aqueous standard was injected and 2) The 
aqueous standard was injected after quenching of the light label but before treatment with the 
heavy label. In this test, no Ringer’s standard was injected. For each test the Ringer’s standard 
consisted of 50 pM (Fig. 23), 100 pM (Fig. 24), or 200 pM (Fig. 25) LE, yaGfl, and ME in Ringer’s 
and the aqueous standard consisted of matching concentrations (either 50, 100, or 200 pM) of LE, 
yaGfl, and ME in water. As expected, for the first test we observed only light product in the mass 
spectra and for the second test we saw only heavy product, indicating complete labeling.  
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Figure 23 Labeling test results for 50 pM Ringer’s standards (left column) and 50 pM aqueous standards (right 
column) for A-B) LE, C-D) yaGfl, and E-F) ME. Peak identifications were made using 
prospector.ucsf.edu/prospector/cgi-bin/mssearch.cgi. 
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Figure 24 Labeling test results for 100 pM Ringer’s standards (left column) and 100 pM aqueous standards 
(right column) for A-B) LE, C-D) yaGfl, and E-F) ME. 
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Figure 25 Labeling test results for 200 pM Ringer’s standards (left column) and 200 pM aqueous standards 
(right column) for A-B) LE, C-D) yaGfl, and E-F) ME. 
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3.5.4  In Vivo Microdialysis Data 
 
Figure 26 Measured LE Levels for Each Rat. To determine the percent basal, all detectable basal light LE peak 
areas were divided by the corresponding heavy peak area to obtain the relative area. The basal relative areas 
for each individual rat were averaged. Each time point was divided by the mean basal relative area and 
expressed as a percentage. Gray shaded areas indicate points that were collected during potassium stimulation. 
The time axis of each rat has been adjusted so that the potassium stimulated points are aligned. 
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Figure 27 Mass spectra at the point of elution for A) light yaGfl and B) heavy yaGfl during 10-minute 
stimulation with 100 mM KCl Ringer’s. Corresponding chromatograms can be found in Figure 21. 
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Figure 28 Comparison of LE, ME, and yaGfl Potassium Stimulated Levels to Basal Levels. Percent basal levels 
were determined by dividing the relative area (light peak area/ heavy peak area) at each time point by the mean 
basal relative area for each rat, which was then expressed as a percentage. The shaded gray area indicates 
points that were collected during potassium stimulation. The time axes have been adjusted so that the potassium 
stimulated points are aligned. The asterisk indicates a statistically significant (p=0.03) increase in LE levels 
during potassium stimulation as determined using a one-tailed t-test (with 95% confidence). The error bars 
represent the SEM of n = 3 rats. 
 
Table 9 Comparison of Basala Levels of ME with Potassium Stimulatedb Levels  
aThe mean of pooled basal levels (± SEM) was 0.260 ± 0.062 for n = 6 measurements. 
bThe mean of pooled potassium stimulated levels (± SEM) was 0.33 ± 0.10 for n = 5 measurements.  
cComparisons were made using a one-tailed t-test with 95% confidence.  
 
Source of 
Variation 
Sum of 
Squares 
Degrees of 
Freedom 
Mean 
Square F P-value 
Between 
Groups 
0.015 1 0.015 0.20 0.67 
Within Groups 0.71 9 0.079   
Total 0.72 10    
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4.0 The Development of Electroosmotic Perfusion-Microdialysis for In vivo Measurement 
of Ectopeptidase Activity 
Neuropeptides are a diverse set of chemical messengers that are involved in a number of 
cognitive processes including learning and memory. Their effects in the extracellular space are 
modulated, in part, by ectopeptidases, membrane-bound enzymes with active sites facing the 
extracellular space. When neuropeptides are degraded by ectopeptidases, their effects are altered 
or ceased and resulting hydrolysis products can have effects different from the parent peptide. 
Thus, release of a particular peptide can initiate a cascade of events throughout the central nervous 
system. Understanding of the fate of neuropeptides in the extracellular space is limited by the lack 
of available methods for quantifying ectopeptidase activity with natural substrates in vivo, 
especially at spatial resolutions relevant to the brain.  
We have developed a technique called electroosmotic perfusion-microdialysis, in which 
substrate peptides are perfused into the brain of an anesthetized rat using current. The substrate 
peptide interacts with ectopeptidases in the extracellular space and hydrolysis products along with 
unhydrolyzed substrate are collected using microdialysis. Using current allows us to control the 
volume of substrate perfused and the residence time in the tissue. Thus, we can make quantitative 
measurements of ectopeptidase activity. We have demonstrated this technique by measuring 
leucine enkephalin (LE, YGGFL) degradation to the product GGFL in the prefrontal cortex of the 
anesthetized rat with a spatial resolution of 100 µm. We also observed a dose-dependent effect on 
LE hydrolysis using an insulin regulated aminopeptidase (IRAP, EC 3.4.11.3) inhibitor. This is 
the first report of a sampling method capable of performing such measurements in the extracellular 
space of the rat brain in vivo.  
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4.1 Introduction 
Ectopeptidases, membrane-bound enzymes with active sites facing the extracellular space2, 
modulate the effects of neuropeptides, a diverse class of signaling molecules.236  Hydrolysis 
products produced by ectopeptidases can have effects that are different from the parent peptide.5 
Thus, at the very least, ectopeptidases can control the local activity of a neuropeptide. The release 
of a particular neuropeptide can sometimes result in a series of effects throughout the central 
nervous system as a result of ectopeptidase activity. The understanding of such processes is limited 
by the lack of suitable methods.1 Making quantitative measurements of ectopeptidase are 
especially challenging in the brain where the role of a peptidase can be tied to its specific location2, 
236, requiring spatially-resolved but minimally-invasive methods for probing the extracellular 
space. In vitro assays128, 268-270 and in situ histological studies120, 271-274 provide important 
information but it is unknown how activities implied by these methods translate to in vivo 
conditions.103, 275 There exists a need for a sampling-based method for measuring membrane-bound 
ectopeptidase activity using natural substrates in an in vivo model, particularly in the brain. 
Microdialysis (MD) is the most commonly used method for sampling the extracellular 
space 78 and has been used to study enzyme activity qualitatively in vitro128-129 and in vivo in the 
brain50-51, 94, 122-125, 276-278 and other tissues130, 132, 279-283. Substrate introduction through the 
membrane (retrodialysis) and collection of substrate and products through the membrane of the 
probe depends on diffusion, probe characteristics and chemical processes in the tissue.131, 135-137  
Thus, there is no experimental parameter to directly control substrate residence time.134 In work 
outside the brain, the Stenken group has explored using extraction fraction, the ratio of the 
concentration of substrate collected at the probe outlet compared to that introduced at the inlet, as 
a measure of enzymatic activity.127-130, 132, 134 They concluded that because the extraction fraction 
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is more affected by mass transport processes than hydrolysis in tissue, it cannot be used to 
quantitatively study enzymatic activity in vivo.134 
Electroosmotic flow is the basis of a method that has been used to study ectopeptidase 
activity in organotypic hippocampal slice cultures (OHSCs).139-140, 148, 150-151, 284 . Electroosmotic 
flow results from a current passing through an electrolyte solution in a matrix with charged walls 
such as a fused silica capillary or tissue.133, 285-287 In tissue, the cell membranes and extracellular 
matrix are negatively charged, and a fused silica capillary naturally has negatively charged-walls. 
Bulk fluid flow is due to the movement of the surface’s counterions in the diffuse layer.285-286 The 
main advantage of using electroosmotic flow is that the current path, and thus spatial resolution, 
is dependent on the positioning of the current source and sink in relation to one another.149 The 
velocity of an ectoenzyme substrate introduced through the tissue, and thus the residence time, can 
be controlled by changing the magnitude of the applied current.139, 148-149 In electroosmotic push-
pull perfusion (EOPPP) as applied in OHSCs a substrate-containing pulled capillary inserted into 
the tissue provides substrate near a collection capillary that is placed perpendicular to the top 
surface of the OHSC140. The collection capillary contains substrate and products of enzymatic 
reactions. EOPPP has been used to identify differential hydrolysis rates of galanin140 and LE151 in 
different regions (CA1 and CA3) of OHSCs. The latter work recently resulted in the first report of 
spatially resolved, quantitative ectoenzyme activity using natural substrates in live tissue.151 The 
CA1 region, which is more vulnerable to oxygen and glucose deprivation than the CA3 region, 
had a greater activity (Vmax) of a bestatin-sensitive ectopeptidase than the CA3 region. This 
difference was correlated with neuronal damage during oxygen and glucose deprivation and was 
abolished by the δ-opioid receptor antagonist naltrindole at which LE acts151. 
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The work described above represents a major technological step in quantitative evaluation 
of ectopeptidase activity in intact tissue using natural substrates. However, it is obviously 
preferable to perform these measurements in vivo. This is especially important for peptide 
substrates that are regulated based on physiological changes like blood flow, such as the 
angiotensins 288. However, transitioning to in vivo models is not as simple as performing the same 
steps in vivo as were done ex vivo. There are several technical issues that must be addressed. The 
most significant problem is flow rate. EOPPP operates in nL/ min flow rates.148 This is 
advantageous for achieving a desirable analyte residence time but results in small sample volumes. 
This is not practical for obtaining multiple samples from a single animal over time. The second 
challenge is reproducibly implanting the two probes at a distance of ~100 µm, the spatial resolution 
at which our previous work was done.140, 151  
Using direct laser writing289-299, we have fabricated a dual-channel electroosmotic 
perfusion – microdialysis (EOP-MD) probe that allows perfusion of a natural substrate into the 
extracellular space where it interacts with ectopeptidases. Hydrolysis products along with any 
unhydrolyzed substrate are collected using the integrated MD probe. Dialysate is analyzed online 
using high-performance capillary liquid chromatography-tandem mass spectrometry (cLC-MS2). 
This allows the monitoring of ectopeptidase activity in near-real time with a spatial resolution of 
approximately 100 µm. Because substrate perfusion velocity is dictated by current, we can control 
the substrate residence time in the ECS of the tissue by changing the magnitude of the current.148, 
151 The dual-channel perfusion tip permits sampling under a pair of matched conditions (± 
inhibitor) without disturbing the probe. 
We have demonstrated that this technique is capable of measuring dose-dependent effects 
of the inhibitor HFI-41966 on LE hydrolysis. HFI-419 is a specific inhibitor of insulin-regulated 
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aminopeptidase (IRAP, EC 3.4.11.3), an ectopeptidase known to hydrolyze neuroprotective 
peptides including the enkephalins17-18, arginine-vasopressin17, 20-21, and oxytocin17, 21 in vitro. 
These measurements were performed in the rat cortex, an area of the brain in which both IRAP300-
301 and LE263, 302 are found.  
This work is novel both technologically and biochemically in that: (1) it is the first account 
of using direct laser writing to fabricate a perfusion/ sampling device for use in the brain, (2) it is 
the first method capable of controlling substrate residence time in the extracellular space of the 
anesthetized rat brain, and (3) it is the first demonstration of IRAP hydrolysis of a natural peptide 
substrate in the presence and absence of a specific IRAP inhibitor in vivo.  
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4.2 Results  
4.2.1  Development of the EOP-MD Probe 
 
Figure 29 (a) Relative size of EOP-MD perfusion tip compared to a nickel. The tip is outlined in red. A 48x 
SEM image is shown in (b) and a 3x stereoscopic photo is shown in (c).  Temporary “wings” on the device allow 
the device to be manipulated during probe assembly. They are were removed prior to insertion in the animal. 
A remnant of one wing can be seen in Fig 29b. The wing-free device, suitable for implanting, is seen in Fig 29c. 
The fully assembled EOP-MD probe is shown in (d). 
We created a device that integrates a source probe, which provides substrate solution, and 
a MD probe, which collects unreacted substrate and products, with the Nanoscribe direct laser 
writing system (Fig 29).  The source probe contains two independent microfluidic channels so that 
different perfusion solutions can be used alternately in the same experiment. Aside from the initial 
designing of the probe and a few steps after fabrication to rinse out any unreacted photoresist, 
direct laser writing is a relatively hands-off process. The distance between the source tip and the 
nearest surface of the microdialysis probe as measured using a stereoscope was 90 ± 5 µm (mean 
± SEM, n = 3). 
 90 
 
Figure 30 Schematic drawing of the general procedure of EOP-MD sampling. An electrode is placed in the 
reservoir surrounding the Nafion wall of the channel containing the perfusion solution. When a positive voltage 
is applied to the electrode, cations carry the current across the Nafion. This current generates electroosmotic 
flow through the capillaries and into the tissue. The current passes through the microdialysis membrane to a 
second Nafion wall in the microdialysis inlet capillary. Analytes, in this case LE plus hydrolysis products and 
the D-amino acid internal standard yaGfl, are collected at the MD probe. The outlet of the MD probe is 
connected to the LC-MS, resulting in online collection and analysis. 
Electroosmotic delivery was achieved (Fig 30) using a constant current. The positive 
current passes through the source capillary, out the source tip, through the medium (tissue or gel), 
through the microdialysis membrane, and up the inlet microdialysis capillary. A short length of 
Nafion tubing is integrated with the current-carrying capillaries. Current flows through the Nafion 
into an electrolyte bath and a Ag electrode.  
 91 
4.2.2  In vitro Fluorescence Studies 
To visualize solute transport from the perfusion tip to the MD probe, we infused fluorescent 
dyes into a hydrogel and monitored the fluorescence intensity over time. The hydrogels have a 
similar zeta potential as that of brain tissue303 and have been used as an in vitro model for 
electrokinetic transport in the brain.287, 304 We used 3 kDa Texas Red (TR3), which is neutral, and 
tris(bipyridyl)Ru(II) (Ru(bpy)32+) as the solutes151. 
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Figure 31 Measuring fluorescence intensity in a hydrogel over time. (a) A 4x brightfield image of the perfusion 
tip and MD probe placement in the gel. TR3 was infused into the hydrogel using a current of 75 μA. The 
intensity of fluorescence was measured (b) prior to turning on current (0 minutes) and after (c) 5 minutes and 
(d) 60 minutes of perfusion at 75 μA. The corresponding false color plots are shown in e-g. Figure h depicts the 
percent increase in fluorescence intensity for TR3 (•) and Ru(bpy)32+ (◼ ) at 75 μA and 0 μA ( ○ for TR3, ☐ for 
Ru(bpy)32+). The error bars represent the SEM of n = 3 replicates for Texas Red and n = 4 replicates for 
Ru(bpy)32+. 
Fig 31a illustrates the brightfield image of the EOP-MD probe positioned in the gel. Prior 
to current flow, there is no apparent fluorescence (Fig 31b). After five minutes of perfusion, Fig 
31c, there a is detectable increase in fluorescence in the hydrogel. Transport of the dye through the 
gel is biased towards the MD probe. This is especially clear in the false color plots (Fig 31e-g). 
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The highest concentration of dye (red) is confined between the EOP tip and the MD probe. This 
indicates that the dye is being carried by the EO flow from the perfusion tip, through the hydrogel, 
and to the MD probe.  
To illustrate the ability of EOP to move molecules of various sizes and charges, we repeated 
the experiments described above with Ru(bpy)32+, a cationic dye with a formula weight of 748.63 
g/ mol (images not shown). We compared the percent increase in fluorescence over the entire 
image over time (Fig 31h). For both dyes we saw an increase in fluorescence intensity over the 
EOP sampling time. Ru(bpy)32+ had a lower increase in fluorescence compared to TR3. Ru(bpy)32+ 
is smaller, and cationic, in contrast to the larger and neutral TR3. Thus, it likely crosses the MD 
membrane more readily than the larger TR3. For both dyes we saw a minor increase in 
fluorescence after 60 minutes in the absence of current. This is due to diffusion. We see slightly 
more diffusion for Ru(bpy)32+ compared to TR3, as we would expect due to the smaller size of 
Ru(bpy)32+.  
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4.2.3  Assessing Mass Transport with yaGfl 
 
Figure 32 (a) Concentration of leu-enkephalin (LE, red diagonal lines) and yaGfl (purple diagonal lines) in 
dialysate during the electroosmotic perfusion of 10 µM LE and yaGfl into a hydrogel at 15 µA and 30 µA using 
the EOP-MD device. The concentration of yaGfl in the dialysate in vivo (solid purple bar) is compared to that 
obtained in vitro (from Fig 32a) in (b). Fig 4c depicts the concentrations of GGFL (solid blue bar), LE (solid 
red bar), and yaGfl measured in the dialysate in in vivo experiments. ‘NS’ indicates that the values shown 
under the bar were not significantly different as determined by ANOVA (p > 0.05) with post hoc Tukey test. 
The single asterisk (*) and double asterisk (**) represent p < 0.05 and p < 0.01, respectively. The error bars 
indicate the SEM for n = 3 replicates for in vitro data and n = 4 replicates for in vivo data. 
In the assessment of enzymatic degradation of a peptide traversing the extracellular space, 
it is helpful to have an internal standard representing what would be observed in the absence of 
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enzymatic activity. Therefore, we use yaGfl as an internal transport standard. It is similar in size 
to LE and has not shown any measurable hydrolysis in the tissue in work with OHSCs.139-140, 148, 
151 We assessed its suitability for use with our EOP-MD device in vitro and in vivo., We performed 
an in vitro experiment in which we perfused a solution of 10 µM LE and yaGfl into a hydrogel 
and measured the concentrations of the recovered peptides in the dialysate at multiple currents. 
The range of currents was appropriate for in vivo use. They were lower than that shown in Fig. 31 
and in the range of those dictated by our previous work done at approximately the same spatial 
resolution151 and consistent with conditions that minimize cell death305.  As seen in Fig 32a, for 
both currents used, there was no significant difference between the concentrations of LE and yaGfl 
in the dialysate. This confirms that yaGfl is a suitable standard for assessing mass transport in the 
absence of hydrolysis and can be used as an estimate of the initial substrate concentration. To 
further validate our use of yaGfl as a mass transport standard, we repeated the experiment in vivo 
in an anesthetized rat. There was no statistical difference (p < 0.05) between the yaGfl 
concentrations in the dialysate in vivo compared to in vitro (Fig 32b). Since there is no hydrolysis 
in the hydrogel and no difference between the yaGfl recoveries in the gel and the tissue, we can 
confirm that there is no significant uptake or hydrolysis of the internal standard in the tissue.  
4.2.4  Effect of Current In Vivo 
An important distinction of EOP-MD compared to other in vivo sampling techniques is the 
ability to control solute velocity and thus residence time. This is achieved by changing the 
magnitude of the applied current. To demonstrate this effect, we performed an in vivo experiment 
in which we perfused a peptide solution with the same concentration as was used in vitro (10 µM 
LE and yaGfl). We observed a statistically significant increase in the dialysate concentration of 
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yaGfl from 5 µA to 15 µA (p < 0.01) as well as from 15 µA to 30 µA (p < 0.05) (Fig 32C). This 
increase is due to higher solute velocity at higher currents leading to a larger volume containing 
substrate at steady state287. There was also a statistically significant difference between [LE] in the 
dialysate compared to [yaGfl] at each current. We attribute this difference to LE hydrolysis. 
Accordingly, the product GGFL was also detected in the dialysate.  
We can calculate a steady-state collection efficiency based on the ratio of the mass flow 
rate (mole/s) of yaGfl out of the microdialysis probe to the same quantity infused by electroosmotic 
flow. Note that the mass flow rate is just the concentration multiplied by the volume flow rate of 
the solution. Given the electroosmotic mobility and conductivity of the extracellular fluid in brain, 
the ratio of electroosmotic flow rate to current is 1.45x10-8 m3/A*s in SI units and 0.87 nL/min per 
µA in more practical terms148, 287. The flux into the brain is the product of this flow rate (at a 
particular current) and the concentration of yaGfl in the source. The volume flow rate in the 
microdialysis probe exit is set and the concentration of yaGfl is determined by LC-MS. Fig 33 
shows the ratios of the mass-flow rate out of the MD probe to the mass-flow rate infused. For 
yaGfl, the increase is not linear. This is because the solute electroosmotic velocity is relatively 
low, so diffusion also contributes significantly to mass flux in the tissue, and more so for lower 
currents287. The reactive LE, on the other hand, demonstrated the effect of a longer residence time 
in the tissue causing a greater extent of hydrolysis. In order to have the dynamic range to reliably 
detect changes in both LE and GGFL, we used the intermediate current, 15 µA, for subsequent 
inhibitor experiments.  
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Figure 33 Effect of current on collection efficiency in vivo for LE (• ) and yaGfl (• ). The collection efficiency 
was calculated by dividing the moles per minute perfused (measured by LC-MS2) divided by the moles per 
minute collected at the MD probe (based on laboratory concentrations). The error bars represent the SEM for 
n = 3 replicates. 
4.2.5  LE Hydrolysis in the Presence and Absence of HFI-419 
Our goal was to determine if we could observe an effect of HFI-41966, a specific IRAP 
inhibitor, on the hydrolysis of LE. To be consistent with our EOP-MD experiments described 
above, we perfused 10 µM LE and yaGfl in the presence and absence of 10, 25, and 50 µM HFI-
419. The product, GGFL is itself subject to hydrolysis by ectopeptidases. Thus, we use as a 
measure of the extent of reaction the loss of substrate as a ratio to initial substrate concentration, 
([S0]-[S]) / [S0]. Recall that the initial substrate concentration is taken to be the concentration of 
the internal standard, yaGfl. Fig 34 is a plot of the resulting data. We observed a statistically 
significant (p < 0.01) decrease in product formation at 25 µM and 50 µM inhibitor concentrations 
compared to perfusing the substrate in the absence of inhibitor (0 µM).  
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Figure 34 Effect of HFI-419 concentration on product formation. Statistical significance was determined using 
ANOVA followed by a Tukey test. The single asterisk (*) indicates p<0.05 and the double asterisk (**) indicates 
p<0.01. ‘NS’ indicates the differences were not significant (p>0.05). The error bars indicate the SEM of n = 9 
replicates for 0 µM inhibitor (3 replicates from each rat) and n = 3 replicates for the 10, 25, and 50 µM inhibitor 
concentrations. 
4.3 Discussion 
4.3.1  Using yaGfl as a Mass Transport Standard 
To determine the relative amount of peptide substrate that is hydrolyzed in the tissue, we 
must know the initial substrate concentration. The laboratory concentration of the substrate in the 
source probe is known but becomes lower due to dilution upon introduction to the tissue.148 Thus, 
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we do not know the concentration of the substrate in the tissue through which we are sampling. A 
standard that has similar diffusion characteristics as the substrate but is resistant to hydrolysis is 
necessary as a surrogate for the bioactive peptide. We use this to infer the amount of substrate that 
would have been recovered in the absence of hydrolysis.  
Fig 32 shows that the collected yaGfl concentration was similar to that of LE in vitro. Thus, 
yaGfl has similar electroosmotic transport through the hydrogel as LE and can be used as a mass 
transport standard. The concentration of yaGfl collected in the in vivo experiments was not 
significantly different from that in the in vitro experiment, suggesting that yaGfl is not hydrolyzed 
to a measurable extent in the tissue. We can use the collected yaGfl levels as a substitute for the 
concentration of LE that would be recovered in the absence of hydrolysis.  
The concentrations of LE and yaGfl in Fig 32c are significantly different at each current 
used in vivo. We attribute this difference to LE hydrolysis in the tissue. Accordingly, we detected 
the major product, GGFL. The sum of the concentrations of LE and GGFL do not equal that of 
yaGfl, suggesting that GGFL is further hydrolyzed.  
4.3.2  Solute Collection Efficiency Depends on Current 
Fig 33 shows increasing collection efficiency with decreasing current for the internal 
standard yaGfl. We can make qualitative observations about solute transport with EOP-MD using 
this plot. The fluorescence experiments shown in Fig 31 suggest that solute is transported around 
the MD probe due to low membrane permeability. The MD probe is not a perfect sink for solute. 
Thus, collection efficiency is dictated both by electroosmotic transport through the tissue and 
transport processes within the MD probe. Simulations of our two-probe EOPPP work in tissue 
cultures showed that, with similar current to that used here, solute transport is both by 
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electroosmosis and diffusion.148 Increased currents resulted in increased recovery of analyte due 
to a greater contribution of convection compared to diffusion.148 Fluid flow through the MD probe 
adds additional transport processes that result in the collection efficiency trend that we observed 
with EOP-MD.  
Fluid flow through the MD probe augments the diffusion-dominated mass transport, not 
by pushing solute where it needs to go, but by replenishing the solute within the diffusion layer in 
the fluid near the inner membrane wall.131 Increasing the flow velocity through the MD probe 
increases mass transport by a power less than one. 131 The flow velocity through the probe also 
controls the residence time of the solute in the membrane area of the probe. This time is linearly 
related to flow rate.131, 306   The result is that the total mass collected within the probe per unit 
time decreases per unit time. It increases by a fractional power due to faster mass transport but 
decreases by the power -1 due to the residence time.306 For a steady concentration outside the 
probe, the collection efficiency decreases with increasing flow rate.  
The combination of solute transport through the tissue and the MD probe results in the 
observed changes in yaGfl collection efficiency with changing current. For LE, we observed 
decreasing collection efficiency with decreasing current. This is due to lower solute velocity 
through the tissue at lower currents and thus higher residence time.  In-depth simulations are 
required to quantitatively understand the relationship between current and collection efficiency.  
Qualitatively, we can use Fig 33 to determine the appropriate current to use for a particular 
application. The optimum current depends on the application. We chose to perfuse substrate using 
15 µA. In our case of looking at enzyme inhibition, we expect an increase in substrate 
concentration. Thus, low substrate recoveries as a result of a low current are not detrimental. In 
observing at a process that would decrease the substrate concentration, such as upregulation of the 
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ectopeptidase, a higher current, and thus higher substrate recovery, would be beneficial so that a 
decrease could be detected.  
At 15 µA the sum of the concentrations of LE and GGFL was less than the concentration 
of yaGfl (Fig 32c). This suggests that GGFL is further hydrolyzed in the tissue. For this reason, 
we cannot make conclusions about product formation based on measured GGFL levels. By 
subtracting the ratio of hydrolyzed substrate ([LE] = [S]) to substrate concentration in the absence 
of hydrolysis ([yaGfl] = [S0]) from 1, we have a measure of the concentration of product formed 
from LE hydrolysis ([P]).  
4.3.3  Observing Changes in LE Hydrolysis in the Extracellular Space 
To demonstrate the utility of the dual probe EOP-MD technique, we perfused the tissue in 
the presence and absence of the IRAP inhibitor HFI-419 within the same rat. Initially, we perfused 
the inhibitor at a concentration of 50 µM and, as shown in Fig 33, we observed a statistically 
significant (p < 0.01) decrease in product formation at that concentration compared to perfusing 
the same concentration of substrate without inhibitor. This shows that we can sample the tissue 
under two different conditions (with and without inhibitor in our case) and observe differing effects 
as a result. We then wanted to see if the EOP-MD technique is sensitive to changes in inhibitor 
concentration, so we repeated the experiment at 10 µM and 25 µM inhibitor concentrations. The 
results in Fig 33 show that our technique is capable of detecting differences in product formation 
with different inhibitor concentrations. More replicates and a wider range of inhibitor 
concentrations would be required to draw biological conclusions pertaining to IRAP activity in 
this region, but these results demonstrate that EOP-MD could be used to gain insight into this 
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ectopeptidase with further studies. This technique could also be used with a variety of inhibitors 
as well as other exogenous substances for the study of ectopeptidases.  
4.3.4  Tissue Perturbation with EOP-MD 
Though the purpose of this study was primarily technical and not biological in nature, it is 
important to assess the extent of tissue perturbation when sampling the extracellular space. Prior 
work in our lab has shown that electric fields used in this work should result in minimal cell death 
284, 305 and we did not observe any visible defects in the tissue post-mortem, aside from the probe 
track (Fig S36). Electric fields have been used in the brain in other in vivo work, such as to guide 
stem cells307 and deliver drugs electrokinetically304. Fekete, et al. performed iontophoretic 
injections of a biotinylated dextran amine tracer using 3-5 µA pulses and recorded neural activity 
with an integrated microelectrode array.308  They found that tissue damage appeared to occur from 
insertion of the probe itself but delivery of the tracer was not affected by this.  
A histological study assessing damage from pressure-driven low-flow push-pull perfusion 
at 50 nL/ min saw 20-30% of cell damage surrounding the probe 309 compared to 10% seen in our 
past EOPPP histological work 305. Based on the applied current of 15 µA used in this work, the 
electroosmotic flow rate was calculated to be approximately 9 nL/ min. 148 Nonetheless, a rigorous 
assessment of tissue damage resulting from this EOP-MD technique is necessary to fully 
understand it’s effect on sampling and for comparison to other techniques.  
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4.4 Conclusion 
We have developed a sampling method known as EOP-MD that allows quantitative study 
of ectopeptidases in vivo using natural substrates. To our knowledge, this is the first report of such 
a technique. We have described the development of this technique and demonstrated that it is 
capable of measuring dose-dependent changes in LE hydrolysis with the IRAP inhibitor HFI-419. 
Simulations of solute transport and histological studies assessing tissue damage as a result of this 
technique will aid in the application of EOP-MD for biological studies concerning ectopeptidase 
activity.   
4.5 Methods 
4.5.1  Direct Laser Writing 
The perfusion probe consisted of three main parts: two inlet ports through which capillaries 
are inserted, two outlet ports through which fluid exits the probe, and a tube for microdialysis 
probe mounting and alignment. The overall dimensions of the probe were 2023 µm (W) x 1015 
µm (L) x 3650 µm (H). The inlet ports were 150 µm in diameter and the outlet ports were 50 µm 
in diameter. The narrow shaft of the probe (containing the outlet ports) was 150 µm wide and 850 
µm long. The microdialysis probe holder had a diameter of 310 µm. 
The pattern for perfusion probe was designed in Solidworks and printed by 3D direct laser 
writer (Nanoscribe Photonic Professional, GT) with IP-S photopolymetric resist. The printing was 
done through two-photon polymerization of IP-S resist by a femtosecond pulsed laser at 780 nm. 
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The Nanoscribe direct laser writer uses a Gaussian laser beam and a unique deep-in-liquid mode 
to print large-height patterns, as well as minimize optical aberration.  
To fabricate the perfusion probe, the 3D model of the pattern was saved in STL file then 
converted into GWL (General Writing Lithography) file through DeScribe conversion software. 
During file conversion, the pattern was sliced and hatched, with a slicing distance of 1 µm and a 
hatching distance of 0.5 µm. The pattern was hatched with the shell and scaffold mode which 
creates a hollow structure to reduce the printing time significantly. Subsequently, the whole pattern 
was split into blocks of 220 μm × 220 μm × 200 μm, with a stitching overlap of 2μm. After 
conversion, the GWL file was loaded into the printing software, Nanowrite, for printing. In the 
printing, a 25x objective lens and ITO-coated glass substrate were used. The laser power was set 
to 100 mW and writing speed was set to 100 mm/s.  
After printing was done, the structure was developed in a propylene glycol monomethyl 
ether acetate (PGMEA) bath overnight to wash out unpolymerized photoresist in the channels 
inside the structure. After the structure was naturally dried in the air, it was placed under UV lamp 
for 30 min with 16 mW/cm2 intensity. This polymerizes the photoresist trapped in the 
shell/scaffold structure to make the whole structure more rigid and robust.  
To inspect the printed structure, it was sputter-coated with about 10 nm AuPd for scanning 
electron microscopy (SEM).  
4.5.2  EOP-MD Probe Assembly 
The steps of the EOP-MD probe assembly are shown in Figure 37. Prior to assembly (Fig 
37a), the EOP tip was fixed to a piece of tape using a small dot of 5-minute epoxy (Devcon, 
Danvers, MA). This permitted handling of the tip during assembly and allowed easy removal from 
 105 
the tape once finished. Two sections of 75 µm ID x 150 µm OD capillary (Polymicro) were cut, 
each 1 cm in length. Each capillary was then pushed into one of the channels of the EOP tip until 
it could go no further (Fig 37b). Then, a 15 cm length of 200 µm ID x 360 µm OD capillary was 
threaded over the top of the 75 µm ID capillary to a distance approximately 0.5 cm from the start 
of the EOP tip, leaving a 0.5 cm portion of the 75 µm ID capillary exposed. A drop of 2-ton epoxy 
(Devcon) was placed onto the exposed portion of the 75 µm ID capillary and the 200 µm ID 
capillary was immediately pushed over the glue and into the EOP probe channel. The EOP probe 
channel is tapered so that the 200 µm ID capillary can only advance 1 mm into the channel. 
Applying the glue in this way serves to seal the junction between the 75 µm ID capillary and the 
200 µm ID capillary and to seal the area between the 200 µm ID capillary and the channel of the 
EOP tip. Attaching the 200 µm ID/ 360 µm OD capillary to the 75 µm ID/ 150 µm OD capillary 
allows easier handling, as the 75 µm ID/ 150 µm OD capillary is rather fragile. This allows easy 
assembly with the Nafion tubing. After the epoxy has cured completely, each channel is tested for 
leaks by flushing the capillaries with water via a syringe.  
Microdialysis probes were assembled by first cutting two 5-cm lengths of 40 µm ID/ 100 
µm OD fused silica capillary (Polymicro). The capillaries were placed side-by-side with the ends 
staggered by 1 mm. The “longer” end was the microdialysis outlet while the “shorter” end was the 
inlet. A 13 kDa Spectra/ Por hollow fiber microdialysis membrane (Spectrum, Los Angeles, CA) 
3 mm in length was then placed over the two capillaries and the open end of the membrane sealed 
with 2-ton epoxy. After the epoxy was completely cured, the membrane was pushed down so that 
it was as close to the outlet capillary as possible without touching it. The probe was then threaded 
through the 250 µm tube integrated on the EOP tip. The membrane was sealed around the 
capillaries by placing a drop of epoxy at the end of the tube furthest from the tip. This also served 
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to fix the microdialysis probe in position, approximately 100 µm from the EOP tip. The probe was 
positioned so that the inlet capillary was closest to the EOP tip.  
Nafion tubing was used to allow the movement of ions through the channels of the EOP 
tip, into the tissue or hydrogel, and to the microdialysis probes. An 8-cm length of 200 µm ID/ 360 
µm OD capillary was threaded approximately 0.5 cm into one end of a 2-cm length of a 0.014 (± 
0.002, tolerance) in. ID x 0.021 (± 0.003, tolerance) in. OD Nafion tubing (Perma Pure, Lakewood, 
NJ). A 5-cm length of 200 µm ID capillary was threaded in the same way on the other end. Both 
Nafion-capillary junctions were sealed with 2-ton epoxy and cured overnight. A small hole was 
punctured in the bottom of a 3-cm plastic centrifuge tube (Fisher) and the capillary was threaded 
through the tube until the tube was surrounding the Nafion membrane with the 5-cm length 
capillary at the bottom of the tube. The area between the tube and the capillary was then sealed 
with epoxy. The 8-cm length of capillary was connected to a channel on the EOP tip using a PTFE 
sleeve while the distal end of the capillary-Nafion apparatus was placed through a hole in the top 
of a microcentrifuge tube (Fisher). This tube acted as the sample reservoir and also had a hole in 
the bottom of the tube through which a 1-cm length of polyethylene tubing (0.38 mm ID x 1.09 
mm OD, Becton Dickinson, Sparks, MD) was threaded. Each channel of the EOP tip was 
connected to a separate Nafion apparatus.  
4.5.3  Electroosmotic Perfusion 
To fill the channels, an insulin syringe (Becton Dickinson) was filled with the perfusion 
solution and inserted into the polyethylene tubing contained in the sample reservoir. The capillary 
corresponding to a particular channel was threaded into the other end of the polyethylene tubing 
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and the microcentrifuge tube filled with the remaining perfusion solution using a pipette. The 
channel was filled with the insulin syringe until several drops were observed coming out of the 
EOP tip. At that point, the distal end of the capillary (furthest from the animal) was removed from 
the polyethylene tubing, followed by the syringe. This ensured that the end of the capillary 
remained in contact with the perfusion solution at all times and prevented bubbles from entering 
the system.  
After each channel was filled with the desired solution, each centrifuge tube surrounding 
the Nafion was filled with the modified Ringer’s solution. The inlet of the microdialysis probe was 
also connected to a Nafion apparatus and the centrifuge tube contained on it was similarly filled. 
To perfuse the solution of a particular channel, a silver electrode was placed in that channel’s 
centrifuge tube surrounding the Nafion. The electrode was connected to the positive terminal of 
the high voltage power supply via an alligator clip. A silver electrode was also connected to the 
negative terminal and placed in the centrifuge tube contained on the inlet of the microdialysis 
probe. The desired current was set on the power supply and the voltage continually adjusted to 
maintain that current. A schematic of the sampling procedure in the context of a rat can be found 
in Figure 30.  
4.5.4  Hydrogels 
Hydrogel pieces were synthesized as previously described by Faraji et al.303 
Poly(acrylamide-co-acrylic acid) hydrogels were prepared by a thermally-initiated radical 
polymerization reaction. The gel had an acrylic acid percentage of 25%; weight of acrylic acid 
(69.0 mg)/weight of all monomer species (206.0mg). The bisacrylamide cross-linker was 
maintained at a fixed weight percentage of approximately 1.4% (4.0mg). Reagents were weighed 
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and dissolved in 4.5 mL of ultrapure water (Cayman Chemical, Ann Arbor, MI) and stirred for 5 
minutes. The pH was adjusted to a range between 7-8 using 1 M NaOH solution. Ultra-pure water 
was used to adjust the final volume to 5 ml. The solutions were then deaerated with nitrogen for 
20 minutes at room temperature and 5.0 mg of ammonium persulfate (0.02 mmol) and 5.2 μL of 
tetramethylethylenediamine (TEMED, 0.03 mmol) were added to each solution. After vigorously 
stirring at room temperature, the solution was poured in a 50 mm x 16 mm Pyrex glass dishes and 
placed inside an oven at 100 ± 5 °C for 2 hours. The Pyrex dishes were removed from the oven 
and allowed to cool for 10 minutes. Next, each gel was individually placed in a covered plastic 
dish filled with approximately 25 mL Glucose Free-Hank’s Balanced Salt Solution (GF-HBSS) 
solution and shaken lightly at 10°C overnight. The buffer solution was exchanged the following 
day with fresh GF-HBSS, placed back in the shaker at 10 °C for another 24 hours. To end, the GF-
HBSS was exchanged once more, and the gels were placed in the refrigerator to complete the 
equilibration. The pH was checked to assure the gels were pH 7.40.  
4.5.5  Fluorescent Dyes 
To observe EOP of fluorescent dyes in vitro, a 3 kDa dextran Texas Red dye (Molecular 
Probes, Eugene, OR) was prepared at a concentration of 166 µM in Modified Ringer’s. A 1 mM 
tris(2,2’-bipyridyl)dichlororuthenium(II) hexahydrate (abbreviated Ru(bpy)32+, Aldrich, 
Milwaukee, WI) solution in Modified Ringer’s was also used. The Modified Ringer’s solution 
consisted of 148 mM NaCl (EMD-Millipore, Darmstadt, Germany), 2.7 mM KCl (Sigma-Aldrich), 
and 0.85 mM MgCl2 (Fisher Scientific) adjusted to a pH of 7.4. All dye solutions were filtered 
with a 0.20 µm PES syringe filter (Corning Inc., Corning, NY) prior to use.  
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4.5.6  Fluorescent Studies 
All fluorescent studies were conducted using an Olympus IX-81 fluorescent microscope 
equipped with an inverted stage and an ORCA-ER high-resolution charged-coupled device 
camera. The MetaMorph 7.6.2.0 software (MDS Analytical Technologies, Sunnyvale, CA) was 
used to capture the images along with an Olympus 4x objective lens. Images were analyzed using 
NIS Elements Advanced Research software version 4.0 (Nikon Instruments, Inc.). The threshold 
function within the NIS Elements software was used to remove the background then the percent 
fluorescence of the image was recorded. Surface intensity plots were also generated using the NIS 
Elements software, where intensities range from 0 (black) to 365 (white).  
To conduct the fluorescent experiments, a small section of hydrogel (approximately 2 cm 
x 2 cm x 5 mm thick) was placed on the microscope stage and the EOP-MD tip was inserted about 
1 mm into the hydrogel. The tip was inserted at an angle to minimize the impact of the background 
fluorescence of the tip. The desired current was induced using a Stanford Research Systems model 
PS350 high-voltage source in which the positive terminal was connected to a silver wire placed in 
the buffer surrounding the Nafion on the EOP capillary using an alligator clip and the negative 
terminal was connected to the MD probe in the same way. The power supply was operated by 
specifying the desired current and the applied voltage was continually adjusted to achieve that 
current. Each dye was perfused for 1 hour and images were acquired every 5 minutes. The 
emission/ excitation wavelengths for each dye were 535/ 610 for Texas Red and 475/ 602 for 
Ru(bpy)32+. Only one channel of the EOP-MD probe contained dye at a time due to overlapping 
wavelengths between Texas Red and Ru(bpy)32+.  
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4.5.7  Offline Labeling 
To minimize analysis time, heavy peptide standards were prepared using an offline 
dimethylation procedure described previously310 with a few modifications. Stock solutions of LE 
(American Peptide, Sunnyvale, CA), GGFL (American Peptide), yaGfl (GL Biochem, Shanghai, 
China), and yasfl (Shanghai Royobiotech, Shanghai, China) were prepared by diluting each solid 
to a concentration of 1 mM in water purified using a Millipore Milli-Q Synthesis A10 filtration 
system (Billerca, MA). Serial dilutions were then performed until a concentration of 5.3 nM was 
obtained for each peptide. An aliquot of 49.6 µL of each peptide was then added to an autosampler 
vial (Thermo Scientific, Rockwood, TN) along with 2 µL of glacial acetic acid (Fisher Chemical, 
Fair Lawn, NJ). Multiple vials were prepared simultaneously then frozen at -20 °C until needed. 
On the day of an experiment, a vial was thawed and a volume of 8 µL of 4% formaldehyde-d2 
(Sigma-Aldrich, St. Louis, MO) was added and the mixture vortexed. Next, 8 µL of 600 mM 
sodium cyanoborohydride (Sigma-Aldrich) was added to the autosampler vial, vortexed, and 
allowed to react for 5 minutes. The reaction was then quenched with the addition of 32 µL of 1% 
ammonium hydroxide (Sigma-Aldrich), vortexed again, and allowed to react for 1 minute. Finally, 
16 µL of 5% formic acid (Sigma-Aldrich) was added to the autosampler vial, after which the 
mixture was vortexed a final time and placed in the refrigerated autosampler at 5 °C. The final 
concentration of each peptide in the sample was approximately 1 nM.  
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4.5.8  Online Labeling 
Primary amines in the dialysate were “light” labeled using an on-column procedure 
described previously.97 Briefly, at the start of each analysis, 1.1 µL of the heavy labeled standard 
(prepared as described in the previous section) was injected onto the column via the autosampler. 
Next, 1.1 µL of dialysate was injected onto the column via the “sample valve” housed in the LC 
oven. The light labeling reagent, consisting of 350 µL of triethylammonium acetate (100 mM 
triethyl amine (Sigma-Aldrich) titrated with 100 mM acetic acid to a pH of 7.4), 3.50 µL of 0.6 M 
sodium cyanoborohydride, and 3.50 µL of 4% formaldehyde (J. T. Baker, Phillipsburg, NJ), was 
then injected onto the column followed by 5% formic acid. Each reagent was injected at a volume 
of 1.1 µL.  
4.5.9  HPLC Instrumentation 
The cLC separation was achieved using a Dionex Ultimate 3000 HPLC system (NCS-
3500RS, Thermo Scientific, Germering, Germany), which consisted of a low-flow loading pump, 
a high-pressure analytical pump fitted with a nanoflow selector, and a column oven in which a 10-
port Cheminert high-pressure 1/16 in. valve (VICI, Valco, Houston, TX) was housed. The column 
oven valve was fitted with a 1.1 µL sample loop through which dialysate was collected and 
injected. The Dionex WPS-3000 RS autosampler was used for heavy standard and reagent 
injections at a volume of 1.1 µL. The autosampler was maintained at 5 °C.  
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4.5.10  Chromatography Columns 
Reversed phase capillary columns were packed in-house as described previously152. 
Briefly, a 20-cm length of 50 µm ID fused silica capillary (Polymicro, Phoenix, AZ) was fritted 
by sintering 2 µm borosilicate spheres (Thermo Scientific, Fremont, CA) in one end of the capillary 
using an electrical arc.  A 65 mg/ mL slurry of Acquity 5 µm BEH C18 particles (Waters, Milford, 
MA) was prepared in isopropanol (Fisher Chemical) and packed into the capillary at 18000 PSI 
using methanol as the packing solvent. The column was trimmed to 15 cm and connected to a 25 
µm ID x 15 cm length of fused silica capillary (Polymicro) via a liquid junction tee (Idex, Oak 
Harbor, WA). The 25 µm ID capillary was then connected to a 6-port 1/16 in. Cheminert high-
pressure valve (VICI, Valco) that was housed on the MS stage. The valve was plumbed so that 
flow could be directed through the capillary and into the column from either the loading pump 
(during labeling) or the analytical pump (during elution). The column was housed on a resistive 
heater held at 50 °C. The fritted end of the column was connected to a fused silica PicoTip emitter 
(New Objective, Woburn, MA) with a tip ID of approximately 10 µm via a PTFE sleeve.  
4.5.11  Mobile Phases 
The loading pump solvent consisted of 0.5% acetic acid, 2% Optima LC-MS grade 
methanol (Fisher Chemical, Fair Lawn, NJ), and 97.5% Optima LC-MS grade water (Fisher 
Chemical) mixed v/v. For the analytical pump, channel A contained 0.5% acetic acid in water 
while channel B consisted of 0.5% acetic acid in methanol. All solvents were used as received 
from the manufacturer.  
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4.5.12  Chromatography 
The dialysate sample and labeling reagents were delivered onto the column using the 
loading pump (containing 0.5% acetic acid/ 2% methanol/ 97.5% water) at a flow rate of 1 µL/ 
min. After the labeling steps were completed, a valve was switched, and 45% B was delivered onto 
the column via the analytical pump at 0.5 µL/min. This effectively created a step gradient. This 
mobile phase composition was maintained for 5.5 minutes, after which it was increased to 85% B 
(nominally in 0.1 minutes) for 0.2 minutes to elute highly hydrophobic contaminants then 
decreased to 2% B (in 0.1 minutes) to allow the column to re-equilibrate for 1 minute prior to the 
start of the next run. The analysis time for a single run including labeling steps was 19 minutes. 
To prevent build-up of salts and contaminants on the MS inlet, the column was manually moved 
out of line with the inlet using the micromanipulators equipped on the MS stage then placed back 
in line with the inlet immediately prior to the elution step.  
4.5.13  Mass Spectrometry 
LC-MS2 analysis was performed using positive ion mode nanospray ionization with an 
LTQ XL linear ion trap mass spectrometer (Thermo Scientific). A spray voltage of 2.3 kV was 
applied at the head of the column via the liquid junction tee. MS2 was performed using collision 
induced dissociation with a normalized collision energy of 35 and an activation time of 30 ms. 
Precursor and daughter ions were chosen based on a method described previously and were 
analyzed in the same way97. The ions used for MS2 fragmentation and extracted ion 
chromatograms can be found in Table 10. To confirm that the method was capable of detecting 
relevant concentrations of peptides, we constructed a calibration curve (Fig 35) using a serial 
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dilution of peptide standards in Modified Ringer’s from 6.25 nM to 0.019 nM. Based on the 
standard deviation of replicates (n = 3) for the lowest concentration used and the slope of the 
calibration curve (Table 11), it was determined that the detection limit was approximately 3.2 ± 
0.1 pM for yaGfl, 7.2 ± 0.8 pM for LE, and 22 ± 3 pM for GGFL.  
4.5.14  Animal Surgeries 
All procedures involving animals were approved by the Institutional Animal Care and Use 
of Committee of the University of Pittsburgh. Male Sprague-Dawley rats (250-350 g, Hilltop, 
Scottsdale, PA) were anesthetized with isoflurane (5% induction, 2.5% maintenance), placed in a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) and adjusted to flat skull for probe 
insertion. The incisor bar was adjusted so the dorsal ventral measurements at lambda and bregma 
were no more than 0.01 mm apart. Rats were wrapped in a heating blanket (37°C) and placed in a 
stereotaxic frame. A small craniotomy was made over the PFC. Probes were lowered slowly (10 
µm/sec) into the PFC (2.3 mm anterior and 3.0 mm lateral from bregma) to final position of 3 mm 
below dura. Aseptic technique was used throughout.  
4.5.15  In Vivo Sampling 
The EOP-MD probe was soaked in 70% ethanol (Decon, King of Prussia, PA) for 20 
minutes. A solution of 100 nM yasfl in Modified Ringer’s was then perfused through the 
microdialysis probe at a flow rate of 0.5 µL/ min using a Harvard Apparatus PHD 4400 
programmable syringe pump (Holliston, MA). The inclusion of yasfl in the perfusate served as a 
control to ensure the MD probes were working as expected.97 One channel of the EOP portion of 
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the probe was filled with a solution of 10 µM LE and yaGfl in Modified Ringer’s while the other 
channel was filled with a Modified Ringer’s solution also containing 10 µM LE and yaGfl as well 
as the HFI-419 IRAP inhibitor (a gift from Dr. Philip Thompson at Monash University). The HFI-
419 concentration (10, 25, and 50 µM) was varied between each rat (n = 3). To check for the 
presence of bubbles, the probe was lowered into a 1-dram vial containing Modified Ringer’s and 
current was applied for 5 minutes for each channel. Absence of current as voltage is applied is 
indicative of a bubble. Once it was apparent that the current was sufficiently stable, the current 
was turned off and the probe lowered into the PFC. Flow was continuous through the microdialysis 
probe during insertion. After 1.5 hours, the current from the high voltage power supply was 
induced and sampling of the peptide solution not containing inhibitor began. The waiting period 
was necessary to achieve steady-state between the tissue and the microdialysis probe as well as a 
stable baseline. Sampling occurred for 35 minutes prior to the first injection and was continuous 
for 2 hours after which the current was stopped, and the electrode moved to the second (peptide + 
inhibitor) channel. Current was then applied for another 2 hours, after which the electrode was 
moved back to the peptide channel. Sampling then continued for another hour.  
4.5.16  Data Analysis 
For each rat, 6 baseline measurements (no inhibitor) were recorded followed by 6 
measurements in the presence of inhibitor (at either 10, 25, or 50 µM). The final 3 measurements 
for each condition (with or without inhibitor) were used for analysis. The relative area for each 
peptide was determined by taking the peak area of the light peptide (from dialysate) and dividing 
it by the peak area of the 1 nM heavy peptide standard. The relative area was then converted to a 
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concentration using the regression in Table 11. Data were analyzed using Minitab Express (State 
College, PA). Significance was determined using one-way ANOVA followed by Tukey tests.  
4.6 Supporting Information for Electroosmotic Perfusion-Microdialysis 
Table 10 Selected Ions for Fragmentation and Quantitation of Neuropeptides 
 aIsolation widths were 3 m/z 
bTolerance was ± 0.5 m/z 
Peptide Abbreviation Precursor m/za Daughter m/zb 
Dimethyl GGFL Light GGFL 421.20 143 + 290 
2H4 Dimethyl GGFL Heavy GGFL 425.20 147 + 294 
Dimethyl LE Light LE 584.30 425 + 453 
2H4 Dimethyl LE Heavy LE 588.30 429 + 457 
Dimethyl yaGfl Light yaGfl 598.30 439 + 467 
2H4 Dimethyl yaGfl Heavy yaGfl 602.30 443 + 471 
Dimethyl yasfl Light yasfl 628.30 479 + 497 
2H4 Dimethyl yasfl Heavy yasfl 632.30 483 + 501 
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Figure 35 Calibration curve obtained using a serial dilution of GGFL (black circles), LE (red squares), and 
yaGfl (blue triangles) in Modified Ringer’s. The relative area refers to the area of the light-labeled standard 
prepared in varying concentrations divided by that of the heavy-labeled standard (1 nM). Error bars represent 
the SEM of n = 3 replicates. 
 
Table 11 Regression Statistics for Figure 35 
aUnitless 
Peptide Slope ± SEM (nM-1) Intercept ± SEMa 
GGFL 0.94 ± 0.04 0.1 ± 0.1 
LE 0.846 ± 0.008 0.05 ± 0.02 
yaGfl 0.911 ± 0.005 0.00 ± 0.01 
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Figure 36 Localization of microdialysis probes in the rat brain. (A) Representative microdialysis probe track. 
(B) Schematic reconstructions of positions of the electroosmotic perfusion – microdialysis (EOP-MD) probe in 
the rat brain. One millimeter coronal slices demonstrate that microdialysis membranes are located in the PFC 
region. Arrow represents the probe location. The red color represents the active area of the probe. 
 
 
Figure 37 EOP-MD probe assembly. Fig 37a depicts the probe following printing. It is temporarily affixed to a 
piece of tape using epoxy so that the 150 µm OD/ 75 µm ID capillaries could be inserted into each channel (Fig 
37b). The MD probe is then inserted through the integrated microdialysis probe holder. Fig 37c depicts the 
assembled EOP-MD probe looking down from the MD probe and Fig 37d shows the space between the EOP 
tip and the MD probe. For more details see the Methods section.  
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5.0 Concluding Remarks 
This dissertation described the development of analytical tools for quantitatively studying 
the fate of neuropeptides in the extracellular space. We have approached the challenges of studying 
neuropeptides in vivo, including low analyte concentration and sample loss upon collection, by 
applying novel approaches to improve capillary liquid chromatograpy (cLC) separation and 
detection and by designing sampling probes for the study of ectopeptidases. Using temperature-
assisted solute focusing (TASF), in which sub-ambient temperature transients resulted in improved 
peak shape for early-eluting analytes, we demonstrated improved detection limits for the reversed 
phase gradient elution of small molecules and peptides with cLC. We also applied the proteomics 
strategy of duplex dimethyl labeling of primary amines to the analysis of neuropeptides in 
microdialysate for a completely online approach to sample collection and analysis with cLC and 
tandem mass spectrometry (MS2). Translating this approach to microdialysis required optimization 
for the analytes, buffers, and time scales necessary for online in vivo analyses and resulted in the 
first quantitative estimates of the neuropeptides leu-enkephalin and met-enkephalin in the rat 
hippocampus using cLC-MS2. Finally, using direct laser lithography, we designed and produced 
an integrated dual-channel electroosmotic perfusion-microdialysis (EOP-MD) probe for the study 
of ectopeptidases, membrane-bound enzymes which hydrolyze neuropeptides, under matched 
conditions (± inhibitor). While further studies of solute transport and tissue damage are required 
for application of EOP-MD to biological questions, we have demonstrated that this is a promising 
technique for the quantitative study of ectopeptidases.  
 120 
Acknowledgements 
Funding for this work was provided by an Arts and Sciences Fellowship from the Kenneth 
P. Dietrich School of Arts and Sciences as well as the National Institutes of Health (R01 
GM044842). Dr. Ed Bouvier and Dr. Moon Chul Jung, both of Waters Corporation, generously 
provided Acquity packing material used in all work described here. For the TASF and on-column 
dimethylation work, we would like to thank Anthony Horner (University of Pittsburgh) for 
assistance with the development of Matlab programs for the analysis of chromatograms as well as 
Bart Degreef (Vrije Universiteit Brussel) and the Dietrich School of Arts and Sciences Machine 
and Electronics Shops (Tom Gasmire, Josh Byler, and Jim McNerney) for help in designing and 
constructing TASF instrumentation and a custom MS stage. For the EOP-MD work, Dr. Philip 
Thompson (Monash University) provided us with the HFI-419 inhibitor and Dr. Amir Faraji 
(University of Pittsburgh Medical Center) provided helpful guidance for animal surgeries. Dr. 
Andrea Jacquins-Gerstl performed the animal surgeries and histology and provided expertise for 
in vivo experiments. Dr. Jun Chen provided expertise on direct laser lithography and fabricated the 
EOP-MD probes. 
 
  
 121 
Bibliography 
1. Antczak, C.; De Meester, I.; Bauvois, B., BioEssays 2001, 23, 251-260. 
 
2. Konkoy, C. S.; Davis, T. P., Trends in Pharmacological Sciences 1996, 17, 288-294. 
 
3. Iversen, L. L.; Lee, C. M.; Gilbert, R. F.; Hunt, S.; Emson, P. C., Proc R Soc Lond B Biol 
Sci 1980, 210, 91-111. 
 
4. Pow, D. V.; Morris, J. F., Neuroscience 1989, 32, 435-439. 
 
5. van den Pol, A. N., Neuron 2012, 76, 98-115. 
 
6. Bodnar, R. J., Peptides 2014, 62, 67-136. 
 
7. Klenowski, P.; Morgan, M.; Bartlett, S. E., Br. J. Pharmacol. 2015, 172, 297-310. 
 
8. Ogren, S. O.; Kuteeva, E.; Elvander-Tottie, E.; Hokfelt, T., Eur J Pharmacol 2010, 626, 
9-17. 
 
9. de Wied, D.; Diamant, M.; Fodor, M., Front Neuroendocrinol 1993, 14, 251-302. 
 
10. de Wied, D.; Sigling, H. O., Neurotox Res 2002, 4, 453-468. 
 
11. Hoyer, D.; Bartfai, T., Chem Biodivers 2012, 9, 2367-87. 
 
12. Albiston, A. L.; Diwakarla, S.; Fernando, R. N.; Mountford, S. J.; Yeatman, H. R.; Morgan, 
B.; Pham, V.; Holien, J. K.; Parker, M. W.; Thompson, P. E.; Chai, S. Y., Br J Pharmacol 2011, 
164, 37-47. 
 
13. Wotjak, C. T.; Landgraf, R.; Engelmann, M., Pharmacol Biochem Behav 2008, 90, 125-
34. 
 
14. Kandror, K.; Pilch, P. F., Journal of Biological Chemistry 1994, 269, 138-142. 
 
15. Keller, S. R.; Scott, H. M.; Mastick, C. C.; Aebersold, R.; Lienhard, G. E., J Biol Chem 
1995, 270, 23612-8. 
 
16. Rogi, T.; Tsujimoto, M.; Nakazato, H.; Mizutani, S.; Tomoda, Y., J Biol Chem 1996, 271, 
56-61. 
 
17. Lew, R. A.; Mustafa, T.; Ye, S.; McDowall, S. G.; Chai, S. Y.; Albiston, A. L., Journal of 
Neurochemistry 2004, 86, 344-350. 
 122 
18. Matsumoto, H.; Nagasaka, T.; Hattori, A.; Rogi, T.; Tsuruoka, N.; Mizutani, S.; Tsujimoto, 
M., Eur. J. Biochem. 2001, 268, 3259-3266. 
 
19. Noble, F.; Banisadr, G.; Jardinaud, F.; Popovici, T.; Lai-Kuen, R.; Chen, H.; Bischoff, L.; 
Parsadaniantz, S. M.; Fournie-Zaluski, M. C.; Roques, B. P., Neuroscience (Oxford, U. K.) 2001, 
105, 479-488. 
 
20. Herbst, J. J.; Ross, S. A.; Scott, H. M.; Bobin, S. A.; Morris, N. J.; Lienhard, G. E.; Keller, 
S. R., Am J Physiol 1997, 272, E600-6. 
 
21. Wallis, M. G.; Lankford, M. F.; Keller, S. R., Am J Physiol Endocrinol Metab 2007, 293, 
E1092-102. 
 
22. Fernando, R. N.; Larm, J.; Albiston, A. L.; Chai, S. Y., J Comp Neurol 2005, 487, 372-90. 
 
23. Albiston, A. L.; McDowall, S. G.; Matsacos, D.; Sim, P.; Clune, E.; Mustafa, T.; Lee, J.; 
Mendelsohn, F. A.; Simpson, R. J.; Connolly, L. M.; Chai, S. Y., J Biol Chem 2001, 276, 48623-
6. 
 
24. Mouw, D.; Bonjour, J. P.; Malvin, R. L.; Vander, A., Am J Physiol 1971, 220, 239-42. 
 
25. Braszko, J.; Wisniewski, K., Pol J Pharmacol Pharm 1976, 28, 667-72. 
 
26. Braszko, J. J., J Pharm Pharmacol 1981, 33, 192-3. 
 
27. Köller, M.; Krause, H. P.; Hoffmeister, F.; Ganten, D., Neuroscience Letters 1979, 14, 71-
75. 
 
28. Baranowska, D.; Braszko, J. J.; Wisniewski, K., Psychopharmacology 1983, 81, 247-251. 
 
29. Braszko, J. J., Behavioural Brain Research 2002, 131, 79-86. 
 
30. Braszko, J. J., Clin. Exp. Hypertens. 2005, 27, 635-649. 
 
31. Braszko, J. J.; Wisniewski, K., Peptides (Fayetteville, N. Y.) 1988, 9, 475-9. 
 
32. Braszko, J. J.; Wisniewski, K.; Kupryszewski, G.; Witczuk, B., Behav. Brain Res. 1987, 
25, 195-203. 
 
33. Braszko, J. J.; Wlasienko, J.; Kupryszewski, G.; Witczuk, B.; Wisniewski, K., Physiol. 
Behav. 1988, 44, 327-32. 
 
34. de Souza, F. A. M.; Sanchis-Segura, C.; Fukada, S. Y.; de Bortoli, V. C.; Zangrossi, H.; de 
Oliveira, A. M., Neurobiol. Learn. Mem. 2004, 81, 100-103. 
 
35. Georgiev, V.; Yonkov, D., Methods Find. Exp. Clin. Pharmacol. 1985, 7, 415-18. 
 123 
 
36. Yonkov, D.; Georgiev, V.; Kambourova, T.; Opitz, M., Methods Find Exp Clin Pharmacol 
1987, 9, 205-8. 
 
37. Yonkov, D.; Georgiev, V.; Opitz, M., Methods Find. Exp. Clin. Pharmacol. 1986, 8, 203-
6. 
 
38. Winnicka, M. M., Pharmacol., Biochem. Behav. 1999, 62, 625-630. 
 
39. Albiston, A. L.; Pederson, E. S.; Burns, P.; Purcell, B.; Wright, J. W.; Harding, J. W.; 
Mendelsohn, F. A.; Weisinger, R. S.; Chai, S. Y., Behav. Brain Res. 2004, 154, 239-243. 
 
40. Borawska, M.; Kupryszewski, G.; Witczuk, B.; Wisniewski, K., Pol. J. Pharmacol. Pharm. 
1989, 41, 227-30. 
 
41. Olson, M. L.; Olson, E. A.; Qualls, J. H.; Stratton, J. J.; Harding, J. W.; Wright, J. W., 
Peptides (N. Y., NY, U. S.) 2004, 25, 233-241. 
 
42. Pederson, E. S.; Harding, J. W.; Wright, J. W., Regul. Pept. 1998, 74, 97-103. 
 
43. Wright, J. W.; Clemens, J. A.; Panetta, J. A.; Smalstig, E. B.; Stubley Weatherly, L.; 
Kramar, E. A.; Pederson, E. S.; Mungall, B. H.; Harding, J. W., Brain Res. 1996, 717, 1-11. 
 
44. Faure, S.; Bureau, A.; Oudart, N.; Javellaud, J.; Fournier, A.; Achard, J.-M., J. Hypertens. 
2008, 26, 2008-2015. 
 
45. Faure, S.; Oudart, N.; Javellaud, J.; Fournier, A.; Warnock, D. G.; Achard, J.-M., J. 
Hypertens. 2006, 24, 2255-2261. 
 
46. Braszko, J. J.; Kupryszewski, G.; Witczuk, B.; Wisniewski, K., Neuroscience 1988, 27, 
777-83. 
 
47. Braszko, J. J., Peptides (N. Y., NY, U. S.) 2004, 25, 1195-1203. 
 
48. Braszko, J. J.; Wlasienko, J.; Koziolkiewicz, W.; Janecka, A.; Wisniewski, K., Brain Res. 
1991, 542, 49-54. 
 
49. Braszko, J. J.; Walesiuk, A.; Wielgat, P., J Renin Angiotensin Aldosterone Syst 2006, 7, 
168-74. 
 
50. Stragier, B.; Sarre, S.; Vanderheyden, P.; Vauquelin, G.; Fournie-Zaluski, M.-C.; Ebinger, 
G.; Michotte, Y., J. Neurochem. 2004, 90, 1251-1257. 
 
51. Beyer, C. E.; Dwyer, J. M.; Platt, B. J.; Neal, S.; Luo, B.; Ling, H. P.; Lin, Q.; Mark, R. J.; 
Rosenzweig-Lipson, S.; Schechter, L. E., Psychopharmacology (Berl) 2010, 209, 303-11. 
 124 
52. De Bundel, D.; Demaegdt, H.; Lahoutte, T.; Caveliers, V.; Kersemans, K.; Ceulemans, A.-
G.; Vauquelin, G.; Clinckers, R.; Vanderheyden, P.; Michotte, Y.; Smolders, I., J. Neurochem. 
2010, 112, 1223-1234. 
 
53. Stragier, B.; Hristova, I.; Sarre, S.; Ebinger, G.; Michotte, Y., Eur J Neurosci 2005, 22, 
658-64. 
 
54. Wright, J. W.; Miller-Wing, A. V.; Shaffer, M. J.; Higginson, C.; Wright, D. E.; 
Hanesworth, J. M.; Harding, J. W., Brain Research Bulletin 1993, 32, 497-502. 
 
55. Wright, J. W.; Stubley, L.; Pederson, E. S.; Kramár, E. A.; Hanesworth, J. M.; Harding, J. 
W., The Journal of Neuroscience 1999, 19, 3952-3961. 
 
56. Swanson, G. N.; Hanesworth, J. M.; Sardinia, M. F.; Coleman, J. K. M.; Wright, J. W.; 
Hall, K. L.; Miller-Wing, A. V.; Stobb, J. W.; Cook, V. I.; Harding, E. C.; Harding, J. W., 
Regulatory Peptides 1992, 40, 409-419. 
 
57. Vanderheyden, P. M., Mol Cell Endocrinol 2009, 302, 159-66. 
 
58. Albiston, A. L.; Fernando, R. N.; Yeatman, H. R.; Burns, P.; Ng, L.; Daswani, D.; 
Diwakarla, S.; Pham, V.; Chai, S. Y., Neurobiol. Learn. Mem. 2010, 93, 19-30. 
 
59. Albiston, A. L.; Mustafa, T.; McDowall, S. G.; Mendelsohn, F. A. O.; Lee, J.; Chai, S. Y., 
Trends in Endocrinology & Metabolism 2003, 14, 72-77. 
 
60. Chai, S. Y.; Fernando, R.; Peck, G.; Ye, S. Y.; Mendelsohn, F. A.; Jenkins, T. A.; Albiston, 
A. L., Cell Mol Life Sci 2004, 61, 2728-37. 
 
61. Wright, J. W.; Harding, J. W., Prog Neurobiol 2011, 95, 49-67. 
 
62. De Bundel, D.; Fafouri, A.; Csaba, Z.; Loyens, E.; Lebon, S.; El Ghouzzi, V.; Peineau, S.; 
Vodjdani, G.; Kiagiadaki, F.; Aourz, N.; Coppens, J.; Walrave, L.; Portelli, J.; Vanderheyden, P.; 
Yeen, C. S.; Thermos, K.; Bernard, V.; Collingridge, G.; Auvin, S.; Gressens, P.; Smolders, I.; 
Dournaud, P., J. Neurosci. 2015, 35, 11960-11975. 
 
63. De Bundel, D.; Smolders, I.; Yang, R.; Albiston, A. L.; Michotte, Y.; Chai, S. Y., 
Neurobiol Learn Mem 2009, 92, 19-26. 
 
64. Diwakarla, S.; Nylander, E.; Groenbladh, A.; Vanga, S. R.; Khan, Y. S.; Gutierrez-de-
Teran, H.; Ng, L.; Pham, V.; Saevmarker, J.; Lundbaeck, T.; Jenmalm-Jensen, A.; Andersson, H.; 
Engen, K.; Rosenstroem, U.; Larhed, M.; Aaqvist, J.; Chai, S. Y.; Hallberg, M., Mol. Pharmacol. 
2016, 89, 413-424. 
 
 
 
 125 
65. Diwakarla, S.; Nylander, E.; Groenbladh, A.; Vanga, S. R.; Khan, Y. S.; Gutierrez-de-
Teran, H.; Saevmarker, J.; Ng, L.; Pham, V.; Lundbaeck, T.; Jenmalm-Jensen, A.; Svensson, R.; 
Artursson, P.; Zelleroth, S.; Engen, K.; Rosenstroem, U.; Larhed, M.; Aaqvist, J.; Chai, S. Y.; 
Hallberg, M., ACS Chem. Neurosci. 2016, 7, 1383-1392. 
 
66. Albiston, A. L.; Morton, C. J.; Ng, H. L.; Pham, V.; Yeatman, H. R.; Ye, S.; Fernando, R. 
N.; De Bundel, D.; Ascher, D. B.; Mendelsohn, F. A.; Parker, M. W.; Chai, S. Y., FASEB J 2008, 
22, 4209-17. 
 
67. Stragier, B.; Demaegdt, H.; De Bundel, D.; Smolders, I.; Sarre, S.; Vauquelin, G.; Ebinger, 
G.; Michotte, Y.; Vanderheyden, P., Brain Res. 2007, 1131, 97-105. 
 
68. Albiston, A. L.; Peck, G. R.; Yeatman, H. R.; Fernando, R.; Ye, S.; Chai, S. Y., Pharmacol 
Ther 2007, 116, 417-27. 
 
69. Andersson, H.; Hallberg, M., Int. J. Hypertens. 2012, 789671, 18 pp. 
 
70. Buchberger, A.; Yu, Q.; Li, L., Annu. Rev. Anal. Chem. 2015, 8, 485-509. 
 
71. Kohsaka, A.; Watanobe, H.; Kakizaki, Y.; Suda, T., Neuroendocrinology 1999, 69, 245-
53. 
 
72. Mizuno, M.; Gearing, M.; Terasawa, E., Endocrinology 2000, 141, 1772-9. 
 
73. Kent, P.; Anisman, H.; Merali, Z., Neuroendocrinology 2001, 73, 203-14. 
 
74. Slaney, T. R.; Nie, J.; Hershey, N. D.; Thwar, P. K.; Linderman, J.; Burns, M. A.; Kennedy, 
R. T., Anal. Chem. (Washington, DC, U. S.) 2011, 83, 5207-5213. 
 
75. Redgrave, P., Pharmacology Biochemistry and Behavior 1977, 6, 471-474. 
 
76. Kottegoda, S.; Shaik, I.; Shippy, S. A., Journal of Neuroscience Methods 2002, 121, 93-
101. 
 
77. Dluzen, D. E.; Ramirez, V. D., Pharmacology Biochemistry and Behavior 1986, 24, 147-
150. 
 
78. Ungerstedt, U.; Hallström, Å., Life Sciences 1987, 41, 861-864. 
 
79. Watson, C. J. V., B. J.; Kennedy, R. T., Anal. Chem. 2006, 1392-1399. 
 
80. Lanckmans, K.; Sarre, S.; Smolders, I.; Michotte, Y., Rapid Commun Mass Spectrom 2007, 
21, 1187-95. 
 
81. Zhou, Y.; Wong, J. M.; Mabrouk, O. S.; Kennedy, R. T., Anal Chem 2015, 87, 9802-9. 
 
 126 
82. Wilson, S. R.; Vehus, T.; Berg, H. S.; Lundanes, E., Bioanalysis 2015, 7, 1799-815. 
 
83. Desmet, G.; Eeltink, S., Analytical chemistry 2013, 85, 543-56. 
 
84. Gilar, M. M., T. S.; Roman, G.; Johnson, J. S.; Murphy, J. P.; Jorgenson, J. W. , J. 
Chromatogr. A. 2015, 1381, 110-117. 
 
85. Snyder, L. R. K., J. J; Dolan, J. W., Introduction to Modern Liquid Chromatography. Third 
ed.; John Wiley and Sons, Inc.: Hoboken, N.J., 2010. 
 
86. Heron, S. T., A.; Chervet, J.-P., Chromatographia 2000, 51, 495-499. 
 
87. Foster, M. D. A., M. A. Nichols, J. A.; Bakalyar, S. R., J. Chromatogr. A 2000, 869, 231-
241. 
 
88. Molander, P. T., S. J.; Bruheim, I. A.; Trones, R.; Greibrokk, T.; Lundanes, E.; Gundersen, 
T. E. , J. High Resol. Chromatogr. 1999, 22, 490-494. 
 
89. Leon-Gonzalez, M. E.; Rosales-Conrado, N.; Perez-Arribas, L. V.; Polo-Diez, L. M., J. 
Chromatogr. A 2010, 1217, 7507-13. 
 
90. Collins, D.; Nesterenko, E.; Connolly, D.; Vasquez, M.; Macka, M.; Brabazon, D.; Paull, 
B., Analytical chemistry 2011, 83, 4307-13. 
 
91. Causon, T. J.; Cortes, H. J.; Shellie, R. A.; Hilder, E. F., Analytical chemistry 2012, 84, 
3362-8. 
 
92. Emmett, M. R.; Andren, P. E.; Caprioli, R. M., J. Neurosci. Methods 1995, 62, 141-147. 
 
93. Lanckmans, K.; Stragier, B.; Sarre, S.; Smolders, I.; Michotte, Y., Journal of separation 
science 2007, 30, 2217-24. 
 
94. André, P. E.; Caprioli, R. M., Journal of Mass Spectrometry 1995, 30, 817-824. 
 
95. Haskins, W. E.; Watson, C. J.; Cellar, N. A.; Powell, D. H.; Kennedy, R. T., Anal Chem 
2004, 76, 5523-33. 
 
96. Haskins, W. E. W., Z.; Watson, C. J.; Rostand, R. R.; Witowski, S. R.; Powell, D. H.; 
Kennedy, R. T., Anal Chem 2001, 73, 5005-5014. 
 
97. Wilson, R. E.; Jaquins-Gerstl, A.; Weber, S. G., Anal Chem 2018, 90, 4561-4568. 
 
98. Ou, Y.; Wilson, R. E.; Weber, S. G., Annu Rev Anal Chem (Palo Alto Calif) 2018, 11, 509-
533. 
 
 127 
99. Frommer, W. B.; Davidson, M. W.; Campbell, R. E., Chem. Soc. Rev. 2009, 38, 2833-
2841. 
 
100. Johansson, M. K.; Cook, R. M., Chem. - Eur. J. 2003, 9, 3466-3471. 
 
101. Razgulin, A.; Ma, N.; Rao, J., Chem. Soc. Rev. 2011, 40, 4186-4216. 
 
102. Koretsky, A. P., Neuroimage 2012, 62, 1208-15. 
 
103. Hingorani, D. V.; Yoo, B.; Bernstein, A. S.; Pagel, M. D., Chem. - Eur. J. 2014, 20, 9840-
9850. 
 
104. Weissleder, R.; Tung, C.-H.; Mahmood, U.; Bogdanov, A., Jr., Nat. Biotechnol. 1999, 17, 
375-378. 
 
105. Tung, C.-H.; Mahmood, U.; Bredow, S.; Weissleder, R., Cancer Res. 2000, 60, 4953-4958. 
 
106. Lee, J.; Bogyo, M., ACS Chem. Biol. 2010, 5, 233-243. 
 
107. Gu, K.; Xu, Y.; Li, H.; Guo, Z.; Zhu, S.; Zhu, S.; Shi, P.; James, T. D.; Tian, H.; Zhu, W.-
H., J. Am. Chem. Soc. 2016, 138, 5334-5340. 
 
108. Rosell, A.; Ortega-Aznar, A.; Alvarez-Sabín, J.; Fernández-Cadenas, I.; Ribó, M.; Molina, 
C. A.; Lo, E. H.; Montaner, J., Stroke 2006, 37, 1399-1406. 
 
109. Gawlak, M.; Górkiewicz, T.; Gorlewicz, A.; Konopacki, F. A.; Kaczmarek, L.; Wilczynski, 
G. M., Neuroscience 2009, 158, 167-176. 
 
110. Gillespie, J. W.; Best, C. J. M.; Bichsel, V. E.; Cole, K. A.; Greenhut, S. F.; Hewitt, S. M.; 
Ahram, M.; Gathright, Y. B.; Merino, M. J.; Strausberg, R. L., The American journal of pathology 
2002, 160, 449-457. 
 
111. Hadler-Olsen, E.; Kanapathippillai, P.; Berg, E.; Svineng, G.; Winberg, J.-O.; Uhlin-
Hansen, L., J. Histochem. Cytochem. 2010, 58, 29-39. 
 
112. Wiera, G.; Nowak, D.; Van Hove, I.; Dziegiel, P.; Moons, L.; Mozrzymas, J. W., Journal 
of Neuroscience 2017, 37, 1240-1256. 
 
113. Jares-Erijman, E. A.; Jovin, T. M., Nature Biotechnology 2003, 21, 1387-1395. 
 
114. Keow, J. Y.; Herrmann, K. M.; Crawford, B. D., Matrix Biol. 2011, 30, 169-177. 
 
115. Renema, W. K. J.; Kan, H. E.; Wieringa, B.; Heerschap, A., NMR Biomed. 2007, 20, 448-
467. 
 
 128 
116. Choi, C.; Ganji, S. K.; DeBerardinis, R. J.; Hatanpaa, K. J.; Rakheja, D.; Kovacs, Z.; Yang, 
X. L.; Mashimo, T.; Raisanen, J. M.; Marin-Valencia, I.; Pascual, J. M.; Madden, C. J.; Mickey, 
B. E.; Malloy, C. R.; Bachoo, R. M.; Maher, E. A., Nat Med 2012, 18, 624-9. 
117. Kanamori, K., Analytical Biochemistry 2017, 529, 179-192. 
 
118. Kanamori, K.; Ross, B. D., Biochem. J. 1993, 293, 461-8. 
 
119. Bivehed, E.; Stromvall, R.; Bergquist, J.; Bakalkin, G.; Andersson, M., Peptides 2017, 87, 
20-27. 
 
120. Grobe, N.; Elased, K. M.; Cool, D. R.; Morris, M., Am. J. Physiol. 2012, 302, E1016-
E1024. 
 
121. OuYang, C.; Chen, B.; Li, L., Journal of The American Society for Mass Spectrometry 
2015, 26, 1992-2001. 
 
122. Zhang, H.; Stoeckli, M.; Andren, P. E.; Caprioli, R. M., J. Mass Spectrom. 1999, 34, 377-
383. 
 
123. Reed, B.; Bidlack, J. M.; Chait, B. T.; Kreek, M. J., J. Neuroendocrinol. 2008, 20, 606-
616. 
 
124. Reed, B.; Zhang, Y.; Chait, B. T.; Kreek, M. J., J. Neurochem. 2003, 86, 815-823. 
 
125. Klintenberg, R.; Andren, P. E., J. Mass Spectrom. 2005, 40, 261-270. 
 
126. Stenken, J. A.; Holunga, D. M.; Decker, S. A.; Sun, L., Anal Biochem 2001, 290, 314-23. 
 
127. Steuerwald, A. J.; Villeneuve, J. D.; Sun, L.; Stenken, J. A., J. Pharm. Biomed. Anal. 2006, 
40, 1041-1047. 
 
128. Sun, L.; Stenken, J. A.; Yang, A. Y.; Zhao, J. J.; Musson, D. G., Anal. Biochem. 2007, 370, 
26-37. 
 
129. Wang, Y.; Zagorevski, D. V.; Stenken, J. A., Anal. Chem. (Washington, DC, U. S.) 2008, 
80, 2050-2057. 
 
130. Sun, L.; Stenken, J. A.; Brunner, J. E.; Michel, K. B.; Adelsberger, J. K.; Yang, A. Y.; 
Zhao, J. J.; Musson, D. G., Anal. Biochem. 2008, 381, 214-223. 
 
131. Bungay, P. M.; Morrison, P. F.; Dedrick, R. L., Life Sciences 1990, 46, 105-119. 
 
132. Mou, X.; Stenken, J. A., Anal. Chem. 2006, 78, 7778-7784. 
 
133. Dubey, S.; Kalia, Y. N., J. Controlled Release 2011, 152, 356-362. 
 
 129 
134. Wang, Y.; Zagorevski, D. V.; Lennartz, M. R.; Loegering, D. J.; Stenken, J. A., Anal. 
Chem. (Washington, DC, U. S.) 2009, 81, 9961-9971. 
 
135. Morrison, P. F.; Bungay, P. M.; Hsiao, J. K.; Ball, B. A.; Mefford, I. N.; Dedrick, R. L., 
Journal of Neurochemistry 1991, 57, 103-119. 
 
136. Chen, K. C.; Höistad, M.; Kehr, J.; Fuxe, K.; Nicholson, C., Journal of Neurochemistry 
2002, 81, 108-121. 
 
137. Yang, H.; Peters, J. L.; Allen, C.; Chern, S.-S.; Coalson, R. D.; Michael, A. C., Analytical 
Chemistry 2000, 72, 2042-2049. 
 
138. Smith, A. D.; Justice, J. B., Journal of Neuroscience Methods 1994, 54, 75-82. 
 
139. Xu, H.; Guy, Y.; Hamsher, A.; Shi, G.; Sandberg, M.; Weber, S. G., Anal Chem 2010, 82, 
6377-83. 
 
140. Rupert, A. E.; Ou, Y.; Sandberg, M.; Weber, S. G., ACS Chem Neurosci 2013, 4, 838-48. 
 
141. Rice, C. L.; Whitehead, R., The Journal of Physical Chemistry 1965, 69, 4017-4024. 
 
142. Probstein, R. F., Physicochemical Hydrodynamics: An Introduction. John Wiley & Sons, 
Inc.: Hoboken, New Jersey, 2003. 
 
143. Kirby, B. J.; Hasselbrink, E. F., Jr., Electrophoresis 2004, 25, 187-202. 
 
144. Rathore, A. S.; Wen, E.; Horváth, C., Analytical Chemistry 1999, 71, 2633-2641. 
 
145. Rathore, A. S., Electrophoresis 2002, 23, 3827-46. 
 
146. Scales, N.; Tait, R. N., J Chem Phys 2006, 125, 094714. 
 
147. Støverud, K. H.; Darcis, M.; Helmig, R.; Hassanizadeh, S. M., Transport in Porous Media 
2011, 92, 119-143. 
 
148. Ou, Y.; Weber, S. G., Anal Chem 2017, 89, 5864-5873. 
 
149. Ou, Y.; Wu, J.; Sandberg, M.; Weber, S. G., Anal Bioanal Chem 2014, 406, 6455-68. 
 
150. Wu, J.; Sandberg, M.; Weber, S. G., Anal Chem 2013, 85, 12020-7. 
 
151. Ou, Y.; Weber, S. G., ACS Chem Neurosci 2018, 9, 535-544. 
 
152. Wilson, R. E.; Groskreutz, S. R.; Weber, S. G., Anal Chem 2016, 88, 5112-21. 
 
 130 
153. Granger, J.; Plumb, R.; Castro-Perez, J.; Wilson, I. D., Chromatographia 2005, 61, 375-
380. 
 
154. Desmet, G.; Eeltink, S., Anal. Chem. 2013, 85, 543-56. 
155. Gika, H. G.; Theodoridis, G. A.; Plumb, R. S.; Wilson, I. D., J. Pharm. Biomed. Anal. 
2014, 87, 12-25. 
 
156. Lee, H.; Griffin, T. J.; Gygi, S. P.; Rist, B.; Aebersold, R., Anal. Chem. 2002, 74, 4353-
4360. 
 
157. Lasonder, E.; Ishihama, Y.; Andersen, J. S.; Vermunt, A. M. W.; Pain, A.; Sauerwein, R. 
W.; Eling, W. M. C.; Hall, N.; Water, A. P.; Stunnenber, H. G.; Mann, M., Nature 2002, 419, 537-
542. 
 
158. Ishihama, Y., J. Chromatogr. A. 2005, 1067, 73-83. 
 
159. Rogeberg, M.; Vehus, T.; Grutle, L.; Greibrokk, T.; Wilson, S. R.; Lundanes, E., J. Sep. 
Sci. 2013, 36, 2838-47. 
 
160. Falkenby, L. G.; Such-Sanmartin, G.; Larsen, M. R.; Vorm, O.; Bache, N.; Jensen, O. N., 
Journal of proteome research 2014, 13, 6169-75. 
 
161. Moruz, L.; Pichler, P.; Stranzl, T.; Mechtler, K.; Kall, L., Anal. Chem. 2013, 85, 7777-85. 
 
162. Theodoridis, G.; Gika, H. G.; Wilson, I. D., TrAC, Trends Anal. Chem. 2008, 27, 251-260. 
 
163. Filla, L. A.; Yuan, W.; Feldman, E. L.; Li, S.; Edwards, J. L., Journal of proteome research 
2014, 13, 6121-34. 
 
164. Chen, S.; Hoene, M.; Li, J.; Li, Y.; Zhao, X.; Haring, H. U.; Schleicher, E. D.; Weigert, C.; 
Xu, G.; Lehmann, R., J. Chromatogr. A 2013, 1298, 9-16. 
 
165. Gao, X.; Zhang, Q.; Meng, D.; Isaac, G.; Zhao, R.; Fillmore, T. L.; Chu, R. K.; Zhou, J.; 
Tang, K.; Hu, Z.; Moore, R. J.; Smith, R. D.; Katze, M. G.; Metz, T. O., Analytical and 
bioanalytical chemistry 2012, 402, 2923-33. 
 
166. Tseng, Y. J.; Kuo, C. T.; Wang, S. Y.; Liao, H. W.; Chen, G. Y.; Ku, Y. L.; Shao, W. C.; 
Kuo, C. H., Electrophoresis 2013, 34, 2918-27. 
 
167. Haggarty, J.; Oppermann, M.; Dalby, M. J.; Burchmore, R. J.; Cook, K.; Weidt, S.; 
Burgess, K. E., Metabolomics. 2015, 11, 1465-1470. 
 
168. Haskins, W. E.; Wang, Z.; Watson, C. J.; Rostand, R. R.; Witowski, S. R.; Powell, D. H.; 
Kennedy, R. T., Anal. Chem. 2001, 73, 5005-5014. 
 
169. Zhou, Y.; Mabrouk, O. S.; Kennedy, R. T., J. Am. Soc. Mass Spectrom. 2013, 24, 1700-9. 
 131 
 
170. Zhang, Z.; Jia, C.; Li, L., J. Sep. Sci. 2012, 35, 1779-84. 
 
171. Maes, K.; Van Liefferinge, J.; Viaene, J.; Van Schoors, J.; Van Wanseele, Y.; Bechade, 
G.; Chambers, E. E.; Morren, H.; Michotte, Y.; Vander Heyden, Y.; Claereboudt, J.; Smolders, I.; 
Van Eeckhaut, A., J. Chromatogr. A 2014, 1360, 217-28. 
 
172. Mabrouk, O. S.; Kennedy, R. T., J. Neurosci. Methods. 2012, 209, 127-33. 
 
173. Han, J.; Ye, L.; Xu, L.; Zhou, Z.; Gao, F.; Xiao, Z.; Wang, Q.; Zhang, B., Anal. Chim. Acta 
2014, 852, 267-73. 
 
174. Shen, Y.; Zhang, R.; Moore, R. J.; Kim, J.; Metz, T. O.; Hixson, K. K.; Zhao, R.; Livesay, 
E. A.; Udseth, H. R.; Smith, R. D., Anal. Chem. 2005, 77, 3090-3100. 
 
175. Wang, F.; Wei, X.; Zhou, H.; Liu, J.; Figeys, D.; Zou, H., Proteomics 2012, 12, 3129-37. 
 
176. Grebe, S. K. G.; Singh, R. J., Clin. Biochem. Rev. 2011, 32. 
 
177. Abbatiello, S. E.; Schilling, B.; Mani, D. R.; Zimmerman, L. J.; Hall, S. C.; MacLean, B.; 
Albertolle, M.; Allen, S.; Burgess, M.; Cusack, M. P.; Gosh, M.; Hedrick, V.; Held, J. M.; 
Inerowicz, H. D.; Jackson, A.; Keshishian, H.; Kinsinger, C. R.; Lyssand, J.; Makowski, L.; Mesri, 
M.; Rodriguez, H.; Rudnick, P.; Sadowski, P.; Sedransk, N.; Shaddox, K.; Skates, S. J.; Kuhn, E.; 
Smith, D.; Whiteaker, J. R.; Whitwell, C.; Zhang, S.; Borchers, C. H.; Fisher, S. J.; Gibson, B. W.; 
Liebler, D. C.; MacCoss, M. J.; Neubert, T. A.; Paulovich, A. G.; Regnier, F. E.; Tempst, P.; Carr, 
S. A., Mol. Cell. Proteomics. 2015, 14, 2357-74. 
 
178. Rauh, M., Journal of chromatography. B, Analytical technologies in the biomedical and 
life sciences 2012, 883-884, 59-67. 
 
179. Alberice, J. V.; Amaral, A. F.; Armitage, E. G.; Lorente, J. A.; Algaba, F.; Carrilho, E.; 
Marquez, M.; Garcia, A.; Malats, N.; Barbas, C., J. Chromatogr. A 2013, 1318, 163-70. 
 
180. Bjellaas, T.; Holm, A.; Molander, P.; Tornes, J. A.; Greibrokk, T.; Lundanes, E., Analytical 
and bioanalytical chemistry 2004, 378, 1021-30. 
 
181. Novotny, M. V.; Daido, I., Microcolumn Separations Columns, Instrumentation, and 
Ancillary Techniques. Elsevier Science Pub. Co.: Amsterdam, New York; New York, 1985. 
 
182. Moore, A. W.; Jorgenson, J. W., Anal. Chem. 1995, 67, 3448-3455. 
 
183. Molander, P.; Thommesen, S. J.; Bruheim, I. A.; Trones, R.; Greibrokk, T.; Lundanes, E.; 
Gundersen, T. E., J. High Resol. Chromatogr. 1999, 22, 490-494. 
 
184. Trones, R.; Tangen, A.; Lund, W.; Greibrokk, T., J. Chromatogr. A. 1999, 835, 105-112. 
 
 132 
185. Prüß, A.; Kempter, C.; Gysler, J.; Jira, T., J. Chromatogr. A. 2004, 1030, 167-176. 
 
186. Wei, H.; Nolkrantz, K.; Parkin, M. C.; Chisolm, C. N.; O'Callaghan, J. P.; Kennedy, R. T., 
Anal. Chem. 2006, 78, 4342-4351. 
 
187. Gilar, M.; McDonald, T. S.; Roman, G.; Johnson, J. S.; Murphy, J. P.; Jorgenson, J. W., J. 
Chromatogr. A. 2015, 1381, 110-117. 
 
188. Snyder, L. R.; Kirkland, J. J.; Dolan, J. W., Introduction to Modern Liquid 
Chromatography. Third ed.; John Wiley and Sons, Inc.: Hoboken, N.J., 2010. 
 
189. Foster, M. D.; Arnold, M. A.; Nichols, J. A.; Bakalyar, S. R., J. Chromatogr. A 2000, 869, 
231-241. 
 
190. Heron, S.; Tchapla, A.; Chervet, J.-P., Chromatographia 2000, 51, 495-499. 
 
191. Layne, J.; Farcas, T.; Rustamov, I.; Ahmed, F., J. Chromatogr. A 2001, 913, 233-242. 
 
192. Rezai, M. A.; Famiglini, G.; Cappiello, A., J. Chromatogr. A 1996, 742, 69-78. 
 
193. Wang, X.; Barber, W. E.; Carr, P. W., J. Chromatogr. A 2006, 1107, 139-51. 
 
194. Grushka, E., Anal. Chem. 1970, 42, 1142-1147. 
 
195. Robards, K.; Haddad, P. R.; Jackson, P. E., Principles and Practice of Modern 
Chromatographic Methods. Academic Press, Inc. : San Diego, CA, 1997. 
 
196. Bird, R. B.; Stewart, W. E.; Lightfoot, E. N., Transport Phenomena. 2nd ed.; John Wiley 
and Sons, Inc.: New York, 2002. 
 
197. Poppe, H.; Kraak, J. C.; Huber, J. F. K.; van den Berg, J. H. M., Chromatographia 1981, 
14, 515-523. 
 
198. Bowermaster, J.; McNair, H., J. of Chromatogr. 1983, 279, 431-438. 
 
199. Zhu, P. L.; Dolan, J. W.; Snyder, L. R., J. Chromatogr. A 1996, 756, 41-50. 
 
200. Jandera, P.; Blomberg, L. G.; Lundanes, E., J. Sep. Sci. 2004, 27, 1402-1418. 
 
201. Giddings, J. C., Unified Separation Science. Wiley-Interscience: New York, 1991. 
 
202. Greibrokk, T.; Andersen, T., J. Sep. Sci. 2001, 24, 899-909. 
 
203. Grushka, E.; Colin, H.; Guiochon, G., J. Chromatogr. 1982, 248, 325-339. 
 
204. Gasslander, U.; Arbin, A.; Albertsson, A.-C., Polymer 2007, 48, 7523-7530. 
 133 
 
205. Holm, A.; Molander, P.; Lundanes, E.; Greibrokk, T., Journal of Separation Science 2003, 
26, 1147-1153. 
 
206. Eghbali, H.; Sandra, K.; Tienpont, B.; Eeltink, S.; Sandra, P.; Desmet, G., Anal. Chem. 
2012, 84, 2031-2037. 
 
207. Groskreutz, S. R.; Weber, S. G., J. Chromatogr. A 2014, 1354, 65-74. 
 
208. Groskreutz, S. R.; Horner, A. R.; Weber, S. G., J. Chromatogr. A 2015, 1405, 133-9. 
 
209. Chuman, H.; Mori, A.; Tanaka, H.; Yamagami, C.; Fujita, T., J. Pharm. Sci. 2004, 93, 
2681-97. 
 
210. Schultz, T. W.; Hewitt, M.; Netzeva, T. I.; Cronin, M. T. D., QSAR & Combinatorial 
Science 2007, 26, 238-254. 
 
211. Neue, U. D.; Kuss, H. J., J. Chromatogr. A 2010, 1217, 3794-803. 
 
212. Zhang, J.; Liu, Y.; Jaquins-Gerstl, A.; Shu, Z.; Michael, A. C.; Weber, S. G., J. 
Chromatogr. A. 2012, 1251, 54. 
 
213. Colin, H.; Martin, M.; Guiochon, G., J. Chromatogr. 1979, 185, 79-95. 
 
214. Snyder, L. R.; Dolan, J. W., High-Performance Gradient Elution: The Practical 
Application of the Linear-Solvent-Strength Model. John Wiley and Sons, Inc.: 2007. 
 
215. Gilpin, R. K.; Jaroniec, M.; Lin, S., Chromatographia 1990, 30, 393-399. 
 
216. Chen, M. H.; Horvath, C., J. Chromatogr. A 1997, 788, 51-61. 
 
217. Liu, H.; Finch, J. W.; Lavallee, M. J.; Collamati, R. A.; Benevides, C. C.; Gebler, J. C., J. 
Chromatogr. A 2007, 1147, 30-6. 
 
218. Jandera, P., Anal. Chim. Acta 2011, 692, 1-25. 
 
219. Soukup, J.; Jandera, P., Biologija 2011, 57, 85-91. 
 
220. Soukup, J.; Jandera, P., J. Chromatogr. A. 2012, 1245, 98-108. 
 
221. Kumar, A.; Heaton, J. C.; McCalley, D. V., J. Chromatogr. A. 2013, 1276, 33-46. 
 
222. Yi, Y. Capillary HPLC Separation of Selected Neuropeptides. University of Pittsburgh, 
Pittsburgh, 2012. 
 
223. Mao, Y.; Carr, P. W., Anal. Chem. 2000, 72, 110-8. 
 134 
 
224. Saifutdinov, B. R.; Emel'yanova, N. S.; Pimerzin, A. A., Prot. Met. Phys. Chem. Surf. 2014, 
50, 317-325. 
 
225. Kuznetsova, E. S.; Buryak, A. K., Colloids Surf, A. 2011, 383, 73-9. 
 
226. Melmer, M.; Stangler, T.; Premstaller, A.; W., L., J. Chromatogr. A 2010, 1217, 6092-
6096. 
 
227. Gaudin, K.; Hanai, T.; Chaminade, P.; Baillet, A., J. Chromatogr. A 2007, 1157, 56-64. 
 
228. Kwaterczak, A.; Bielejewska, A., Anal Chim Acta. 2005, 537, 41-46. 
 
229. Moeckel, H. J.; Braedikow, A.; Melzer, H.; Aced, G., J. Liq. Chromatogr. 1991, 14, 2477-
2498. 
 
230. Snyder, L. R.; Dolan, J. W. High-Performance Gradient Elution: The Practical 
Application of the Linear-Solvent-Strength Model. John Wiley and Sons, Inc.: 2007. 
 
231. Eghbali, H. S., K.; Tienpont, B.; Eeltink, S.; Sandra, P.; Desmet, G., Anal. Chem. 2012, 
84, 2031-2037. 
 
232. Madison, D. V.; Nicoll, R. A., Journal of physiology 1988, 398, 123-130. 
 
233. Piguet, P.; North, R. A., The Journal of Pharmacology and Experimental Therapeutics 
1993, 266, 1139-1146. 
 
234. Yoshitake, S.; Ijiri, S.; Kehr, J.; Yoshitake, T., Neurochem. Int. 2013, 62, 314-323. 
 
235. Lee, S. Y.; Park, S. H.; Chung, C.; Kim, J. J.; Choi, S. Y.; Han, J. S., Sci Rep 2015, 5, 
18540. 
 
236. Murphy, N. P., ACS Chem Neurosci 2015, 6, 94-107. 
 
237. Andren, P. E.; Caprioli, R. M., Brain Research 1999, 845, 123-129. 
 
238. Baseski, H. M.; Watson, C. J.; Cellar, N. A.; Shackman, J. G.; Kennedy, R. T., J Mass 
Spectrom 2005, 40, 146-53. 
 
239. Emmett, M. R.; Andren, P. E.; Caprioli, R. M., J. Neurosci. Methods 1995, 62, 141-147. 
 
240. Maidment, N. T.; Brumbaugh, D. R.; Rudolph, V. D.; Erdelyi, E.; Evans, C. J., 
Neuroscience 1989, 33, 549-557. 
 
241. Zhou, Y.; Mabrouk, O. S.; Kennedy, R. T., J Am Soc Mass Spectrom 2013, 24, 1700-9. 
 
 135 
242. Li, Q. Z., J.; Kennedy, R. T., Anal Chem 2009, 81, 2242-2250. 
 
243. Maes, K.; Van Liefferinge, J.; Viaene, J.; Van Schoors, J.; Van Wanseele, Y.; Bechade, 
G.; Chambers, E. E.; Morren, H.; Michotte, Y.; Vander Heyden, Y.; Claereboudt, J.; Smolders, I.; 
Van Eeckhaut, A., J Chromatogr A 2014, 1360, 217-28. 
 
244. Zestos, A. G.; Kennedy, R. T., AAPS J 2017. 
 
245. Song, P.; Mabrouk, O. S.; Hershey, N. D.; Kennedy, R. T., Anal Chem 2012, 84, 412-419. 
 
246. Wong, J.-M. T.; Malec, P. A.; Mabrouk, O. S.; Ro, J.; Dus, M.; Kennedy, R. T., J. 
Chromatogr. A 2016, 1446, 78-90. 
 
247. Raijmakers, R.; Berkers, C. R.; de Jong, A.; Ovaa, H.; Heck, A. J.; Mohammed, S., Mol 
Cell Proteomics 2008, 7, 1755-62. 
 
248. Boersema, P. J.; Raijmakers, R.; Lemeer, S.; Mohammed, S.; Heck, A. J., Nat Protoc 2009, 
4, 484-94. 
 
249. Maiolica, A.; Borsotti, D.; Rappsilber, J., Proteomics 2005, 5, 3847-50. 
 
250. Mitala, C. M.; Wang, Y.; Borland, L. M.; Jung, M.; Shand, S.; Watkins, S.; Weber, S. G.; 
Michael, A. C., J Neurosci Methods 2008, 174, 177-85. 
 
251. Paxinos, G.; Watson, C., The Rat Brain in Stereotaxic Coordinates. Academic Press: 1998. 
 
252. Hsu, J.; Huang, S.; Chow, N.; Chen, S., Anal Chem 2003, 75, 6843-6852. 
 
253. Guo, K.; Ji, C.; Li, L., Anal Chem 2007, 79, 8631-8. 
 
254. Lanckmans, K.; Clinckers, R.; Van Eeckhaut, A.; Sarre, S.; Smolders, I.; Michotte, Y., J 
Chromatogr B Analyt Technol Biomed Life Sci 2006, 831, 205-12. 
 
255. Greco, S.; Danysz, W.; Zivkovic, A.; Gross, R.; Stark, H., Anal Chim Acta 2013, 771, 65-
72. 
 
256. Douglas, W. W.; Poisner, A. M., J. Physiol. 1964, 172, 1-18. 
 
257. Chavkin, C. B., C.; Weber, E.; Bloom, F. E., Proc. Natl. Acad. Sci. 1983, 80, 7669-7673. 
 
258. Podvin, S.; Bundey, R.; Toneff, T.; Ziegler, M.; Hook, V., Mol Cell Neurosci 2015, 68, 
177-185. 
 
259. Rocha, L.; Evans, C. J.; Maidment, N. T., J Neurochem 1997, 68, 616-624. 
 
260. Rocha, L.; Maidment, N. T., Hippocampus 2003, 13, 472-80. 
 136 
 
261. Rossier, J.; Vargo, T. M.; Minick, S.; Ling, N.; Bloom, F. E.; Guillemin, R., Proc Natl 
Acad Sci U S A 1977, 74, 5162-5165. 
 
262. Simantov, R.; Kuhar, M. J.; Uhl, G. R.; Snyder, S. H., Proc Natl Acad Sci U S A 1977, 74, 
2167-2171. 
 
263. Hughes, J. K., H. W.; Smith, T. W., Br. J. Pharmacol. 1977, 1977. 
 
264. Bloom, F.; Battenberg, E.; Rossier, J.; Ling, N.; Guillemin, R., Proc Natl Acad Sci U S A 
1978, 75, 1591-1595. 
 
265. Ploj, K.; Roman, E.; Gustavsson, L.; Nylander, I., Brain Research Bull 2000, 53, 219-226. 
 
266. Nylander, I. V., M.; Terenius, L., Brain Res 1995, 683, 25-35. 
 
267. Rupert, A. E.; Ou, Y.; Sandberg, M.; Weber, S. G., ACS Chem Neurosci 2013, 4, 838-848. 
 
268. Ban, L.; Pettit, N.; Li, L.; Stuparu, A. D.; Cai, L.; Chen, W.; Guan, W.; Han, W.; Wang, P. 
G.; Mrksich, M., Nat. Chem. Biol. 2012, 8, 769-773. 
 
269. Yates, N. A.; Deyanova, E. G.; Geissler, W.; Wiener, M. C.; Sachs, J. R.; Wong, K. K.; 
Thornberry, N. A.; Sinha Roy, R.; Settlage, R. E.; Hendrickson, R. C., International Journal of 
Mass Spectrometry 2007, 259, 174-183. 
 
270. Bothner, B.; Chavez, R.; Wei, J.; Strupp, C.; Phung, Q.; Schneemann, A.; Siuzdak, G., J. 
Biol. Chem. 2000, 275, 13455-13459. 
 
271. Van Noorden, C. J. F., J. Histochem. Cytochem. 2010, 58, 481-497. 
 
272. Vandooren, J.; Geurts, N.; Martens, E.; Van den Steen, P. E.; Opdenakker, G., Nat Methods 
2013, 10, 211-20. 
 
273. Bivehed, E.; Stroemvall, R.; Bergquist, J.; Bakalkin, G.; Andersson, M., Peptides (N. Y., 
NY, U. S.) 2017, 87, 20-27. 
 
274. OuYang, C.; Chen, B.; Li, L., J. Am. Soc. Mass Spectrom. 2015, 26, 1992-2001. 
 
275. Wienkers, L. C.; Heath, T. G., Nat Rev Drug Discov 2005, 4, 825-33. 
 
276. Kostel, K. L.; Lunte, S. M., Journal of Chromatography B: Biomedical Sciences and 
Applications 1997, 695, 27-38. 
 
277. Freed, A. L.; Cooper, J. D.; Davies, M. I.; Lunte, S. M., J. Neurosci. Methods 2001, 109, 
23-29. 
 
 137 
278. Maidment, N. T.; Siddall, B. J.; Rudolph, V. R.; Erdelyi, E.; Evans, C. J., Neuroscience 
(Oxford) 1991, 45, 81-93. 
 
279. Wen, X.-D.; Yang, J.; Ma, R.-H.; Gao, W.; Qi, L.-W.; Li, P.; Bauer, B. A.; Du, G.-J.; 
Zhang, Z.; Somogyi, J.; Wang, C.-Z.; Yuan, C.-S., J. Chromatogr. B: Anal. Technol. Biomed. Life 
Sci. 2012, 895-896, 162-168. 
 
280. Sandeep, T. C.; Andrew, R.; Homer, N. Z. M.; Andrews, R. C.; Smith, K.; Walker, B. R., 
Diabetes 2005, 54, 872-879. 
 
281. Sato, T.; Obata, T.; Yamanaka, Y.; Arita, M., Br J Pharmacol 1998, 125, 493-8. 
 
282. Obata, T., Life Sciences 2002, 71, 2083-2103. 
 
283. Wang, L.; Pi, Z.; Liu, S.; Liu, Z.; Song, F., Sci. Rep. 2017, 7, 1-11. 
 
284. Rupert, A. E.; Ou, Y.; Sandberg, M.; Weber, S. G., ACS Chem Neurosci 2013, 4, 849-57. 
285. Guy, Y.; Sandberg, M.; Weber, S. G., Biophys J 2008, 94, 4561-9. 
 
286. Guy, Y.; Muha, R. J.; Sandberg, M.; Weber, S. G., Anal Chem 2009, 81, 3001-7. 
 
287. Guy, Y.; Faraji, A. H.; Gavigan, C. A.; Strein, T. G.; Weber, S. G., Anal Chem 2012, 84, 
2179-87. 
 
288. McKinley, M. J.; Albiston, A. L.; Allen, A. M.; Mathai, M. L.; May, C. N.; McAllen, R. 
M.; Oldfield, B. J.; Mendelsohn, F. A. O.; Chai, S. Y., The International Journal of Biochemistry 
& Cell Biology 2003, 35, 901-918. 
 
289. Aksit, A.; Arriaga, M.; Wang, X.; Watanabe, H.; Kasza, K. E.; Lalwani, A. K.; Kysar, J. 
W.; Arteaga, D. N.; Lalwani, A. K.; Kysar, J. W., Biomed Microdevices 2018, 20, 47. 
 
290. Di Giacomo, R.; Krodel, S.; Maresca, B.; Benzoni, P.; Rusconi, R.; Stocker, R.; Daraio, 
C., Sci. Rep. 2017, 7, 45897. 
 
291. Faraji Rad, Z.; Nordon, R. E.; Anthony, C. J.; Bilston, L.; Prewett, P. D.; Arns, J.-Y.; Arns, 
C. H.; Zhang, L.; Davies, G. J., Microsystems &Amp; Nanoengineering 2017, 3, 17034. 
 
292. Hong, N.; Yang, G. H.; Lee, J.; Kim, G., J Biomed Mater Res B Appl Biomater 2018, 106, 
444-459. 
 
293. Lissandrello, C. A.; Gillis, W. F.; Shen, J.; Pearre, B. W.; Vitale, F.; Pasquali, M.; Holinski, 
B. J.; Chew, D. J.; White, A. E.; Gardner, T. J., J Neural Eng 2017, 14, 036006. 
 
294. Malinauskas, M.; Baltriukiene, D.; Kraniauskas, A.; Danilevicius, P.; Jarasiene, R.; 
Sirmenis, R.; Zukauskas, A.; Balciunas, E.; Purlys, V.; Gadonas, R.; Bukelskiene, V.; Sirvydis, 
V.; Piskarskas, A., Appl. Phys. A: Mater. Sci. Process. 2012, 108, 751-759. 
 138 
 
295. Marino, A.; Tricinci, O.; Battaglini, M.; Filippeschi, C.; Mattoli, V.; Sinibaldi, E.; Ciofani, 
G., Small 2018, 14. 
 
296. Miller, P. R.; Boehm, R. D.; Skoog, S. A.; Edwards, T. L.; Rodriguez, M.; Brozik, S.; 
Brener, I.; Byrd, T.; Baca, J. T.; Ashley, C.; Narayan, R. J.; Polsky, R., Electroanalysis 2015, 27, 
2239-2249. 
 
297. Son, A. I.; Opfermann, J. D.; McCue, C.; Ziobro, J.; Abrahams, J. H., III; Jones, K.; 
Morton, P. D.; Ishii, S.; Oluigbo, C.; Krieger, A.; Liu, J. S.; Hashimoto-Torii, K.; Torii, M., Sci. 
Rep. 2017, 7, 1-16. 
 
298. Suzuki, M.; Sawa, T.; Takahashi, T.; Aoyagi, S. In Ultrafine three-dimensional (3D) laser 
lithographic fabrication of microneedle and its application to painless insertion and blood 
sampling inspired by mosquito, 2015 IEEE/RSJ International Conference on Intelligent Robots 
and Systems (IROS), 28 Sept.-2 Oct. 2015; 2015; pp 2748-2753. 
 
299. Xu, H.; Medina-Sanchez, M.; Magdanz, V.; Schwarz, L.; Hebenstreit, F.; Schmidt, O. G., 
ACS Nano 2018, 12, 327-337. 
 
300. Fernando, R. N.; Luff, S. E.; Albiston, A. L.; Chai, S. Y., J. Neurochem. 2007, 102, 967-
976. 
 
301. Hernandez, J.; Prieto, I.; Segarra, A. B.; de Gasparo, M.; Wangensteen, R.; Villarejo, A. 
B.; Banegas, I.; Vives, F.; Cobo, J.; Ramirez-Sanchez, M., Behav. Brain Res. 2015, 287, 42-48. 
 
302. Gray, A. C.; Coupar, I. M.; White, P. J., Life Sci. 2006, 79, 674-685. 
 
303. Faraji, A. H.; Cui, J. J.; Guy, Y.; Li, L.; Gavigan, C. A.; Strein, T. G.; Weber, S. G., 
Langmuir 2011, 27, 13635-42. 
 
304. Faraji, A. H.; Jaquins-Gerstl, A. S.; Valenta, A. C.; Weber, S. G., J Neurosci Methods 2019, 
311, 76-82. 
 
305. Hamsher, A. E.; Xu, H.; Guy, Y.; Sandberg, M.; Weber, S. G., Anal Chem 2010, 82, 6370-
6. 
 
306. Chen, K. C.; Höistad, M.; Kehr, J.; Fuxe, K.; Nicholson, C., Journal of Neurochemistry 
2002, 81, 94-107. 
 
307. Feng, J. F.; Liu, J.; Zhang, L.; Jiang, J. Y.; Russell, M.; Lyeth, B. G.; Nolta, J. A.; Zhao, 
M., Stem Cell Reports 2017, 9, 177-189. 
 
308. Fekete, Z.; Pálfi, E.; Márton, G.; Handbauer, M.; Bérces, Z.; Ulbert, I.; Pongrácz, A.; 
Négyessy, L., Sensors and Actuators B: Chemical 2016, 236, 815-824. 
 
 139 
309. Cepeda, D. E.; Hains, L.; Li, D.; Bull, J.; Lentz, S. I.; Kennedy, R. T., J Neurosci Methods 
2015, 242, 97-105. 
 
310. Koehler, C. J.; Arntzen, M. O.; de Souza, G. A.; Thiede, B., Anal Chem 2013, 85, 2478-
85. 
 
